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A growing number of potential drug candidates display poor bioavailability 
related to poor water solubility of the drug molecules in biological fluids. Poorly water 
soluble drugs require an appropriate technology to engineer particles with enhanced 
physicochemical properties and deliver it to desired targets in the body. Particle 
engineering technologies such as evaporative precipitation into aqueous solution (EPAS), 
controlled precipitation (CP) and ultra-rapid Freezing (URF) were developed to enhance 
drug dissolution and bioavailablity through the production of stabilized drug 
nanoparticles and microparticles. The physicochemical properties of nanoparticles and 
their behavior on exposure to physiological media are greatly dominated by their primary 
particle size, morphology and surface characteristics. 
 ix
Both EPAS and CP are nucleation technologies which involve the precipitation of 
drug from an organic solution into aqueous solution, resulting in rapid nucleation rates 
and the formation of small stabilized particles. These technologies are different from one 
another in the type of solvent system and in the specific nozzle mixing (or dispersing) 
design.  The challenge of these technologies is that during the precipitation procedure the 
growing of the nucleating drug particles must be limited by use of a stabilizer in order to 
control the particle size.  
 In contrast to the precipitation technologies, URF utilizes rapid freezing of a drug 
solution to engineer porous amorphous drug/excipient particles with high dissolution 
rates.  The flexibility of URF provides the potential for the production of particles with a 
wide array of drug and various dosage forms such as oral, injection, and inhalation. For 
lung transplant, administering high surface area compositions via pulmonary 
administration that have been manufactured using nanoparticle technologies represents 
new potential opportunities to achieve high bioavailability at the target organ. The effect 
of the differences in the properties of these two types of particles on supersaturation 
(amorphous vs crystalline) and how it impact on drug absorption were evaluated. Mice 
were dosed with the inhaled nebulizer dispersions and the lung and whole blood 
concentrations were studied. Nanostructured aggregates containing amorphous or 
crystalline nanoparticles of tacrolimus produced by URF showed to be effectively 
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CHAPTER 1:  Nanoparticle-Based Drug Delivery Technologies 
and Their Applications for Particulate Drug Delivery Systems 
 
1.1 INTRODUCTION 
Recent advances in nanotechnology and nanoscience have the potential to 
bring benefits in areas of research as diverse as engineering, materials science, 
physics, chemistry and molecular biology [1-3]. This potential has attracted 
worldwide investment from governments and private organizations. Overall, 
worldwide investment in nanotechnology research and development has increased 
approximately 9-fold in the past nine years, from $432 million in 1997 to about 
$4 billion in 2005 [4]. The annual federal funding level in the United States for 
nanotechnology research and development has increased from an initial budget of 
$270 million in fiscal year 2000 to $1054 million requested for fiscal year 2006 
[4]. In 2000, the United States established a multidisciplinary strategy for 
nanoscale science and engineering research and development through the 
National Nanotechnology Initiative (NNI) [5,6]. The vision of the NNI for 
nanotechnology research and development provides an understanding of the full 
potential of nanoscale science, and will facilitate the transfer of new technologies 
into products. Potential research and development targets for 2015 suggested by 
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NNI are shown in Table 1.1 [7]. About half of these potential targets are relevant 
to drug development and delivery systems. These relevant targets include no 
suffering and death from cancer when treated with chemotherapeutic agents, 
advanced materials and manufacturing processes, pharmaceutical synthesis and 
delivery, converging technologies from the nanoscale, and life-cycle 
biocompatible/sustainable development.  
The field of nanotechnology is currently gaining attention from 
researchers and government funding agencies and undergoing explosive 
development for applications in the pharmaceutical industry [8-10]. Examples of 
current research include nanoparticle technologies that enable enhanced drug 
delivery leads and superior performance characteristics of the product, either by 
increasing efficacy or improving safety and patient compliance. These 
technologies also permit delivery of drugs that are poorly soluble in water or 
unstable in biological fluids. As a matter of fact, nanoparticles have long been 
prepared and employed in parenteral therapies since the 1980s [11-13]. However, 
technologies that enable one to control and engineer the drug itself in 
nanoparticulate form have only recently become integrated into the drug 
development process.  This chapter provides a comprehensive review of the 
nanoparticle technologies that are being developed for drug delivery as reported 
in the literature, with a brief discussion of the background, technological 
advantages and disadvantages, and recent progress cited for each technology. 
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These nanoparticle processes include the use of mechanical technologies, 
emulsification, supercritical fluid technologies, precipitation technologies and 
cryogenic spray technologies. The challenges and major findings regarding drug 
delivery systems over the past decade are discussed. Finally, the chapter 
highlights therapeutic applications including bioavailability enhancements and 
site-specific delivery, especially the potential for drug targeting for treatment of 
infection are discussed. 
1.2 SIGNIFICANT IMPACT OF NANOPARTICLE TECHNOLOGIES TO DRUG 
DELIVERY SYSTEMS 
Current drug development and delivery systems are increasingly 
challenging, inefficient and costly. [14-16]. Successful delivery of drugs often 
requires processing in order to create more desirable physicochemical properties 
for effective drug delivery. Due to rapid advancements in nanotechnology, 
significant effort has been devoted to developing nanoparticle processes in order 
to address issues associated with the current pharmaceutical challenges. These 
challenges include delivering drugs with poor water solubility, target-specific 
drug therapy, cost-reduction and product lifecycle extension. In addition, these 
technologies offer a suitable means of delivering a wide range of drugs including 
small molecular weight drugs, as well as macromolecules such as proteins, 
peptides or genes by either localized or targeted delivery to the tissue of interest. 
 4
Nanoparticle technologies have already had a significant impact on drug delivery 
systems in terms of improving the performance of existing drugs and enabling the 
use of new drug candidates. It will be discussed, later in this chapter, that 
nanoparticle technologies can enable the use of certain chemical entities or 
biologics that were previously impractical because of their low systemic 
bioavailability and/or high toxicity. Schematics of different nanotechnology-based 
drug delivery systems discussed in this review are shown in Figure 1.1 [8]. 
1.2.1 Solubility Enhancement  
 
Aqueous solubility of drugs continues to be a significant challenge and 
major obstacle to overcome for pharmaceutical scientists [17] in their quest to 
optimize delivery of drugs. The poor wetting and slow dissolution rate of poorly 
soluble drugs in the biological environment affect their absorption and subsequent 
distribution, resulting in limiting the drug’s clinical drug application [18]. Poorly 
water soluble drugs often show low systemic bioavailability and erratic 
absorption. Indeed, a great number of newly developed drugs are poorly soluble 
in water and in other solvents. As a result, the bioavailability of such drugs is 
insufficient to achieve the required therapeutic level. Many approaches have been 
used in an effort to increase the solubility, wetting and dissolution rate of poorly 
water soluble drugs including chemical modification (salt formation and prodrug) 
[19], complexation with cyclodextrins [20], formation of solid dispersions [21] 
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and solubilization in surfactant systems [22]. However, there are several 
disadvantages associated with these approaches. For example, the alteration of 
chemical structure by forming water-soluble derivatives often requires long 
processing times at a very expensive cost to derive the new chemical entities 
(NCEs) [23]. The use of solubilizing excipients is often limited by their toxicity. 
For example, the nonionic surfactant polyoxyethylated castor oil (Cremophor EL) 
has been shown to cause nephrotoxicity, hypersensitivity reactions and lowering 
of the white blood cell count (neutropenia) [24]. These are considered the severe 
side effects associated with administration of Taxol® which contains paclitaxel 
dissolved in a 50:50 v/v mixture of Cremophor EL and dehydrated ethanol. 
Furthermore, excipients often limit drug potency in the final product to well 
below 50% (drug wt./tot. wt.).  The large quantities of required solubilizing 
excipients may also limit the choice of route of administration. Oral delivery, for 
example, may be impractical because the size of tablet or capsule would be too 
large and difficult to administer.  
In addition to the general solubility enhancement approaches described 
above, the most direct approach for enhancing solubility is to reduce the particle 
size and size distribution range, thereby increasing surface area and dissolution 
rate. According to the Noyes-Whitney equation, the dissolution rate correlates 






s −=                                                                                          Eq. (1) 
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Where dm/dt is the rate of dissolution, S is the surface area, D is the diffusion 
coefficient, Cs is the apparent solubility of the drug in the dissolution medium, C 
is the solubility of the drug at time t, and h is the boundary layer thickness. The 
surface area can primarily be increased by reducing the particle size or increasing 
the porosity of the particles or a combination of both factors.  
Nanoparticle technologies have increased dissolution and bioavailability 
of poorly water soluble drugs after oral administration [25-27]. For example, 
Liversidge et al was able to enhance the bioavailability of danazol through the 
production of nanocrystalline particles of drug using wet milling [28]. In this 
study, danazol particles were milled to the mean size of 169 nm. The absolute 
bioavailability of danazol nanosuspension (82.3 ± 10.1%) was much higher than 
the conventional suspension consisting of microparticles (5.1 ± 1.9%). However, 
the bioavailability was similar to that of a complex of danazol and 2-
hydroxypropyl-β-cyclodextrin (106.7 ± 12.3%). Therefore particle size reduction 
is a rational way to increase the dissolution rate of poorly water soluble drugs and 
is encouraged as a primary strategy to consider. 
 Another important factor that influences the dissolution rate according to 
Noyes–Whitney is the saturation solubility, Cs. The value of Cs may be enhanced 
through formation of amorphous states with higher free energies than the 
crystalline state.  Amorphous drug particles can reach much higher concentrations 
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in aqueous solution compared to the crystalline form of the drug. Supersaturation 
is defined as follows [29], 
eq
d C
tCS )(= ,                                                                                                      Eq. (2) 
where C(t) is the measured concentration at time t and Ceq is the equilibrium 
solubility of crystalline drug in the dissolution media at a given temperature.  The 
amorphous form of drugs has been used to form supersaturated solutions that 
exhibit large increases in membrane flux when compared to saturated solutions 
[30,31]. The ability of the nanoparticulate and amorphous particles to 
supersaturate in the biological fluids may have a profound impact on increasing 
the bioavailability of poorly water soluble drugs, as has been suggested in several 
recent studies [32-34]. These studies indicate that forming amorphous solid 
solutions with the drug and excipients can provide superior dissolution properties 
of the formulation and subsequently enhance drug systemic bioavailability, which 
is defined as the rate and extent of drug that reaches systemic circulation. 
1.2.2 Site Specific Drug Targeting  
 
Another focus of research is the development of nanoparticle technologies 
to improve and enable drug targeting. Most drugs currently on the market are 
delivered in a non-specific manner throughout the whole body, rather than 
directly to the site of action where they are needed. This may result in 
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unintentional side effects or toxicity in other tissues. Drugs used in cancer therapy 
represent an excellent example of this problem. These drugs can kill not only 
target cancer cells, but also normal cells in the body. Site specific targeting (both 
passive and active targeting) can reduce systemic toxicity by enabling drugs to 
accumulate selectively in the target tissue. As a result, the local concentration of 
the drug at the site of action will be high, while its concentration in non-target 
tissue will be below a certain minimum level to prevent side effects. In addition, 
targeting ability may allow for lower dosing requirements which also potentially 
decrease side effects of the drug while maintaining the same therapeutic results. 
The need to achieve selective delivery of drugs to specific areas of the body has 
been recognized for many years.  
Utilization of nanoparticle technologies represents a potential opportunity 
in the field of drug targeting [10,35]. Engineered drug particles in the nanometer 
size range are generally taken up by cells of the reticular endothelium system 
(RES), also called the mononuclear phagocytotic system (MPS). This allows 
efficient delivery of drug to target tissue or organ through passive targeting 
process [36]. A schematic diagram of intracellular targeted drug delivery using 
colloidal carriers is shown in Figure 1.2. This schematic gives an overview of the 
uptake mechanisms involved in the opsonization, adhesion and internalization of 
nanoparticles by the cells of the MPS.  
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 Additionally, nanoparticles can be delivered to remote target sites or non-
MPS sites by attaching a ligand onto the surface of the particle which could direct 
them to the intended organ in the body [37]. The surface-bound ligand, such as 
monoclonal antibodies or polymer conjugate, can be recognized and bound 
specifically to target cells. This approach, called active targeting, provides a 
means of drug delivery to the sites of action with a high degree of specificity. The 
development of "stealth" technology has provided opportunities for active 
targeting of nanoparticles. The stealth strategy also avoids major uptake by the 
MPS cells resulting in an increased systemic circulation time of the nanoparticles 
[38]. Recently, several groups have reported stealth coatings for nanoparticles 
consisting of the linkage to the nanoparticles of poly(ethylene glycol) derivatives 
[39-41]. The linkages resulted in a lower uptake of nanoparticles by the MPS cells 
and therefore longer circulation times.  
 On the other hand, the surface of nanoparticle alternatively can be 
coated which phagocytes will recognize as “self ” to improve biological uptake 
[41]. By way of example, American Bioscience, Inc. (ABI) has developed a 
unique nanoparticle-based technology known as nanoparticle albumin-bound 
(nab) technology. It involves binding of water-insoluble drug in a nanoparticle 
state with albumin while retains the full biological properties of albumin. The 
coating mimics a natural protein in the body and may potentially exploit an 
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inherent pathway for albumin receptor-mediated transport of drugs across 
endothelium that becomes permeable due to the presence of tumors.  
Albumin is common protein found in the human body thereby the resulting 
product is readily biocompatible for patients use. It has been shown to accumulate 
in areas of inflammation and in tumour cells [42]. Furthermore, in vivo studies 
have confirmed an accumulation of nanoparticles in tumor sites. Abraxane® is the 
first marketed product to incorporate this technology and use for treatment of 
metastatic breast cancer. It was initially developed to avoid the toxicities 
associated with Cremophor EL used in the conventional formulation Taxol® for 
drug solubilization. It is significant that Abraxane® can be safely administered to 
both young and elderly patients. This formulation showed a superior efficacy with 
high reconciled target lesion response rate in the patients with metastatic breast 
cancer when compared with the conventional formulation Taxol®. The 
development of drug nanoparticulate for targeted drug delivery systems has been 
reviewed extensively by Moghimi et al [40]. 
1.2.3 Extending Product and Patent Lifecycles  
 
In the pharmaceutical industry, advancements in nanoparticle technology 
represent a powerful, strategic tool not only to improve drug performance but also 
to expand the original compound’s product lifecycle [9]. The technology is a cost 
effective resource enabling one to expand the success rate for promising 
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compounds in the pipeline, and to expedite their commercialization to market. 
Also, they can improve the likelihood of success for compounds that were 
previously thought to be undeliverable or unstable, or compounds that displayed 
sub-optimum absorption. Further, applications of nanoparticle technologies are 
increasing the range of possibilities for biologics because many first-generation 
biologics are under the threat of generic competition. Reformulation of existing 
drugs has become valuable near the end of a drug’s patent life. It is the best way 
to maximize a drug's viable time on the market and contributes to creating a new 
market in the field of drug delivery. In recent years, many pharmaceutical 
products have been increasingly focused on patented formulation technologies 
rather than on developing new chemical entities.  For example, Roche, Wyeth-
Ayerst and Bristol Meyers Squibb have reportedly entered into collaborative 
research agreements with Élan to develop micron or submicron based drug 
preparations for the sole purpose of enhancing dissolution and bioavailability of 
poorly water soluble drugs.  Furthermore, nanoparticle technology involves lower 
cost research relative to that expended for the discovery of new drug substances.  
The use of nanoparticles may reduce the required dose of drug to be administered 
and thereby lowering the overall requirement for an expensive drug.  This should 
reduce the cost of the product and undesirable effects in the human body resulting 
from higher dosing.  
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1.3 NANOPARTICLE TECHNOLOGIES 
In the pharmaceutical field, the term “nanoparticle” is generally used to 
describe submicron sized particles. The drug of interest is dissolved, entrapped or 
encapsulated within the particles as depicted in Figure 1.1. Nanoparticle 
technologies have been used as important strategies to deliver drugs, including 
peptides and proteins, vaccines and more recently nucleotides [14,35,43,44]. 
Nanoparticles can be produced by either mechanical or chemical approaches. 
Mechanical forces during comminution (crushing, grinding, and milling) often 
cause thermal stress resulting in degradation of heat-sensitive drugs [45]. In 
contrast, nucleating and growing particles from a solution in a controlled manner 
requires less particle handling and harsh conditions. These solution-based 
technologies involve the use of conventional liquids or supercritical fluids (either 
as solvents or antisolvents) or cryogenic media for ultra-rapid freezing. Such 
technologies typically result in formation of nanoparticles in amorphous form 
leading to increasing solubility and dissolution rate. The selection of the 
appropriate process for production of nanoparticles depends on the 
physicochemical properties of the drug and excipient(s). The following is an 
overview of the currently available methods used for production of drug 
nanoparticles and their noteworthy features. 
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1.3.1. Mechanical Technologies 
The mechanical technologies are conventional approaches used for many 
years in pharmaceutical industry for producing fine powders. These technologies 
include mechanical milling and high pressure homogenization. Effective size 
reduction generally requires high-energy input, resulting in enormous impact 
forces. High energy shear forces mechanically break down large particles. 
Conventional dry milling technologies such as ball and jet milling have the 
disadvantage of being inefficient for producing drug particles in the nanometer 
range. The typical particle size of powders milled with these technologies ranges 
from 0.1 µm to 25 µm [46,47].  The proportion of particles in the nanometer 
range is low due to the absence of stabilizing excipients, such as surfactants and 
hydrophilic polymers, during processing to prevent particle growth and 
aggregation. In addition, particle handling of nanoparticles in the dry state are 
difficult because of the presence of electrostatic forces on the surface of particles. 
Later, the wet milling (NanoCrystal technology) was developed by 
NanoSystems™ (part of Elan Corporation) to overcome these problems by 
milling particle in presence of hydrophilic stabilizer(s) to prevent  particle 
agglomeration [47, 48]. 
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1.3.1.1 Wet Milling Technology 
Wet milling is a particle size reduction technology whereby drug crystals 
are comminuted using high-shear media mills in the presence of surface 
stabilizer(s) and grinding media [25, 49]. The grinding media consist of rigid 
media with an average size ranging from 0.4 to 3 mm. The grinding materials may 
be composed of glass, zirconium oxide, ceramics and plastics (e.g., cross-linked 
polystyrene resin). The typical process temperature during is less than 40oC to 
prevent thermal degradation. In general, the technology involves pre-dispersing 
drug in aqueous solution containing hydrophilic stabilizers and then the slurry is 
wet milled with a grinding media over a specified time period.  High energy shear 
forces and the forces generated during impaction mechanically break down drug 
crystals into nanometer-sized particles which are suspended in a polymer solution. 
Wet milling often requires grinding for hours to days in order to achieve a desired 
size range of nanocrystalline particles. The level and type of stabilizer are 
important parameters to achieve nanoparticle size using this technology and 
should be investigated for each situation. It was found that higher molecular 
weight polymeric stabilizers were optimal for effective particle size reduction and 
shelf stability. Additionally, the size of the grinding media, flow rate and speed of 
the mill rotor can also be adjusted to achieve optimum results. 
NanoSystems™ has commercialized its technology resulting in two 
products. The first product approved by the United States Food and Drug 
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Administration (FDA) is the reformulation of Rapamune®, a lipophilic macrolide 
immunosuppressant (marketed by Wyeth Pharmaceuticals). Previously, 
Rapamune® (sirolimus) was only available as an oral solution which contains 
solubilizing agents such as polysorbate 80, phosphatidylcholine, mono- or di-
glycerides and propylene glycol. The current oral formulation requires storage 
under refrigerated conditions and additional preparation steps prior to use. A new 
formulation is now available as a tablet dosage in which the of the particle size of 
the drug substance is reduced to less than 200nm in order to improve drug’s water 
solubility. The new tablet formulation also enables more convenient 
administration and storage than the Rapamune oral solution. The second product 
is Emend® (aprepitant) developed as a new drug in a NanoCrystal® formulation. It 
is an antiemetic therapeutic agent used to prevent and control nausea and 
vomiting caused by chemotherapy treatment. 
1.3.1.2 High Pressure Homogenization Technology 
High pressure homogenization is another mechanical technology that 
involves the use of high shear forces to break up particles or droplets into the 
nanometer range [50, 51]. Traditionally, homogenizers have been used in the 
pharmaceutical industry for emulsification. More recently, high-pressure 
homogenization was successfully employed to prepare liposomes, 
nanosuspensions and solid-lipid nanoparticles [50]. Mechanical forces during 
homogenization cause droplet or particle size reduction by shear, turbulence, 
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cavitation and collision of the particles against each other at high velocity. Shear 
is caused by elongation and subsequent breakup of droplets, due to acceleration of 
a liquid. During homogenization, fracture of drug particles is caused by 
cavitation, high shear forces and by the collision of particles with each other. As 
the dispersion is forced through a narrow homogenization gap, the pressure 
suddenly rises to ambient pressure leading to implosion of vapor bubbles 
(cavitation). These cavitation forces are sufficiently high enough to cause 
disintegration of the suspended microparticles into nanoparticles. The particle size 
of the starting material for production of nanoparticulate suspensions is normally 
less than 100 µm in order to prevent the blockade of homogenization gap [52]. 
This technology has been used in the commercialization of drug nanoparticles 
such as Disso Cubes® owned by SkyePharma [53]. The Disso Cubes® are 
produced by using piston-gap type high-pressure homogenizers operating at 
pressures varying from 100 to 2000 bars. Characteristics of the particles (particle 
size distribution) are influenced by homogenizer type, applied pressure, number 
of homogenization cycles and hardness of the drug particles. Changes in drug 
crystallinity have been reported for high pressure homogenization technology 
[54]. The use of high pressures can cause changes in the crystal structure and may 
also produce uncontrollable variations of amorphous structure.  
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1.3.2 Emulsion Technology 
The production of nanoparticles employing emulsions and microemulsions 
as templates has been reported in the literature [55-57]. Emulsions are 
heterogeneous systems consisting of two immiscible liquids (i.e. organic and 
aqueous) in which one liquid is dispersed in the form of small droplets throughout 
the second liquid.  Emulsions are generally classified as oil-in-water (o/w) or 
water-in-oil (w/o) systems, where the first component represents the dispersed 
phase, although more complex systems (i.e. w/o/o, w/o/o/o) are feasible. 
Conventionally, the dispersion of nanoparticles can be prepared through 
mechanical emulsification which consists of two steps. The first step involves the 
application of high mechanical energy to break up the dispersed phase. In many 
cases, the nanoparticle dispersion is produced using a colloid mill, sonication or 
high pressure homogenization. The second step involves stabilization of the 
newly formed interfaces by the surfactant.  In addition to the method mentioned 
previously, nanoparticles can also be prepared by the emulsification–solvent 
evaporation technology [58]. Briefly, the drug of interest is dissolved in the 
organic solvent, which is subsequently emulsified by adding water and a 
surfactant to form an oil-in-water (o/w) emulsion. The organic solvent is then 
evaporated leading to the formation of nanoparticles. These particles are usually 
collected by centrifugation and lyophilization. Similar processes using both 
emulsification and diffusion has been developed by Quintanar-Guerrero et al. 
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[59]. Drug or polymer was added to a water miscible solvent as the oil phase. 
After the addition of water, the water miscible solvent diffuses to the water phase 
resulting in the precipitation of nanoparticles. This emulsification procedure is 
followed by the removal of the solvent by vacuum steam distillation, producing a 
dispersion of nanoparticles with an average sizes ranging from 0.1–0.3 µm. 
In contrast to emulsions, microemulsions are bicontinuous systems of oil-
in-water (or water-in-oil) stabilized by an interfacial film of surfactant and co-
surfactant. The particle size can be varied depending on the amount of surfactant 
and co-surfactant used during stabilization of the microemulsion. The application 
of a microemulsion as a template to produce nanoparticulate drug is usually 
limited due to limitations on the use of high surfactant concentrations. Trotta et al. 
were able to obtain griseofulvin nanoparticles from o/w microemulsions [60]. 
These particles were formed in the average particle size range of 80 – 300 nm. 
Moreover, microemulsions have been shown to increase solubility or 
bioavailability of a drug. For example, the microemulsion-based formulation of 
cyclosporin A (Neoral®) was developed to provide more consistent absorption of 
the drug from the gastrointestinal tract. Drug absorption of this formulation was 
improved and more reproducible than the conventional oil-based emulsion 
(Sandimmune®) due to significant decrease in particle size [61].  
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1.3.3 Supercritical Fluid Technologies 
Particle formation processes that use supercritical fluids (SCFs), especially 
carbon dioxide, have been applied in a variety of fields including 
superconductors, catalysts, inorganic compounds, polymers and pharmaceutical 
compounds [62]. Carbon dioxide (CO2) is the most commonly used SCFs for 
pharmaceutical applications due to its unique properties, such as low toxicity, 
non-flammable, inexpensive and high solubilizing power compared to regular 
gases. It has a relatively low critical temperature (31.1°C) and pressure (73.8 bar). 
The solubilizing power of SCFs can be controlled by changing in pressure or 
temperature. The attractive features of supercritical fluid-based technologies 
include ease of scale-up, enhanced solubility power, ability to control and vary the 
nanoparticle size and shape whenever required, use of inert carrier gases like CO2 
and obviously due to advantageous properties of supercritical fluids like high 
diffusivity, low viscosity, low surface tension and higher solubilizing power. The 
commonly used technologies based on supercritical fluids include rapid expansion 
from supercritical solutions (RESS), rapid expansion from supercritical to 
aqueous solutions (RESAS) and supercritical anti-solvent technologies (SAS) 
[63]. Within these technologies, the supercritical fluid is used either as the solvent 
or anti-solvent during particle formation. The choice of method depends on the 
solubility of the drug of interest in the appropriate SCF. The following section is 
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brief explanation of the principles of the methods discussing the technological 
advantages and disadvantages. 
1.3.3.1 Rapid Expansion from Supercritical Solutions (RESS), Rapid 
Expansion from Supercritical to Aqueous Solutions (RESAS) 
In the RESS technology, the supercritical fluid acts as the solvent. The 
solute is first dissolved into the supercritical carbon dioxide. This mixture is then 
expanded through a nozzle and sprayed into a collection chamber at atmospheric 
conditions.  Upon expansion, the atomization and evaporation of CO2 causes rapid 
nucleation and precipitation of dissolved solute in the form of small particles. A 
schematic representation of the RESS technology is shown in Figure 1.3a [63]. 
The technology has been applied to engineer the nanoparticles of griseofulvin and 
β-sitosterol [63]. Türk was able to produce particles of less than 500 nm in 
diameter by RESS-technology [64]. More recently, rapid expansion from 
supercritical to aqueous solution (RESAS) has been developed to reduce particle 
growth and aggregation in the expansion of RESS [65]. In RESAS, the surfactant 
diffuses rapidly to the particle surface to impede particle agglomeration and 
growth.  The RESAS technology has successfully incorporated aqueous 
stabilizing solutions into the RESS technology to produce nanoparticles of  poorly 
water soluble drugs. For example, cyclosporine (CsA) nanoparticles produced by 
RESAS using Tween 80 to prevent particle agglomeration [65]. The particle sizes 
of 500-700 nm were achieved with drug concentrations as high as 37.5 mg/ml. 
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The wide size distributions of drug particles were found at a high drug/surfactant 
ratio (above 0.6-0.7) due to insufficient stabilizer by surfactant. RESAS typically 
produces smaller particle sizes of water-insoluble drug than does RESS into air. 
Micron-sized particles were found when cyclosporine A was sprayed directly into 
air without the aqueous surfactant solution. In these technologies, the 
characteristics of the particle are dependent on nozzle design, temperature of the 
mixture before and in the nozzle and pressure in the spray chamber. The major 
disadvantage of these technologies is the low solubility of many drugs and 
excipients (e.g. polymers) in SCFs. Therefore, this technology can only be used 
when the drug of interest has a significant solubility in the SCFs. In addition, low 
drug loading into SCFs may result in low production rates of powders.  This 
makes RESS not attractive for industrial-scale productions of such low-soluble 
materials.  
1.3.3.2 Supercritical Anti-solvent and Related Processes (GAS, PCA, SAS, 
ASES, SEDS) 
The fact that many compounds have very low solubility in SCFs has given 
rise to the use of the SCFs as antisolvents to precipitate particles from 
conventional solvents. The principle is similar to that of conventional liquid 
antisolvent recrystallization tech. Supercritical antisolvent technologies have been 
performed using different process arrangements and apparatuses. The 
technologies relevant to this group include gas anti-solvent precipitation (GAS), 
 22
supercritical antisolvent (SAS), precipitation with a compressed fluid anti-solvent 
(PCA), aerosol solvent extraction system (ASES) and solution enhanced 
dispersion by supercritical fluids (SEDS). These technologies are different from 
one another in the contact mode between solution and anti-solvent, in the specific 
nozzle mixing (or dispersing) design, in the flow direction and in the process 
mode (batch or semi-continuous). However, different acronyms are often used to 
indicate the same technology depending on the author’s use of the terms. For 
example, Jung and Perrut have used the acronym GAS to refer to both GAS and 
SAS technology [66]. In other papers, the SAS or SEDS technology has also been 
referred to as PCA [67, 68].  In this chapter, we have further classified the 
supercritical antisolvent into two main distinct groups according to the process 
mode and the physical state antisolvent of used.  The first group includes GAS 
technology which uses high-pressure gas as an anti-solvent (gaseous antisolvent). 
This technology is typically operated as a batch process which involves the 
addition of CO2 to lower the solvent power of a polar liquid solvent in which the 
solute(s) is dissolved, thus causing the solute to precipitate or re-crystallize. This 
technology allows the unidirectional mass transfer of the CO2 diffusion into the 
organic phase.  A schematic representation of the GAS technology is shown in 
Figure 1.3b [63]. In this technology, the rate of addition of anti-solvent to the 
organic solution is an important parameter which affects the particle size and the 
particle size distribution of the precipitated particles. The second group includes 
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the semi-continuous processes such as PCA, SAS, ASES and SEDS. These 
technologies employ either liquid or supercritical carbon dioxide as the 
antisolvent. Figure 1.3c illustrates a schematic representation of PCA, SAS and 
ASES [63]. The liquid solution containing the dissolved drug and the anti-solvent 
are injected separately into the precipitation chamber, resulting in intense 
atomization and rapid two-direction mass transfer. In this way, high mass transfer 
rates are achieved and thereby creating nanoparticles [69].  
Based on currently published manuscripts, there are no distinctions 
between the well known SCF antisolvent technologies such as PCA, SAS and 
ASES [66, 67].  SEDS is the only process that is differentiated due to the use of a 
nozzle with two coaxial passages with a mixing chamber to improve atomization 
and mass transfer rates. Figure 1.4 illustrates the SEDS apparatus and the coaxial 
nozzle [70]. This nozzle design yielded better mixing which enables one to 
produce nanoparticles with narrow size distributions. Briefly, the drug in organic 
solvent and the pre-pressurized liquid or supercritical CO2 are co-introduced using 
a coaxial nozzle.  The two streams are thoroughly mixed in the mixing chamber 
of the nozzle to ensure highly efficient mixing prior to dispersing into the particle-
forming vessel via a restricted orifice.  Such a nozzle facilitates intense 
atomization and rapid mass transfer rates causing precipitation and disintegration 
of small particles. 
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1.3.4 Precipitation Technologies 
Other technologies used for the preparation of drug nanoparticles include 
precipitation from solution. The precipitation process involves nucleation and 
crystal (particles) growth of drug particles from a supersaturated solution.  The 
supersaturated solution is a solution in which the concentration of solute exceeds 
the saturation or equilibrium solute concentration at a given temperature.  Thus, a 
supersaturated solution is not at equilibrium, and crystallization of the solute 
occurs in order to move the solution towards equilibrium.  After initial particle 
nucleation, both nucleation and crystal growth attempt to bring the supersaturated 
solution to equilibrium.  The time required for crystallization depends on the 
driving force of supersaturation.  The particles are formed in a supersaturated 
solution through nucleation mechanisms. Nucleation of particles occurs as a 




CS = ,                                                                                                          Eq. (3) 
where Co and Cf are the concentration of drug before and after mixing the two 
solutions.  If mixing is done rapidly, a higher level of supersaturation is created 
before significant nucleation occurs. The rate of primary nucleation is given by 
the equation [71], 
B0 = A exp[(-16πσ3v2)/(3k3T3(ln S)2)]                                                           Eq. (4) 
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where B0 is the nucleation rate, σ is interfacial tension, ν is molar volume, A 
is frequency factor , T is temperature and S is supersaturation. The nucleation rate 
increases with increasing temperature and degree of supersaturation, but decreases 
with increasing surface energy.  High nucleation rates offer the potential to 
produce a large number of submicron particles in the final dispersion, as long as 
the growth can be arrested by stabilizers.   
Precipitation technologies are used in both the chemical and 
pharmaceutical industries for the production of nanoparticles [29, 72]. The 
conventional precipitation technologies, including solvent evaporation and salting 
out, have in common the disadvantages of poor control over particle morphology 
and particle size and size distribution producing a wide range of particle sizes 
[72]. Innovative technologies have been introduced to overcome these problems 
in the past several years, including solvent displacement, evaporative precipitation 
into aqueous solution and controlled precipitation. Each technology requires 
solvation of the drug into a solvent and then precipitation in an antisolvent or 
evaporation of the solvent leading to precipitation.  These technologies differ by 
the type of solvent/antisolvent used and the process parameters (such as 
temperature and pressure) at which the technology is carried out. The physical 
state of the drug can be varied from crystalline to amorphous. 
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1.3.4.1 Solvent Displacement or Nanoprecipitation 
The concept of nanoprecipitation based on interfacial polymer deposition 
following solvent displacement was developed and patented by Fessi and co-
workers [73, 74]. It requires the use of two miscible solvents. This technology is 
suitable for hydrophobic compounds which are soluble in ethanol or acetone (the 
solvent), but with limited solubility in water (the non-solvent). Both the polymer 
and the drug are dissolved in the solvent, which is subsequently poured into the 
non-solvent while stirring. Nanoparticles are formed instantaneously by rapid 
solvent diffusion, and the organic solvent is then removed from the dispersion 
under reduced pressure. Nanoprecipitation enables the production of nanoparticles 
with average diameter ranging from 100–300 nm and narrow monomodal size 
distributions. The use of polymeric stabilizers was fundamental to obtain stable 
dispersions without significant particle aggregation. The wide range of polymers 
can be used, such as poly(lactic acid) (PLA) and copolymers of lactic acid with 
glycolic acid (PLGA), poly ε-caprolactone (PLCL) and cellulose derivatives. 
Recently, Hyvonen et al were able to incorporate water insoluble drugs 
such as beclomethasone dipropionate into low molecular weight poly(L-lactic 
acid) nanoparticles using nanoprecipitation [75]. However, the major limitation of 
this method is related to drug solubility that is required for efficient encapsulation 
[76]. Guzman et al. reported that drug loading efficiency of cyclosporine in poly 
ε-caprolactone nanoparticles was only 0.46 mg/g of polymer [77]. Similar 
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findings of low drug encapsulation efficiency of other water insoluble drugs such 
as indomethacin (2.0% w/w) and dexamethasone (0.9% w/w) into PLGA 
nanoparticles was also found by Fessi et al.[74]. In addition, this method is not 
suited for the encapsulation of water-soluble drugs, which rapidly diffuse from the 
organic phase into water resulting in loss of drug into the aqueous phase [78]. 
1.3.4.2 Evaporative Precipitation into Aqueous Solution (EPAS) 
EPAS particle engineering technology was developed to engineer small 
particles with high dissolution rates. This technology is patented by The 
University of Texas at Austin and licensed to The Dow Chemical Company. 
EPAS creates small particles through rapid phase separation. Evaporation of the 
primary solvent results in loss of solvent power and precipitation of very small 
particles of the dissolved solute. In this technology, drug dissolved in a water 
immiscible organic solvent is sprayed through an atomizing nozzle into an 
aqueous solution containing a hydrophilic stabilizer to produce an aqueous 
dispersion [79].  Rapid evaporation of the organic solvent at elevated 
temperatures produces very high supersaturation and rapid precipitation of the 
drug in the form of suspended particles. The particles may be stabilized by a 
variety of stabilizers present in either or both the organic and aqueous phases. The 
stabilizers diffuse to the surface of the growing particles to prevent particle 
growth during re-crystallization. The enhanced dissolution rates characteristic of 
EPAS can generally be accounted for by one of the following mechanisms: 
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increased surface area available for dissolution by decreasing the particle size of 
drug, precipitation as a metastable crystalline form or a decrease in substance 
crystallinity and/or by optimizing the wetting characteristics of the drug surface 
due to adsorption of hydrophilic stabilizer [80]. Nanoparticle suspensions of 
cyclosporine A with a particle size ranging from 130 nm to 460 nm was produced 
by the EPAS technology [81]. A variety of hydrophilic stabilizers were found to 
diffuse to the surface of the growing particles rapidly enough to prevent growth of 
the nanoparticles. The EPAS technology has been successfully used to produce 
high potency formulations with rapid dissolution rates of hydrophobic drugs such 
as danazol [82] and itraconazole [83, 84]. The resulting stabilizer-coated drug 
particles had high drug-to-stabilizer ratios greater than 12, corresponding to 
potencies (wt drug/wt drug + wt surfactant) as high as 93%.  The relatively small 
amount of adsorbed stabilizer was sufficient to stabilize the particle and produce 
high wettability and dissolution rates during EPAS technology.   
1.3.4.3 Controlled Precipitation (CP) 
More recently, the controlled precipitation technology was developed by 
The Dow Chemical Company. It involves growing the particles in a controlled 
fashion to attain the desired particle size and morphology. Briefly, the drug is 
dissolved in a water miscible organic solvent, which is then rapidly mixed with an 
aqueous phase (antisolvent) in a controlled manner.  This ensures sudden high 
supersaturation, resulting in rapid nucleation and the formation of small particles. 
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Stabilizers can be added in either the organic or aqueous phase for preventing 
particle agglomeration during solvent evaporation and storage. The addition of 
aqueous solution leads to the lost of solvent power, thus causing the precipitation 
or re-crystallization of the dissolved drug. The dispersion of drug nanoparticles 
can be further processed to remove the solvent using vacuum distillation 
apparatus. Upon solvent removal, the stripped dispersion can be dried by spray 
drying or lyophilization. The main idea behind this technology is that the anti-
solvent should be highly soluble in the solvent, while the solute is insoluble or 
insignificantly soluble in the anti-solvent in order to promote precipitation. In the 
recent research, CP has found success in the nanoparticle production of danazol 
and naproxen [27]. The particle sizes of both drugs increased as the was 
temperature increased from 3°C to 50°C in the mixing zone. The nanoparticles 
obtained by CP yields better dissolution profile in comparison to the physical 
mixtures, micronized and wet-milled drugs. Scale-up of this technology was 
shown to be successful for large-scale production of nanoparticles on the 
kilogram scale with good recovery and low residual solvent levels. The ability for 
large-scale production is an important requirement for the nanoparticle 
technologies to be introduced into the pharmaceutical industry applications. 
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1.3.5 Cryogenic Spray-freezing Technologies 
Cryogenic technologies have been developed to produce small particles 
without the introduction of mechanical forces or heat which can cause 
degradation of the drug. The basic advantage of this technology is its applicability 
to drugs that are poorly water soluble. In addition, techniques are especially 
suitable in thermosensitive drugs such as proteins and peptides micronization. The 
freeze drying technique reported in the literature is spray-freeze drying (SFD). It 
typically involves the spray of protein or drug solution into a cold vapor phase 
over a cryogenic liquid to form fine droplets. For the spray-freeze-drying process 
at atmospheric pressure, the frozen droplets are dried during the following 
atmospheric freeze drying in the cold desiccated air stream by sublimation. It has 
however a number of disadvantages, which is related to the poor heat transfer 
[85]. As the result, the droplets may not be freeze immediately. Webb et al. 
reported the aggregation and precipitation of recombinant human interferon-γ 
produced by SFD [86]. The passage of the droplets may allow freezing to begin 
during the time of flight through the cold vapor phase which takes about one 
second before reaching cryogenic liquid phase where completely freeze occurred. 
Therefore this occurrence allowed protein to diffuse and aggregate at the air–
liquid interface. 
The relatively new process of spray freezing into liquid (SFL) was 
developed to overcome this problem. In the SFL technology, the feed solution 
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containing drugs and excipient(s) is atomized through a nozzle below the surface 
of liquid nitrogen. The droplets are immediately frozen upon contact with the 
cryogenic liquid phase. The frozen particles are then lyophilized to obtain dry, 
free flowing powders. The ultra-rapid freezing rates prevent the phase separation 
of solutes within the feed solution and induce formation of amorphous structures.  
The success of the SFL technology results from intense atomization of a feed 
liquid directly into a cryogenic liquid to produce the molecular dispersion of 
amorphous nanostructured particles with high surface areas and enhanced 
dissolution rates [87]. Their utility for engineering of microparticles and 
microparticulate drug carrier systems has been very well established. SFL has 
been successfully used to produce micron-sized aggregates of nanoparticles in 
various compounds such as insulin [88, 89], bovine serum albumin [90] and 
poorly water soluble drugs [26, 91-93].  
1.4 POTENTIAL THERAPEUTIC APPLICATIONS OF NANOPARTICLE-BASED 
DRUG DELIVERY TECHNOLOGIES 
Nanoparticle-based technologies are changing the way drug delivery is 
being approached, offering new ways to deliver drugs effectively, to reduce the 
amount of those drugs used, to localize the delivery of potent compounds and, 
therefore, to reduce side effects. They have become important in several areas of 
drug delivery, potentially via numerous administration routes, including 
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parenteral, oral, brain and pulmonary routes. The unique characteristics of 
nanoparticles have enabled their application to delivering a wide range of 
compounds such as hydrophilic drugs, hydrophobic drugs, peptides, proteins, 
vaccines, etc. Examples of the most recent research carried out using different 
nanoparticulate systems are reviewed in Table 1.2 [94]. The general aspects on 
nanoparticles have been extensively reviewed [95-97] and the present chapter will 
focus on the recent findings in drug delivery systems. 
1.4.1 Injectable Drug Delivery 
Parenteral administration of drugs by injection is the most common route 
of administration to achieve rapid therapeutic drug levels for the treatment of 
acute treatment [98]. Because of their small size below 1 µm, nanoparticles are 
primarily developed for intravenous administration to prevent blocking the fine 
capillaries leading to embolism [98, 99]. They can be injected either 
intravenously, intramuscularly or subcutaneously or direct injection into solid 
tissues or organs. When given intravenously, nanoparticles are taken up by direct 
endocytosis or phagocytosis into monocytes, macrophages, leukocytes and other 
cells of the RES whose function is to scavenge foreign particles and 
microorganisms. One of the main interests of nanoparticles is their higher 
intracellular uptake compared to microparticles, which makes nanoparticles 
potential candidates for delivering drug to infected macrophages for effective 
microbial killing [100-102]. Treatment of many intracellular infections in the 
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MPS is often fails to eradicate the organism because of the inability of drugs to 
penetrate infected cells [100]. Therefore, there may be promising applications of 
nanoparticles for treatment of infectious diseases when administered 
intravenously. For examples, Forestier et al. studied the efficacy of ampicillin-
loaded poly(isobutylcyanoacrylate) (PIBCA) nanoparticles against the activity of 
L. monocytogenes in macrophages compared with that of free ampicillin [103]. 
Ampicillin-bound nanoparticles showed more effective than free ampicillin for 
inhibiting intracellular growth of L. monocytogenes. After 30 h of incubation, 
nanospheres-bound ampicillin inhibited bacterial growth by 99% with a lag period 
of 9 h while free ampicillin was ineffective. This effect was attributed to high 
cellular uptake of the ampicillin-loaded nanoparticles and the diffusion of the 
drug through the cell. 
Also nanoparticles can provide slow release of the drug when accumulated 
in the in phagocytic cells or administered subcutaneously [104].  Such particles 
that slowly dissolve may enable passive targeting of the lung, liver and spleen via 
the RES, followed by sustained release. Subcutaneous administration of 
nanoparticles was achieved mainly for the delivery of peptides and vaccines 
[104]. It allows sustained release depot of the drugs therefore reducing the 
number of administrations, increasing blood half-life of the active drug, and 
finally, in some cases, reducing side effects. The rate of release may be controlled 
by the nature of the carrier materials and particle size. 
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1.4.2 Oral Drug Delivery  
Nanoparticles have been successfully used as carriers for oral drug 
delivery to increase bioavailability of many drugs with poor absorption 
characteristics ranging from anticoagulants[105], antihypertensives [106, 107], 
anti-cancer drugs [50, 108], antibiotics [109] and hormones [26, 28, 82]. In 
addition, these studies have revealed a great potential of nanoparticle technologies 
in tackling problems associated with delivery of poorly water-soluble drugs 
regarding low oral bioavailability, high intersubject variability and poor or 
suboptimal therapeutic response. Different effects have been observed depending 
on the particle technology used. Vaughn et al. have compared the properties of 
nanoparticles (composed of danazol and PVP K-15) formed by EPAS and SFL 
and correlated to the in vivo performance of the drug [87]. The differences in 
particle morphology and degree of miscibility of the drug and polymer were 
found using Z-contrast scanning transmission electron microscopy (STEM). The 
results indicated that the SFL technology produced amorphous solid solutions 
particles with mean size of 30 nm. On the other hand, the EPAS technology 
results in formation of solid dispersion with partially crystalline form of larger 
nanoparticles (500 nm). The result was attributed to the differences in the particle 
formation mechanisms for the EPAS and SFL technologies, precipitation versus 
rapid freezing, respectively. Both EPAS and SFL formulations, however, were 
able to achieve 27% and 33% supersaturation, respectively compared to the 
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physical mixture (crystalline microparticles with PVP K-15) and remained above 
supersaturation for 60-90 minutes. An in vivo study has been conducted in mice 
and demonstrated an increased in the rate and extent of absorption for danazol 
produced by EPAS and SFL compared to the physical mixture and commercial 
Danocrine® capsules. 
Nanoparticles are generally stabilized using different types of polymers 
and surfactants which can change the surface charge of the particle preventing 
electrostatic forces from causing aggregation. Various polymers have been used 
to fabricate nanoparticles include synthetic polymers such as polylactide–
polyglycolide copolymers, polyacrylates and polycaprolactones or natural 
polymers such as albumin, gelatin, alginate and chitosan. The release of drug 
from nanoparticles can be controlled by modulating polymer characteristics to 
achieve desired therapeutic level in target tissue for required duration and optimal 
therapeutic efficacy [110]. Recently, it was shown that the use of nanoparticles 
containing rifampicin, isoniazid and pyrazinamide were achieved high 
concentrations and maintained in the plasma for 8 days following a single oral 
administration in mice [109]. Therapeutic drug concentrations of these 
nanoparticles were also found in the organs including lungs, liver and spleen for 
10 days whereas free drugs were cleared by 24–48 hrs.  
Nanoparticles have also shown a certain degree of success for the oral 
delivery of macromolecules, such as peptides, proteins, oligonucleotides and 
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plasmids to the systemic circulation and to the immune system [95, 111, 112].  
The oral delivery of these compounds is unresolved challenge leading to low 
bioavailability mainly because of their poor penetration across biological 
membranes and their susceptibility to enzymatic degradation.  The major obstacle 
for using nanoparticles as an oral delivery system is the prerequisite that particles 
need to be absorbed from the gastrointestinal tract with a sufficient rate and 
extent. The adhesion of the particles to the mucosal surface is an essential step 
before the translocation of the particles can take place [113, 114]. Therefore, 
mucoadhesion may play an important role in the uptake process. Ponchel et al. 
have studied the adsorption of poly (styrene) latexes in different particle sizes 
[114] . The adsorption isotherms followed Langmuir-behavior as shown in Figure 
1.5. The adsorption of nanoparticles rapidly increased (sharp initial slope) before 
reach the plateau suggesting that nanoparticles exhibits stronger affinity with the 
mucus layer than those of micron size particles. This demonstrated that 
nanoparticles were able to penetrate into the mucous layer more efficiently than 
micron sized particles of the same material. Mucoadhesive polymers have been 
used to prolong contact times of nanoparticle systems at the absorption site 
allowing high drug adsorption [113].  Typical mucoadhesive polymers include 
polysaccharides such as chitosan and xanthan gum; cellulose based polymers such 
as hydroxypropylmethyl cellulose (HPMC); acrylate polymers such as 
poly(acrylic acid) and carbomers; and sodium alginate. The improvement of oral 
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absorption for protein and peptide drugs including  insulin and calcitonin has been 
well reported using the specialized delivery system of mucoadhesive 
nanoparticles [115].  
 
1.4.3 Pulmonary Drug Delivery  
The pulmonary route has been used for decades to administer drug to the 
lung for the treatment of asthma and other respiratory diseases [116]. Currently, 
this route has attracted great attention because it may become an important non-
invasive route for systemic drug delivery. In general, non-invasive routes have 
higher patient compliance than parenteral routes but achieving rapid onset of 
therapeutic drug levels can be challenging. The recent example of pulmonary 
administration for systemic drug delivery is insulin inhalation.  The first 
commercial pulmonary formulation of rapid-acting insulin (Exubera®) is now 
approved by the FDA. It is manufactured by Pfizer using Nektar Therapeutics 
proprietary inhalation technology. This is considered a significant step forward 
and a breakthrough approach in the treatment of type 1 and type 2 diabetics by 
delivering insulin to the lungs via inhalation. Inhaled insulin enters the blood 
circulation more rapidly than by subcutaneous injection while increasing patient 
compliance [117].  
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Pulmonary administration of drugs can be expected to achieve faster onset 
of action and higher systemic bioavailability than other noninvasive routes 
because of the huge surface area with highly vascularized regions and relatively 
low drug-metabolizing enzyme activity in the lung [118]. In addition, the 
pulmonary route is not subject to first pass metabolism, so this is especially useful 
for many drugs which undergo extensive metabolism in liver. For example, 
pulmonary delivery has long been viewed as a promising approach for improving 
the systemic bioavailability of immunosuppressive drugs and reducing their 
toxicity [119-121]. It is well known that the oral absorption of these drugs is 
variable and incomplete because of the drug efflux back into the intestine by the 
membrane pump p-glycoprotein and drug metabolism in the intestine and hepatic 
by CYP3A family of enzymes [122] . Many studies have demonstrated that 
aerosolized cyclosporine (CsA) is an effective therapeutic for preventing allograft 
rejection at a reduced dose compared to intravenous or oral dosage forms [123-
125].  In early clinical studies, CsA was simply dissolved in the solvents such as 
ethanol or propylene glycol [126-129]. However, the results were unsatisfactory 
due to the irritating properties of these solvents. More importantly, the 
nebulization procedure was complicated due to the precipitation of CsA within 
the nebulization chamber. 
Until recently, research has been focused on new aerosol delivery systems 
using inhaled nanoparticles as therapeutic carriers [130-132]. This is an active 
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area of research by numerous groups because of the appealing aspect of inhaled 
nanoparticles in significantly improving the systemic bioavailability of the drug. 
This was attributed to the rapid dissolution rate of nanoparticles in the airway 
epithelium via surface energetics in comparison with microparticles. In addition, 
nanoparticles may also be considered as drug targeting approach to facilitate 
intracellular delivery particularly to alveolar macrophages and lymphocytes for 
treating infections of the MPS system [133-135]. Some microorganisms, 
particularly in the lung macrophages, including mycobacteria and aspergillus 
fungus, are difficult to reach with a normal treatment. The delivery of an 
antifungal agent directly to the lung has recently been evaluated as a promising 
way to improve the treatment of invasive fungal infections compared to the 
conventional treatment. It has been recently reported that nanoparticles of 
itraconazole (ITZ) processed using SFL were taken up by pulmonary 
macrophages [136]. Further, aerosolized nanoparticles of ITZ were able to 
achieve high and sustained levels in the lung tissue. The efficacy studies 
conducted against the Aspergillus fumigatus in mice was also shown to 
significantly prolong survival of infected mice through the inhalation of ITZ 
nanoparticles compared to the commercial product using Sporanox ® oral 
solution [137]. 
However, a potential limitation of using nanoparticles for pulmonary 
delivery is their extremely low inertia causing the particles to escape from lung 
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deposition. As a result, a large portion of the inhaled particles would be exhaled 
from the lungs after inspiration. Various particle technologies and designs have 
been investigated in order to deliver nanoparticles to the deep lung [138-141]. The 
nebulization technology was used to produce the aerosolized droplets of 
nanoparticles which can then be inhaled [142]. The aerodynamic diameters of 
these droplets are within the 1-5 µm range which is optimum for delivery into the 
lung. Similar concepts of incorporating nanoparticles into the matrix of micron 
sized carrier particles using both spray-drying and freeze-drying techniques has 
also been reported [139, 140, 143]. Sham et al. have successfully produced 
nanoparticle-loaded microspheres using lactose as the carrier [143]. They used the 
spray drying technique to form microparticles which contain gelatin or 
polybutylcyanoacrylate nanoparticles. The aerodynamic diameter of the spray 
dried particles was 3.0±0.2 µm while the average particle size of the nanoparticles 
was 242±14 nm for gelatin and 173±63 nm for polybutylcyanoacrylate. Further, 
Tsapis et al. have also utilized large porous particles as carriers for nanoparticles 
(trojan particles) [141].  Such particles have the potential in delivering 
nanoparticles to the alveolar region and avoid elimination from the lungs because 
of their large size and low density. Another approach is to use bioadhesive and 
biodegradable polymers in order to retain the nanoparticles within the lungs [117, 
144]. A polymer also allows for the slow and sustained release of drugs, which 
leads to a less frequent and attenuated drug treatment regimen. To date, these 
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approaches are not presently being explored commercially or clinically, as the 
technologies are relatively new and are still being developed. 
 
1.4.4 Brain Drug Delivery  
One of the more recent applications includes employing nanoparticles as 
drug delivery systems to the brain (143-145). The administration of drugs to the 
central nervous system (CNS) is a significant challenge because many drugs have 
great difficulty crossing the blood–brain barrier (BBB). The blood brain barrier is 
a complex structure composed of endothelial cells connected by highly restrictive 
tight junctions (146). This unique structure protects the brain against peripheral 
neurotransmitters, cytotoxins and microorganisms. However, it also restricts the 
passage of potential drugs for the treatment of neurological or psychiatric 
disorders, and of other brain pathologies (such as infections and tumors). 
Conventional methods for delivering drugs to the CNS involves invasive surgical 
procedures (147). Attempts have been made to disrupt the BBB (increased 
paracellular diffusion) in order to enhance delivery of drug to the brain using 
vasoactive agents such as leukotrienes, histamine, bradykinin, and the synthetic 
bradykinin analog RMP-7 (receptor-mediated permeabilizer (147). However, 
junctional openings of the BBB may break down the self-defense mechanism of 
the brain allowing entry of toxins and unwanted molecules. Recently, 
nanoparticles have been revealed as efficient carriers to deliver drugs through the 
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BBB into the brain (145, 148, 149). It was reported that the use of poly 
(butylcyanoacrylate) nanoparticles (PBCA) coated with surfactants, especially 
polysorbate 80 led to a high drug concentrations in the brain following 
intravenous administration (150).  Drugs that have successfully been delivered 
across the BBB using PBCA nanoparticles include hexapeptide dalargin, the 
dipeptide kytorphin, tubocurarine and doxorubicin (147). The mechanism by 
which the nanoparticles deliver drugs into the brain has not yet been fully 
elucidated. The possible transport mechanism has been suggested to be cellular 
endothelial endocytosis following adsorption of plasma proteins especially 
apolipoprotein E (apo E) after intravenous injection (36).  The polysorbate-coated 
nanoparticles interact with the low density lipoproteins (LDL) receptors on the 
endothelial cells, resulting in their uptake by brain endothelial cells into the brain. 
On the other hand, the particles without the surfactant coating remained in the 
blood vessels. 
1.5 CONCLUSION 
Nanoparticle technology represents a valuable tool for optimizing and 
enhancing drug formulations by improving their efficacy, safety, convenience and 
compliance. The integration of nanoparticle technologies into the pharmaceutical 
drug development process is beginning to demonstrate tremendous potential in 
drug development including success of commercial applications, patent protection 
and successful investment from governments around the globe. The use of 
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nanoparticle technology in drug development is presently in its infancy and still 
being explored. However, recent works have shown promise for nanoparticle-
based technologies as potential methods to enhance drug bioavailability and 
enable drugs to be incorporated into formulations for targeted drug delivery. Also, 
nanoparticle-based technologies have been used with various routes of 
administration, including oral, injectable, brain and the lungs.  It is often difficult 
or impossible to obtain drug nanoparticles by conventional technologies using jet 
and ball milling, spray drying, and recrystallization using solvent evaporation. 
Currently, the engineering of drug nanoparticles using mechanical, emulsification, 
precipitation, supercritical fluids and cryogenic has been successfully 
demonstrated. The technologies such as wet milling and high-pressure 
homogenization have enabled successful commercialization of drug nanoparticles. 
There are, however, some challenges facing the successful implementation for the 
widespread use of nanoparticle technologies in pharmaceutical industry including 
large scale production and harvesting of particles with the desired characteristics. 
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1.7 DISSERTATION OBJECTIVES AND OUTLINE 
In the past decades, there is a growing demand for more effective and 
versatile technologies to overcome formulation and bioavailability problems 
associated with poorly-water-soluble drugs. Nanoparticle engineering 
technologies represent an important strategy to deliver and enhance drug 
performance by improving the dissolution rate and bioavailability of these drugs. 
The basic concepts of different nanoparticle engineering technologies, 
technological advantages and disadvantages and their current applications in drug 
delivery systems are discussed in Chapter 1. These technologies include 
mechanical technologies, supercritical fluid technologies, freezing technologies, 
and precipitation technologies.   
Physicochemical properties of engineered particles are dependent on the 
technology employed and on the properties and proportion of the excipient used. 
Drug potency (wt drug/wt drug + wt stabilizer) for most formulations is 50% or 
less. Typically, the ratio of drug-to- stabilizer ranges from 1:10 to 1:1. It is  
challenging to achieve rapid release with a high drug-to- stabilizer ratio or 
payload, especially for low potent compounds with high dose requirements. Such 
formulation can offer several advantages such as low administration dose 
improving patient compliance and less potential of toxicity and interactions from 
an excipient.   
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Evaporative precipitation into aqueous solution (EPAS) is a particle 
engineering technology by which a drug solution in a water immiscible organic 
solvent is sprayed through an atomization nozzle into a heated aqueous solution 
containing hydrophilic stabilizer (s) at high temperature. The rapid evaporation of 
the small organic droplets results in fast nucleation leading to submicron to 
micron particles dispersions. The adsorption of water soluble stabilizers on the 
drug particle surfaces facilitates the dissolution rates of the final powder after 
drying.  This is also a key factor to achieve high potency formulation while at the 
same time maintain high dissolution rates of the drug. High-potency (≥ 90%) drug 
particles with high dissolution rates produced using EPAS technology, followed 
by removing the non-adsorbed stabilizer were successfully developed and 
investigated in Chapter 2. The hypothesis is that the high potency ITZ powders 
can be produced by an optimum choice of stabilizer(s) which adsorb very rapidly 
onto the ITZ particle surfaces during the very short spray times employed in the 
EPAS process. The very small amount of adsorbed stabilizers was sufficient to 
form a hydrophilic layer on the particle surface resulting in increased particle 
wettability and dissolution.  
Poorly-water-soluble compounds are often difficult to develop as drug 
products using conventional formulation techniques. The rapidly disintegrating 
and dissolving tablets containing ITZ particles produced by EPAS were prepared 
by direct compression altering the stabilizer species and levels, and the factors 
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affecting the drug release properties from the matrix tablets were investigated in 
Chapter 3. We hypothesized that the high dissolution properties of EPAS particles 
can be maintained after incorporate into tablets. The ability to maintain rapid 
dissolution rates of tablets containing ITZ EPAS powders offers great promise for 
pharmaceutical development and manufacturing to improve dissolution rates of 
poorly water soluble drugs for oral delivery systems.  
Controlled precipitation (CP) is another precipitation technology where a 
drug solution in a water miscible organic solvent is mixed with an aqueous 
solution containing a surfactant(s). Upon mixing, the supersaturated solution leads 
to nucleation and growth of drug particles, which may be stabilized by surfactant 
or polymer. Enhanced in vitro dissolution and supersaturation can be achieved by 
forming high energy, amorphous drug particles with high surface areas. The 
stabilization of amorphous drug to prevent crystallization upon contact aqueous 
media and during storage was studied in Chapter 4. The objective of this study is 
to investigate the influence of different water-soluble polymers, including HPMC 
E5, PVP K15, PVA and PEG 8000, on the dissolution rate and supersaturation 
behavior of amorphous REP particles formed by CP. 
Ultra-rapid freezing (URF), is a cryogenic technology which enhances the 
dissolution of poorly water soluble drugs by producing nanostructured particles 
with high degrees of porosity. URF technology involves dissolving the drug and 
excipient in a suitable organic solvent or aqueous co-solvent and applying to the 
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surface of cryogenic solid substrate. A solution of drug is frozen instantaneously 
onto the surface of cryogenic solid substrate in a continuous manner, giving the 
final product a uniform character. URF powders exhibit desirable properties for 
enhancing bioavailability such as high surface area and increased drug dissolution 
rates. In Chapter 5, the feasibility of URF in producing nanostructured drug 
particles which suitable for administering via inhalation were studied in a mouse 
model. More specific objective was to compare the effects of the differences in 
the properties of two types of particles (amorphous vs crystalline) on 
supersaturation and drug absorption. Lung and whole blood concentrations 
following single pulmonary were also evaluated. The application of particle 
engineering technology for pulmonary drug delivery represents new potential 
opportunities for therapeutic application not only for immunosuppressive drugs 
but also other poorly water soluble drugs. The successful delivery system may 
provide a convenient, noninvasive method for the administration of drugs to the 
lungs to treat local diseases and/or to provide systemic drug delivery without the 





CHAPTER 2:  Stabilizer Choice for Rapid Dissolving High 
Potency Itraconazole Particles Formed by Evaporative 
Precipitation Into Aqueous Solution 
2.1 ABSTRACT   
The objective of this study was to investigate the influence of stabilizer 
type on the physicochemical properties, including dissolution, of ultra-high 
potency powders containing itraconazole (ITZ) formed by Evaporative 
Precipitation Into Aqueous Solution (EPAS). ITZ was dissolved in 
dichloromethane, which was then atomized through a heated coil at 80°C into an 
aqueous solution over precise periods of time. Stabilizers were present in either 
the aqueous, organic or both phases.  The dispersions were centrifuged and the 
supernatant was removed. Three hydrophilic stabilizers were investigated, 
including polysorbate 80, polyvinyl pyrrolidone and poloxamer 407. Rapid 
dissolving ultra-high potency of ITZ powders was successfully produced. Greater 
than 80% of ITZ was dissolved in 5 min. compared to only 13% of ITZ bulk 
powders. The resulting stabilizer-coated drug particles had high drug-to-stabilizer 
ratios greater than 12, corresponding to potencies (wt drug/wt drug + wt 
surfactant) as high as 93%.  An increase in dissolution rate was correlated with 
the amount of stabilizer adsorbed and the wettability. The combination of 
polysorbate 80 and poloxamer 407 present in the aqueous and organic phases, 
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respectively, was superior in achieving high wetting and rapid dissolving ITZ 
powders. The ability to control the adsorption behavior of stabilizers by using 
synergistic combinations affords the opportunity to achieve high dissolution rates 
with higher potencies compared to previously reported values.  
 
2.2 INTRODUCTION   
Itraconazole (ITZ) is an orally active triazole antifungal agent with a 
potent broad spectrum of activity against Candida species and Aspergillus species 
which are the two most common human fungal pathogens. It has a molecular 
formula C35H38Cl2N8O4 and molecular weight of 705.64. ITZ is categorized as a 
Class II compound by the Biopharmaceutics Classification System (BCS), and is 
water insoluble (Solubility ~ 1 ng/mL at neutral pH) but highly permeable [1]. 
This compound is a weak base (pKa=3.7) and reportedly has an octanol:water 
partition coefficient (log P) of greater than 5 at pH 6 [2]. ITZ was chosen as the 
model drug for this study due to its low solubility and poor wetting in water, and 
hence low and variable bioavailability [3]. There have been many attempts to 
improve the bioavailability and dissolution rate of poorly water soluble drugs like 
ITZ. These include reducing the particle size by mechanical means to increase 
surface area [4]; solubilization in surfactant systems [5,6]; formation of water-
soluble complexes [7] and manipulation of solid state of the drug substance by 
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inhibiting crystallization to form amorphous particles [8].  Particle size reduction 
is a promising way to increase dissolution rates of poorly water soluble drugs 
[9,10]. 
Evaporative precipitation into aqueous solution (EPAS) is a particle 
engineering technology reported to produce submicron to micron-sized drug 
particles stabilized by surfactants or polymers and dispersed in an aqueous 
medium [11-13].  During processing, drug dissolved in an organic solvent is 
sprayed through an atomizing nozzle into an aqueous solution containing a 
hydrophilic stabilizer to produce an aqueous dispersion (Figure 2.1). Rapid 
evaporation of the organic solvent at elevated temperature produces very high 
supersaturation and rapid precipitation of the drug in the form of suspended 
particles. The particles may be stabilized by a variety of stabilizers present in 
either or both the organic and aqueous phases. The stabilizers adsorb onto the 
newly formed drug particle surfaces consequently decreasing the surface energy 
and providing steric and/or electrostatic repulsion between particles. This process 
may be dictated by the thermodynamic and kinetic aspects of stabilizer 
adsorption: the stabilizer must adsorb on the newly created surface and attain a 
conformation that is conducive to steric stabilization. The primary objective of 
this study is to prepare rapid dissolving ultra-high potency ITZ powders by the 
EPAS process.  We desire to have extremely high drug-to-stabilizer ratios greater 
than 12, corresponding to potencies (wt drug/wt drug + wt surfactant) above 90%.  
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In a previous study, Chen et al.[14], reported potencies of ITZ produced by the 
EPAS process ranging from 40 up to only 72%. We believe that by choosing the 
optimal stabilizer type, and by optimizing the phase that the stabilizer is present 
in, that even higher potencies can be achieved for highly wettable and rapidly 
dissolving ITZ powders.  It is challenging to increase the drug-to-stabilizer ratio 
to values of up to 12, while at the same time maintaining high surface areas, 
stabilized particles with enhanced wetting and high dissolution rates. We 
hypothesize that the ultra-high potency ITZ powders, greater than those reported 
by Chen et al., with low levels of adsorbed stabilizer can be produced by an 
optimum choice of stabilizer(s) which can adsorb very rapidly onto the ITZ 
particle surfaces during the very short spray times employed in the EPAS process. 
The very small amount of adsorbed stabilizers was sufficient to form a 
hydrophilic layer on the particle surface resulting in increased particle wettability 
and dissolution.  
 
2.3 MATERIALS AND METHODS   
2.3.1 Materials 
 
ITZ was purchased from Hawkins, Inc. (Minneapolis, MN).  The stabilizers 
including a nonionic surfactant (polysorbate 80;  MW = 1,310) and a 
homopolymer; polyvinyl pyrrolidone (PVP K-15, MW =15,000) were purchased 
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from Spectrum Chemicals (Gardena, CA). The polyoxyethylene-
polyoxypropylene copolymer (poloxamer 407, MW =11,700) was purchased from 
BASF (Mount Olive, NJ).  HPLC grade acetonitrile was obtained from EM 
Industries Inc. (Gibbstown, NJ) and dichloromethane was purchased from Fisher 
Scientific Co. (Houston, TX).  Other chemicals and solvents were of analytical 
reagent grade. Purified water was obtained from an ultra-pure water system 
(Milli-QUV plus, Millipore S. A., Molsheim Cedex, France).   
 
2.3.2 Particle Formation using EPAS Process 
 
 A schematic diagram of the EPAS apparatus is shown in Figure 2.1.  The 
EPAS process consisted of spraying a 15.0% (w/w) solution of ITZ containing 
2% w/v stabilizer dissolved in dichloromethane via an HPLC pump (Model PU-
2086, Jasco Inc., Baltimore, MD) through a 1/16 inch outer diameter (o.d.) × 
0.030 inch inner diameter (i.d.) preheating coil contained within a 1-1/2 inch o.d. 
× 15 inch long plastic water jacket (Model 95023D, Alltech Associates Inc., 
Deerfield, IL) into 50 mL of  2.0 w/w% aqueous solution of stabilizers. Water 
was circulated through the jacket with a temperature controller (Julabo MP, 
Julabo USA Inc., Allentown, PA).  The temperature of the water bath and the 
heating jacket was maintained at 80 °C. The nozzle was made by cutting stainless 
steel tubing (1/16 inch o.d. ×0.030 inch i.d.) [15] to form an elliptical conical 
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orifice. The crimped end of the nozzle was filed back until the desired flow rate of 
1 mL/min was achieved giving a pressure drop of about 20 MPa across the 
orifice. This type of nozzle produces very high pressure drops resulting in intense 
atomization of the organic drug solution at the tip of the nozzle. The nozzle was 
submerged approximately 10 cm under the surface of the aqueous solution.  After 
atomizing for 5 min., an aqueous dispersion containing a drug-to-stabilizer ratio 
of 0.68 was recovered. The dispersions were centrifuged (Model J2-21, Beckman, 
Fullerton, CA) at 10000 rpm for 20 min. to concentrate the particles, as described 
previously for particles formed by EPAS [13]. The supernatant was decanted to 
remove the unbound stabilizer in order to increase the potency (wt drug/wt drug + 
wt surfactant)  in the precipitate.  The particles were frozen by submerging in 
liquid nitrogen and then lyophilized.  
2.3.3 Potency Test 
 
 The potency of dry powders (wt drug/wt drug + wt surfactant) was determined 
by dissolving a known amount of dry powder (ca. 10mg) into 50mL of mobile 
phase and then determining ITZ concentration by HPLC. Reverse-phase HPLC 
was conducted using a Shimadzu VP-AT series LC10 HPLC (Columbia, MD) to 
measure the quantity of ITZ in the prepared sample. The mobile phase consisted 
of acetonitrile: water (70:30 v/v) containing 0.02% diethylamine. The flow rate 
was 1.0 mL/min and the detector wavelength was 263 nm. ITZ was eluted from 
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an Inertsil 5um ODS-2 column (4.6 mm i.d. x 150 mm; Alltech Associates, Inc., 
Deerfield, IL) at 5 min using an injection volume of 50 µl.  
2.3.4 Adsorption Studies 
 
 To measure the amount of stabilizer adsorbed onto the particles 
immediately after EPAS processing, 15% w/v itraconazole solution containing 
2% stabilizer dissolved in dichloromethane was sprayed into 50 mL aqueous 
solution containing 2% stabilizer at a flow rate of 1 mL/min. After 5 min. of 
spraying, the EPAS dispersion with a drug-to-stabilizer ratio of 0.68 (drug: 
organic stabilizer: aqueous stabilizer of 0.75:0.1:1), and total concentration of 
itraconazole of 15 mg/mL was recovered.  The pressure drop was 20 MPa and the 
temperature of both organic and aqueous phases was 80oC.  Immediately after the 
dispersions were formed, aliquots of 4 mL of the dispersion were centrifuged at 
10,000 rpm for 20 min for complete separation of the solids, leaving a clear 
supernatant at the top. After centrifugation, the supernatant and precipitate were 
weighed before and after drying at 40oC to determine the amount of stabilizer 
adsorbed gravimetrically.    
A separate set of experiments was designed to determine the equilibrium 
adsorption isotherm for each pure stabilizer as a function of stabilizer 
concentration. 2% (w/v) ITZ dissolved in dichloromethane was sprayed into 15 
mL aqueous solution containing stabilizer at a flow rate of 1 mL/min. Various 
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concentrations (from 0.1% to 3%) of stabilizers dissolved in the organic phase 
were used to prepare the EPAS samples in triplicate. After 5 min. of spraying, the 
EPAS dispersion was agitated at 37 oC for 24 hr, to allow adsorption to reach 
equilibrium. Aliquots of 4 mL of the dispersion were centrifuged at 10,000 rpm 
for 20 min. to concentrate the solids. After centrifugation, the supernatant and 
precipitate were weighed before and after drying at 40oC to determine the amount 
of stabilizer adsorbed gravimetrically.   
 Stabilizer adsorption was measured gravimetrically based on the mass 
balance between the supernatant and particles. The composition of the small 
amount of supernatant left on the precipitate was assumed to be the same as that 
in the bulk supernatant and the amount of ITZ in the precipitate was at least 50 
times more than ITZ dissolved in micelles. The amount of adsorbed stabilizer on 













Wsup,wet =  weight of the supernatant before drying 
Wsup,dry  = weight of the supernatant after drying to remove water 
Wppt,wet = weight of the precipitate before drying 
Wppt,dry  = weight of the precipitate after drying 
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Wdrug,ppt = amount of ITZ in the precipitate measured by HPLC 
Wsurf,ads =      amount of adsorbed surfactant or stabilizer on ITZ 
 
2.3.5 Dissolution Testing 
 
Dissolution testing (Vankel 7000, Vankel Technology Group, Cary, NC) 
was conducted on isolated ITZ EPAS powders using the United States 
Pharmacopoeia (USP) apparatus II (paddles) at 50 rpm. Dry powder containing 
approximately 10 mg of ITZ was weighed out and placed into 900 ml of 
dissolution media that contained enzyme-free simulated gastric fluid with 0.5% 
sodium lauryl sulfate (pH 1.2). The dissolution media was maintained at 37 °C 
and degassed prior to use by sonication for 2 min.  Sink conditions were 
maintained throughout the testing.  Aliquots of the dissolution media (5 mL) were 
collected at 2, 5, 10, 20, 30, 60 and 120 min. intervals. After 60 min, the paddle 
speed was increased to 200 rpm to approximate complete dissolution of ITZ at the 
2 hour time point. The samples were filtered using 0.45µm filters (Gelman GHP 
Acrodisc 0.45µm, VWR, West Chester, PA). To ensure that no precipitation 
occurred during HPLC analysis, 0.1 mL of acetonitrile was added to 4 mL of 
filtered samples. These were mixed using a vortex mixer for approximately 5 sec. 
and again filtered through a 0.45µm filter into an HPLC vial for drug content 
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analysis by reverse phase HPLC. Dissolution profiles for ITZ EPAS powders 
were determined in replicates of 6. 
2.3.6 Transmission Electron Microscopy (TEM)  
 
A JEOL 2010F field emission transmission (JEOL) with Energy 
Dispersive X-ray Spectroscopy (EDS) (Peabody, MA ) was used to examine the 
primary particle size and determine the chemistry of the sample. The dry powders 
were redispersed in water and placed on a Cu grid, fixed on the TEM holder and 
inserted into the TEM column.  
2.3.7 Contact Angle Measurement 
 
Dry powder was compressed at 1000 kg compression force using a Carver 
Laboratory Press (Model M, ISI Inc., Round Rock, TX) with 6mm diameter flat-
faced punches.  A droplet of water (3 µl) was placed onto the surface of the 
compact and observed using a low power microscope.  The contact angle was 
determined by measuring the tangent to the curve of the droplet on the surface of 
the compact using a Goniometer (Model No.100-00-115, Ramè-Hart Inc., 
Mountain Lakes, NJ). 
2.3.8. Surface Area Analysis 
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The specific surface area was determined using a Nova 3000 surface area 
analyzer (Quantachrome Corporation, Boynton Beach, FL) to measure N2 
sorption at 77.40oK.  The surface area per unit powder mass was calculated from 
the fit of adsorption data to the Brunauer, Emmett, and Teller (BET) equation. 
2.3.9 Powder X-Ray Diffraction 
 
Powder X-ray diffraction was conducted using CuKα1 radiation with a 
wavelength of 1.54054 Å at 40 kV and 20 mA from a Philips 1720 X-ray 
diffractometer (Philips Analytical Inc., Natick, MA).  The sample powders were 
placed in a glass sample holder.  Samples were scanned from 5o to 50o (2θ) at a 
rate 0.05o/sec.  For comparative purposes, the three highest values for relative line 
intensity and the corresponding 2θ angle were compared.  
2.4 RESULTS AND DISCUSSION  
2.4.1 Adsorption Studies 
2.4.1.1 Adsorption Isotherms of Stabilizers onto ITZ Particle Surface after 24 
Hours Equilibration  
The adsorption isotherm for each of the stabilizers investigated with ITZ 
particles produced by EPAS is shown in Figure 2.2. The adsorption isotherms for 
poloxamer 407 and PVP followed Langmuir-behavior characterized by a steep 
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initial slope at low concentration and a plateau, indicating the point where most of 
the adsorption sites on the ITZ particle surface are occupied. In the adsorption of 
polysorbate 80, the shape of the isotherm was more complex with changes in 
concavity.  The adsorption increased rapidly to an initial plateau and then further 
gradually increased toward a second plateau.  This adsorption behavior could be 
related to the increase of aggregate concentration typical of micelle formation. As 
can be seen in Figure 2.2, the polysorbate 80 adsorption exhibited a strong affinity 
to ITZ particle surfaces as indicated by the sharp initial slope and a higher 
adsorption at all concentrations. Polysorbate 80 molecules would be expected to 
adsorb onto the hydrophobic ITZ surfaces with the PEO groups extended into 
water to provide steric stabilization. Luckham et al. [16] found that lower 
molecular weight ethoxylated polymers adsorb on carbon black surfaces more 
strongly than higher molecular weight polymers. The nonadsorbing ethylene 
oxide block hinders the adsorption of the higher molecular weight stabilizers. This 
may explain why polysorbate 80, which has shorter PEO chains, adsorbed onto 
the particle surfaces to a greater extent than poloxamer 407 with PEO chains 
about 100 segments long.   In addition, polysorbate 80 with a lower HLB value 
(HLB=15) would be expected to adsorb more strongly onto the hydrophobic 
surface than poloxamer 407 and PVP.  The homopolymer PVP is very hydrophilic 
and has a small thermodynamic driving force for adsorption [17].  Sato and 
Kohnosu [18] reported that the amount of PVP adsorbed onto the hydrophobic 
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surface of TiO2 is low in aqueous solution, which is in agreement with the results 
obtained by Pattanaik and Bhaumik [19]. Therefore, low adsorption of PVP found 
in this study was also consistent with previously reported studies. 
 
2.4.1.2 Adsorption of Stabilizers onto ITZ Particle Surface after EPAS Process 
The adsorption (Wsurf,ads/Wdrug,ppt) of  stabilizers in each EPAS 
formulations was measured immediately after forming the dispersions, and the 
results are listed in Table 2.1. The results demonstrated that the combination of 
poloxamer 407 and polysorbate 80, present in the organic and aqueous phases, 
respectively, showed the highest adsorption (10.72% w/w) after the short spray 
time of 5 minutes. The much larger adsorption for this surfactant blend produced 
greater wettability and hence a faster dissolution rate in contrast with much 
smaller adsorption values for compositions containing poloxamer 407 in both 
phases, where only 6.46% w/w stabilizer-to-drug was adsorbed. Chen et al [13] 
found that the adsorption dynamics of the copolymer poloxamer 407 is rather 
slow when added alone in the aqueous phase. Chen et al showed that adsorption 
of poloxamer 407 increased from 3.87 to 11.21% w/w surfactant-to-drug after 
storage at 25oC for 72 hours. This increase might be caused by slow surface 
rearrangement of the adsorbed polymer layer to provide space for further 
adsorption [20]. Moreover, the increase in viscosity of poloxamer 407 at high 
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temperature could also cause the longer diffusion time. However, in the present 
study, we found that the combination of poloxamer 407 and polysorbate 80, 
present in the organic and aqueous phases, respectively, showed the highest 
adsorption immediately upon particle formation. Poloxamer 407 is added in the 
same (organic) phase as the ITZ where it precipitates from the evaporating 
organic droplets, and, hence, requires a relatively short time to diffuse and adsorb 
onto the nucleating particle surfaces. Moreover, employing a second surfactant 
like polysorbate 80 may facilitate orientation of poloxamer 407 at the solid-liquid 
interface, and enable a much shorter equilibration time to attain optimal surfactant 
conformation.  Chen et al required much longer equilibration times using 
poloxamer 407 alone, which resulted in larger particles. Polysorbate 80 is a much 
smaller molecule (MW: 1310) than poloxamer 407 (MW: 11,700).  The small size 
of polysorbate 80 may be expected to lead to faster diffusion [21] to the particle 
surface and faster adsorption kinetics at the surface, to inhibit the otherwise rapid 
crystallization. In addition, the adsorption for pure polysorbate 80 was 
substantially larger than for the other stabilizers as was shown in Figure 2.2.  
Several authors have reported results of the interactions of Pluronic block 
copolymer with surfactant systems [22,23]. In particular, Couderc et al. [24] 
reported on the synergistic behavior in mixed micelle formation of binary 
surfactant mixtures of poloxamer 407 and nonionic surfactant containing an EO 
group (C12EO6). Polymer–surfactant association is influenced by many factors 
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including interactions with ions, hydrogen bonding, the hydrophobicity of the 
polymer and the non-polar tail of the surfactant, and the structural conformation 
and flexibility of the polymer. It has also been reported that some non-ionic 
surfactants may significantly increase emulsifying capacity of polymeric 
surfactants [25]. Thus the highest adsorption produced with polysorbate 80 and 
poloxamer 407 is consistent with the previously observed favorable interactions 
between these stabilizers.   However, this interaction was not found in the 
combination of polysorbate 80 and PVP K15 which yielded low adsorption 
(5.86% w/w ).   It may possible that a layer of PVP K15 which was present in the 
organic phase with ITZ coated the nuclei first and that polysorbate 80 could not 
adsorb on the polymer layer. Moreover the small adsorption could also due to the 
competitive adsorption of these stabilizers onto surfaces of the ITZ particles [26].  
It is constructive to further compare the different intermolecular interactions of 
the surface of ITZ particles with poloxamer 407 and PVP K15. A small amount of 
adsorbed stabilizers was observed (5.70% w/w) compared to the combination of 
poloxamer 407 and polysorbate 80. This may be attributed to the lower adsorption 
after 24 hours for both poloxamer 407 and PVP K15, relative to polysorbate 80.  
Since PVP has higher molecular weight than poloxamer 407, it will take longer to 
diffuse and adsorb onto the ITZ particle surfaces.  The combination of PVP K15 
by itself also yielded low adsorption (5.38% w/w).  
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2.4.2 Dissolution Testing 
 
 Dissolution profiles of ITZ EPAS powders are presented in Figure 2.3. 
The dissolution rate of all formulations is significantly greater than that compared 
to the bulk powder.  A high dissolution rate was observed for all EPAS 
formulations in spite of the fact that the crystallinity of each of the EPAS powders 
was observed to be high, as will be discussed later in this paper. The dissolution 
rate was also correlated to the amount of stabilizer adsorbed. It was much higher 
for the formulation containing polysorbate 80 and poloxamer 407 than the other 
stabilizers. In five min., 80% of ITZ prepared by EPAS was dissolved as 
compared to 13% determined for the bulk powder.  Results presented below 
(Sections 3.3 and 3.4) indicate that this observation of the highest dissolution rate 
is consistent with the high wettability (lowest contact angle) and very small 
primary particle size of ITZ produced by EPAS, respectively.  
2.4.3 Transmission Electron Microscopy (TEM)  
 
TEM was used to investigate the primary particles and morphology of ITZ 
particles after redispersion of the dried EPAS powders in water. In Figure 2.4, the 
TEM micrograph of ITZ with polysorbate 80 and poloxamer 407 indicate 
aggregation of small particles after being redispersed in water. The particles were 
composed of small primary particles which aggregated during the drying process. 
This explains why the highest dissolution occurred in the formulation containing 
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polysorbate 80 and poloxamer 407 even though the particle size of dry powders 
was about 7 µm measured by laser diffraction, which most probably represented 
aggregates being measured by laser light diffraction. Since these aggregates were 
not easily deaggregated into their discrete particles, laser diffraction was not used 
to quantitate particle size.  Energy dispersive spectroscopy (EDS) was used to 
qualitatively determine and confirm the elemental compositions of particles in this 
image.  The EDS spectrum was obtained, the constituent elements identified and 
the occurrence classified into a compositional type. The EDS spectrum showed 
the presence of C, N, O and Cl , as shown in Figure 2.5. The presence of both N 
and Cl atoms which are only present in the ITZ molecule, is indicative that the 
large particle is ITZ which consisted of very small aggregated primary particles. It 
clearly showed that the bright spots of highest elemental intensity could be 
overlaid on the pattern of the ITZ structure. Other elements of Cu and Si were 
present on the film and supporting grid. The rapid evaporation of the heated 
organic solution in the EPAS process produces high supersaturation and rapid 
precipitation of ITZ in the form of a nanoparticle dispersion that is stabilized by a 
variety of stabilizers. The results also further confirmed the potential of EPAS 
process in producing nanoparticles of poorly water soluble drugs. 
2.4.4 Contact Angle Measurement 
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Surfactants or stabilizers generally improve wetting by adsorbing on the 
surface to cause a reduction in the solid-liquid interfacial energy. The contact 
angle results are shown in Table 2.2.  Adsorbed hydrophilic stabilizer on the 
particle surface reduced the contact angle indicating improved wettability 
compared to bulk powder. It is likely that different stabilizers and their 
combination may display variation in wetting particle surface.   The decrease in 
contact angle correlated with an increase in dissolution rate as reported in Table 
2.2. For the EPAS formulation of polysorbate 80 and poloxamer 407, the contact 
angles were lowest due to high adsorption and wetting of particle surfaces 
resulting in the highest dissolution rate profile. Reduction in contact angle from 
61.6o for bulk ITZ to 30.3o was achieved at a high drug potency of 90%, with a 
corresponding increase in drug dissolution from 14 to 80% in 5 minutes. This may 
be expected as the ITZ surface is largely hydrophobic in nature so the bulk 
powder does not break the interfacial tension of the dissolution media at the 
air/liquid boundary.  The ITZ particles without stabilizers float on the surface 
throughout the dissolution experiment. The contact angle of the corresponding 
physical mixture of ITZ with polysorbate 80 and poloxamer 407 was 52.3°, 
indicating a much less hydrophilic surface.  Therefore increasing the accessibility 
for wetting by the dissolution media is an important factor to enhance the 
dissolution rate of ITZ.  Miyazaki et al. [27] reported that the dissolution rate 
enhancement of phenylbutazone was mostly due to the enhanced wetting. 
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2.4.5 Surface Area Analysis 
 
The surface areas of the dry powders were determined by BET and the 
results are shown in Table 2.2. The surface areas of ITZ EPAS formulations were 
higher than that of the bulk powder except for the formulations containing 
polysorbate 80. Polysorbate 80 is a liquid at room temperature, and consequently, 
it caused aggregation of the dry powder at room temperature, and subsequently 
low surface area as shown in Table 2.2. The calculated surface area for 
monodisperse spheres of ITZ with particle diameter about 8 µm would be 2.3 
m2/g.  The larger surface area for the powders suggests that the particles were not 
uniform spheres but were aggregates composed of smaller primary particles as 
can be seen from the TEM results.  This morphology results in high dissolution of 
all EPAS formulations compared to the bulk powders. The dissolution rates for 
the systems with higher surface areas on the order of 5-6 m2/g, were lower than 
for the formulation of polysorbate 80 and poloxamer 407 which had somewhat 
lower surface areas.  The reduced wetting and dissolution can be attributed to the 
observation that these powder samples remained for a longer time on the top of 
dissolution medium before being wetted completely.   
2.4.6 Powder X-Ray Diffraction 
 
 X-ray diffraction was used to analyze the crystallinity of the dry powders. 
As shown in Figure 2.6, all profiles show no change in crystallinity.  The 
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crystalline peak positions were the same as for the bulk ITZ.   The degree of 
crystallinity for these samples did not appear to correlate with dissolution results. 
As shown by the dissolution results, all EPAS formulations yielded very good 
dissolution profiles, indicating that high dissolution rates may be achieved for 
high surface area crystalline powders. Moreover, in terms of thermodynamics, the 
crystalline solids are preferable since they are more physically and 
thermodynamically stable compared to amorphous solids which may re-
crystallize. Amorphous or disordered material is a metastable state and tends to 
revert back to the more stable crystalline state under unfavorable humidity and 
temperature conditions. Water, from the atmosphere, can be absorbed and reduce 
the glass transition temperature [28] thus decreasing the energy barrier to re-
crystallization [29]. However, the stability of amorphous materials can be 
enhanced by storage well below the glass transition temperature (Tg) and by using 
high Tg material such as polyvinylpyrrolidone, polyethylene glycol and various 
cellulose derivatives like hydroxypropyl methylcellulose, hydroxypropylcellulose, 
etc. [30,31]. 
2.4.7 Potency of ITZ Powders and Drug-to-Stabilizer Ratio after 
Centrifugation 
 The potencies of the powders after centrifugation are listed in Table 2.2. 
The potency of ITZ in the dry powders was greater than 90%, corresponding to a 
drug-to-stabilizer ratio greater than 9:1. The high potencies result from the 
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removal of a large amount of non-adsorbed stabilizer in the supernatant. This 
concept has been successfully used to produce high potency danazol and ITZ in 
the EPAS studies [13,14]. Chen et al reported the potency of itraconazole particles 
was increased to only 70% after 25 minutes of spraying followed by removal of 
the unbound surfactant. In the present study, we were able to increase the potency 
up to 90%, while maintaining high dissolution rates and small primary particle 
sizes. In the present study, we used high ITZ concentration in the feed solution 
(drug-to-organic stabilizer ratio of 7.5) with a short spray time only 5 min. These 
conditions allow less time for stabilizers to adsorb onto the particles and can led 
to the extremely high potency values up to 93% with rapid dissolution. The final 
drug-to-stabilizer ratios varied from 9:1 to 15:1. In general, the ratio of drug-to-
stabilizer ranges from 1:10 to 1:1 when drugs are dissolved in micelles, vesicles 
or liposomes [32,33]. There are several advantages of the formulation with high 
drug-to-stabilizer ratio such as low administration dose and less potential 
interactions from the excipients.  Potential stability problems can result from 
interactions of drug substances with excipients in solid dosage forms [34]. 
2.5CONCLUSIONS  
 Rapid dissolving formulations containing ultra high potency of ITZ 
powders were achieved using the EPAS process.   Polysorbate 80, poloxamer 407, 
PVP K-15 and their combinations showed differences in the degree of improving 
wettability and dissolution of ITZ depending on their adsorption onto the particle 
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surface. The adsorption of stabilizers is influenced by the HLB of the stabilizer 
and the hydrophobicity of the particle surface. For very lipophilic compounds, 
such as ITZ (log P>5), polysorbate 80, with a lower HLB value, was adsorbed 
more strongly than poloxamer 407 and PVP. The synergistic stabilization effect 
was demonstrated to be optimal for combinations of polysorbate 80 and 
poloxamer 407, when incorporated into the aqueous and organic phases, 
respectively. The stabilization observed for this mixed stabilizer system has been 
explained in terms of strong adsorption for the small polysorbate 80 to 
compensate for the limited amount of adsorption for the copolymer poloxamer 
407 after 24 hours. EPAS followed by removal of free stabilizer produced high 
potencies up to 93% and rapid dissolution rates. The highest dissolution rates, i.e. 
80% in 5 minutes were obtained for ITZ produced by EPAS with polysorbate 80 
and poloxamer 407, as stabilizers in the aqueous and organic phases respectively. 
The dissolution rates are enhanced due to the small primary particle size and by 
adsorbed stabilizers that raise the surface hydrophilicity, as shown by a decrease 
in the contact angle. The optimum choice of stabilizer(s) which adsorb rapidly 
onto the ITZ particle surfaces during the very short spray times employed in the 
EPAS process can help produce the extremely high drug-to-stabilizer ratios 
greater than 12, corresponding to potencies above 90%.  The very small amount 
of adsorbed stabilizers was sufficient to form a hydrophilic layer on the particle 
surfaces resulting in increased particle wettability and dissolution. These results 
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provide evidence that the selection of appropriate stabilizer(s) is an important 
consideration in formulation development. 
 This study also demonstrated the usefulness of the EPAS process as a 
method in controlling particle characteristics and enhancing drug dissolution.  
This process is a very versatile drug delivery platform and is suitable for many 
commonly used routes of administration such as oral, nasal and pulmonary 
delivery.  
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CHAPTER 3:  Rapidly Disintegrating and Dissolving Tablets 
Containing Itraconazole Particles Formed by Evaporative 
Precipitation Into Aqueous Solution 
 
3.1 ABSTRACT  
In this study, the rapidly disintegrating and dissolving tablets containing 
itraconazole (ITZ) particles produced by evaporative precipitation into aqueous 
solution (EPAS) were prepared by direct compression. The objective was to 
examine the effects of formulation factors including stabilizer types and levels 
used in EPAS process on the physicochemical properties of these tablets. During 
EPAS process, ITZ (15%w/v) and stabilizer (2%w/v) were dissolved in 
dichloromethane solution. This ITZ/stabilizer/organic feed solution was pumped 
through a heating coil at 80°C and atomized by a crimped nozzle into an aqueous 
solution containing stabilizer (2%w/v). Different stabilizers were investigated, 
including polyvinyl pyrrolidone K15, poloxamer 407 and poloxamer 188. The 
resulting EPAS dispersion was dried to powder.  The dissolution rate, contact 
angle, surface area, X-ray diffraction, scanning electron microscopy and particle 
size were determined for each EPAS micronized powder composition. Tablets 
were prepared by direct compression using a single-punch tabletting machine. 
Rapidly disintegrating and dissolving tablet formulation contained ITZ EPAS 
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powders (40%w/w), microcrystalline cellulose (34% w/w), lactose monohydrate 
(20% w/w), sodium starch glycolate (5%w/w), silicone dioxide (0.5%w/w) and 
magnesium stearate (0.5%w/w). The tablets were characterized by hardness, 
friability, disintegration and dissolution. Rapidly disintegrating and dissolving 
tablets were successfully developed using EPAS processed powders containing 
nanoparticles of ITZ. Greater than 70-80% of ITZ was dissolved at 5 min, 
compared to only 14% and 80% of the bulk ITZ at 5 and 120 min, respectively.  
EPAS processed powders containing ITZ with poloxamer 407 yielded the highest 
surface area (8.79 + 0.42 m2/g) and the lowest contact angle (30.2 + 0.62o) 
subsequently achieving the highest dissolution rate. Tablets compacted from 
EPAS processed powders showed the similar release profiles with a complete 
dissolution of ITZ within the test time. All tablets had friability about 0.14-0.23%, 
hardness about 10-12 kg and disintegration time about 20-25 s. EPAS processed 
powders demonstrated to be suitable as matrix material for preparing rapidly 
disintegrating and dissolving tablets with sufficient mechanical integrity and well 
reproducible drug dissolution profiles.  
 
3.2 INTRODUCTION   
 Development of solid dosage forms for poorly water-soluble drugs has been 
a major challenge and often results in low bioavailability since the rate of drug 
absorption from the gastrointestinal tract can be severely limited by dissolution 
 100
rate (1-3). There has been an increasing interest in the development of 
nanoparticles during the past few decades. Small particle engineering processes 
enable poorly soluble drugs to increased solubility and dissolution rate, resulting 
improving drug bioavailability. There are various reviews for particle engineering 
technologies (4-7). Evaporative precipitation into aqueous solution (EPAS) 
technology is a promising approach to engineer small particles with high 
dissolution rates offers a great potential in the development of oral drug delivery 
and overcome this problem. EPAS is a particle formation process developed to 
produce submicron to micron-sized hydrophobic drug particles. EPAS has been 
successfully used to enhance dissolution for numerous drugs including 
cyclosporine, carbamazepine, itraconazole and danazol (8-13). The EPAS process 
creates small particles through rapid phase separation. Evaporation of the primary 
solvent results in loss of solvent power and precipitation of very small particles of 
the dissolved solute. Briefly, drug dissolved in an organic solvent is sprayed 
through an atomizing nozzle into an aqueous solution containing a hydrophilic 
stabilizer to produce an aqueous dispersion. Rapid evaporation of the organic 
solvent at elevated temperature produces very high supersaturation and rapid 
precipitation of the drug in the form of suspended particles. The particles may be 
stabilized by a variety of stabilizers from either or both of organic and aqueous 
phases. The stabilizers adsorb onto the newly formed drug particle surfaces 
consequently decreasing the surface energy and providing steric and/or 
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electrostatic repulsion between particles to minimize particle aggregation. The 
enhanced dissolution rate characteristic of EPAS can generally be accounted for 
by one of the following mechanisms; increase the surface area available for 
dissolution by decreasing the particle size of drug, precipitation as a metastable 
crystalline form or a decrease in substance crystallinity and by optimizing the 
wetting characteristics of the drug surface due to adsorption of hydrophilic 
stabilizer. EPAS dispersion can be administered in the form of an aqueous 
dispersion as the final dosage form or incorporate into solid dosage forms for oral 
delivery.  
 Among the currently used solid dosage forms, rapidly disintegrating and 
dissolving tablets offer the major advantage over traditional tablets and capsules 
through their convenience in administration and suitability for patients who have 
swallowing difficulties such as children, elderly patients, and psychotic or 
disabled patients. Also, patients who are traveling, or who have little or no access 
to water are good candidates for rapidly disintegrating and dissolving tablets. 
These tablets in the market are prepared by various techniques including 
lyophilization, molding and direct compression. The commercially available 
tablets which disintegrate in less than 1 min are brittle, friable and have low 
physical resistance. These products require special packaging resulting in higher 
costs.  
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 In this study, the rapidly disintegrating and dissolving tablets of ITZ with 
sufficient mechanical integrity were developed, involving the use of EPAS 
process to improve drug dissolution for the production of tablets. The main 
objective was to investigate the influence of the stabilizer types and levels on the 
physicochemical properties of EPAS processed powder and its corresponding 
tablet. We hypothesized that the high dissolution properties of EPAS particles can 
be maintained after incorporate into tablets using direct compression method.  
Itraconazole (ITZ), a Biopharmaceutics Classification System Class II (BCS) 
drug, was selected as the model drug in this study due to its extremely low water 
solubility. The absolute bioavailability of ITZ given orally is reported to be about 
16% (18-19).  Previously, we have also demonstrated the effect of design 
stabilizer on the properties and dissolution rates of ITZ particles produced by 
EPAS process. The resulting stabilizer-coated drug particles achieved high 
dissolution rates even with unusually high potencies by using a synergistic 
combination of properly chosen stabilizers. 
 
3.3 MATERIALS AND METHODS   
3.3.1 Materials 
 
 ITZ was purchased from Hawkins, Inc. (Minneapolis, MN).  The stabilizers 
including a homopolymer; polyvinyl pyrrolidone (PVP K-15, MW =15,000) was 
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purchased from Spectrum Chemicals (Gardena, CA). The polyoxyethylene-
polyoxypropylene copolymer (poloxamer 407, MW =11,700) and (poloxamer 
188, MW =11,700) were purchased from BASF (Mount Olive, NJ).  Lactose 
Monohydrate and magnesium stearate were purchased from Spectrum Quality 
Products Inc. (Gardena, CA). Microcrystalline cellulose (Avicel PH101) was 
obtained from FMC BioPolymer (Newark, DE) and sodium starch glycolate 
(Explotab) were purchased from Penwest Pharmaceuticals Co. (Patterson, NY).  
Colloidal silicon dioxide (Cab-o-sil) was obtained from Cabot Corporation 
(Tuscola, IL).  HPLC grade acetonitrile was obtained from EM Industries Inc. 
(Gibbstown, NJ) and dichloromethane was purchased from Fisher Scientific Co. 
(Houston, TX).  Other chemicals and solvents were of analytical reagent grade. 
Purified water was obtained from an ultra-pure water system (Milli-QUV plus, 
Millipore S. A., Molsheim Cedex, France).   
 
3.3.2 Particle Formation Using EPAS Process 
 
 A schematic diagram of the EPAS apparatus is shown in Figure 3.1.  The 
EPAS process consisted of spraying a 15.0% (w/w) solution of ITZ containing 
2% w/v stabilizer dissolved in dichloromethane via an HPLC pump (Model PU-
2086, Jasco Inc., Baltimore, MD) through a preheating coil (1/16 inch outer 
diameter (o.d.) × 0.030 inch inner diameter (i.d.) contained within a 1-1/2 inch 
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o.d. × 15 inch long plastic water jacket (Model 95023D, Alltech Associates Inc., 
Deerfield, IL) into 50 mL of  2.0 w/w% aqueous solution of stabilizers. Water 
was circulated through the jacket with a temperature controller (Julabo MP, 
Julabo USA Inc., Allentown, PA).  The temperature of the water bath and the 
heating jacket was maintained at 80 °C. The nozzle was made by cutting stainless 
steel tubing (1/16 inch o.d. ×0.030 inch i.d.) (10) to form an elliptical conical 
orifice. The crimped end of the nozzle was filed back until the desired flow rate of 
1 mL/min was achieved giving a pressure drop of about 20 MPa across the 
orifice. This type of nozzle produces very rapid pressure drops resulting in intense 
atomization of the organic drug solution at the tip of the nozzle. The nozzle was 
submerged approximately 10 cm under the surface of the aqueous solution.  After 
atomizing for 5 min., an aqueous suspension containing a drug-to-stabilizer ratio 
of 0.68 was recovered. For higher potency, the suspensions were centrifuged 
(Model J2-21, Beckman, Fullerton, CA) at 10000 rpm for 20 min. to concentrate 
the particles, as done previously for particles formed by EPAS (11-13). The 
supernatant was decanted off to remove the unbound stabilizer in order to increase 
the potency in the precipitate.  The particles were frozen by submerging in liquid 




3.3.3 Characterization of EPAS Powders 
 
3.3.3.1 Scanning Electron Microscopy (SEM) 
 A Hitachi Model S-4500 field emission scanning electron microscope 
(Hitachi Instruments, Irvine, CA) was used to visualize the particles and evaluate 
surface morphology of the particles.  Samples were sputter coated with gold after 
being deposited on carbon tape on a microscope stage. The samples were sputter 
coated for 30 seconds. 
3.3.3.2 Particle Size Analysis 
 The particle size was determined by light scattering with a Mastersizer-S 
(Model MAM2145, Malvern Instruments Inc., Southborough, MA). The particle 
size distribution was calculated on a volume weighted basis. To measure the 
particle size distribution, 5 mL of the suspension was diluted with 500 mL 
saturated ITZ solution, to produce a light obscuration in the range of 10-30%.  
The diluted suspension was sonicated for 30 sec. to break up any agglomerated 
particles. To study the redispersibility of the dry powders after centrifugation and 
lyohilization, about 20 mg dry powder were redispered into 500 mL saturated ITZ 
solution to produce an obscuration in the range 10-30%.  After 1 min, the particle 
size distribution was measured.  Ultrasound was used in the measurement to break 
up the agglomerated particles. 
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3.3.3.3 Potency Test  
 The potency of dry powders was determined by dissolving a known 
amount of dry powder (ca. 10mg) into 50 mL of mobile phase and then 
determining measuring ITZ concentration by HPLC. Reverse-phase HPLC was 
carried out using a Shimadzu VP-AT series LC10 HPLC (Columbia, MD) to 
measure the amount of ITZ. The mobile phase consisted of acetonitrile: water 
(70:30 v/v) containing 0.02% diethylamine. The flow rate was 1.0 mL/min and 
the detector wavelength was 263 nm. ITZ was eluted from an Intertsil 5um ODS-
2 column (4.6 mm i.d. x 150 mm; Alltech Associates, Inc., Deerfield, IL) at 5 min 
using an injection volume of 50 µl.  
3.3.3.4 Contact Angle 
 
Dry powder was compressed at 1000 kg compression force using a Carver 
Laboratory Press (Model M, ISI Inc., Round Rock, TX) with flat-faced 6mm 
diameter punches.  A droplet of dissolution medium (3 µl) was placed onto the 
surface of the compact and observed using a low power microscope.  The contact 
angle was determined by measuring the tangent to the curve of the droplet on the 
surface of the compact using a Goniometer (Model No.100-00-115, Ramè-Hart 
Inc., Mountain Lakes, NJ). 
 
 3.3.3.5 Surface Area Analysis 
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The specific surface area of EPAS powders was determined using a Nova 
3000 surface area analyzer (Quantachrome Corporation, Boynton Beach, FL) to 
measure N2 sorption at 77.40 deg K.  The surface area per unit powder mass was 
calculated from the fit of adsorption data to the Brunauer, Emmett, and Teller 
(BET) equation. Samples were degassed by applying vacuum at room temperature 
for 24 hr. prior to determination of the specific surface area. Three samples of 
each EPAS formulation were analysed. 
3.3.3.6 Powder X-Ray Diffraction 
 
Powder X-ray diffraction was conducted using CuKα1 radiation with a 
wavelength of 1.54054 Å at 40 kV and 20 mA from a Philips 1720 X-ray 
diffractometer (Philips Analytical Inc., Natick, MA).  The sample powders were 
placed in a glass sample holder.  Samples were scanned from 5o to 50o (2θ) at a 
rate 0.05o/sec.  For comparative purposes, the three highest values for relative line 
intensity and the corresponding 2θ angle were compared.  
3.3.4 Preparation of Tablets 
The tablets with a theoretical weight of 200 mg containing ITZ EPAS 
powders were prepared with 30 mg drug content .The model formula of tablet 
formulations used in this study comprised ITZ EPAS powders, directly 
compressible diluents, and magnesium stearate was used as lubricant. Diluents 
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used are: avicel PH-101 and lactose monohydrate as the fillers; sodium starch 
glycolate as a disintegrant and cab-o-sil as a glidant.  The powder mixtures, 
except for magnesium stearate, were geometrically diluted and introduced into a 
V- Blender (York Model, Patterson-Kelly Company, East Stroudsburg, PA) and 
mixed for 10 min.  Magnesium stearate was then added and mixed for an 
additional 5 minute. The blended powders were compressed using a single-punch 
tabletting machine (Strokes-F, Philadelphia, PA) equipped with 9 mm shallow 
concave punches. The prepared tablets were stored in a desiccators at room 
temperature for at least 48 h before being subjected to any characterization to 
remove any residual humidity. The uniformity of tablet weight was investigated. 
The average tablet weight was determined from 20 individually weighed tablets. 
The tablets were characterized by evaluation of hardness, friability, disintegration 
and dissolution. Means and relative standard deviations were calculated. 
3.3.5 Characterization of Tablets 
 
3.3.5.1 Tablet Friability 
Tablet friability was calculated as the percentage weight loss of tablets 
after 100 rotations in a friabilator (Vanderkamp, Model 10801, Van-kel Industrial 
Inc., Chatham, NJ).  According to section <1216> of the USP 24/NF19 (20), the 
tablet friability was determined for 33 tablets (corresponding to 6.5 g). The tablets 
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were carefully dedusted prior to testing. Accurately weigh the tablet sample, and 
place the tablets in the drum. Rotate the drum at a speed of 25 rpm for 4 min., and 
remove the tablets. Remove any loose dust from the tablets as before, and 
accurately weigh. Tablet friability (n=3) was calculated as the percentage weight 
loss of 20 tablets after 100 rotations in a friabilator. 
3.3.5.2 Tablet Tensile Strength 
The tablet tensile strength was calculated from its diametral crushing force 
measured using a hardness tester (Herberlein). Ten tablets from each formulation 
were analysed.  
3.3.5.3 Disintegration Time 
The disintegration time (n=6) was tested using the disintegration test 
apparatus (Vander, Model 71A-174A-3, Chatham, N.J.).Water kept at 37 °C was 
used as a medium and the basket was raised and lowered at a constant frequency 
of 30 cycles/min. Six tablets from each formulation were evaluated.   
 
3.3.6 Dissolution Study 
Dissolution testing of ITZ from the EPAS processed powders and the 
tablets was determined using the United States Pharmacopoeia (USP) apparatus II 
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(Vankel 7000, Vankel Technology Group, Cary, NC) at 50 rpm. The dissolution 
media was composed of 900 mL of enzyme-free simulated gastric fluid 
containing 0.5% SLS (pH 1.2) and was degassed prior to use. The dissolution 
media was maintained at 37 °C. Sink conditions were maintained throughout the 
testing.  Aliquots of the dissolution media (5 mL) were collected at 2, 5, 10, 20, 
30, 60 and 120 min. intervals. After 60 min, the paddle speed was increased to 
200 rpm for 2 hours time point. These samples were filtered using 0.45µm filters 
(Gelman GHP Acrodisc 0.45µm, West Chester, PA). To ensure that no 
precipitation occurred during HPLC analysis, 0.1 mL of acetonitrile was added to 
4 mL of filtered samples. These were mixed using a vortex mixer for 
approximately 5 sec. and then filtered using a 0.45µm filter into an HPLC vial for 
drug content analysis by reverse phase HPLC. The mean of six determinations 
was used to calculate the drug release from each of the formulations.  
 
3.3.7  Statistical Analysis 
Statistical evaluation of the data was compared using a student’s t-test of 
the two samples assuming equal variances to evaluate the differences.  The 
significance level (α = 0.05) was based on the 95% probability value (p < 0.05). 
3.4 RESULTS AND DISCUSSION  
 
3.4.1 Characterization of EPAS Powders 
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The main composition of EPAS formulations other than drug is stabilizers. 
Several EPAS formulations containing different stabilizers were prepared and 
their compositions were given in Table 3.1. The type of stabilizer was varied from 
formulation E1 to formulation E3. The stabilizers included polyvinyl pyrrolidone 
K15 (PVP K15) as homopolymer, poloxamer 407 and poloxamer 188 as 
copolymers. The purpose behind the design of these two series of triblock 
copolymers was to evaluate the effect of both EO and PO block length (where EO 
is polyethylene oxide, PO is polypropylene oxide) on physicochemical of EPAS 
particles. The favorable effect of poloxamer 407 on dissolution rate has also been 
previously demonstrated (13). Therefore, it was worthy to extend our 
investigations and compare the performance of these polymers in improving 
dissolution behavior of ITZ. Poloxamers are nonionic triblock copolymers of poly 
(ethylene oxide) and poly (propylene oxide) used primarily in pharmaceutical 
formulations as surface active agents (21-22). The poly (ethylene oxide) segment 
is hydrophilic while the poly (propylene oxide) segment is hydrophobic. The two 
different types of poloxamers were investigated in this study. Poloxamer 407 and 
poloxamer 188 are chemically similar in composition, differing only in the 
relative amounts of EO and PO added during manufacture. Their physical and 
surface-active properties vary over a wide range and a number of different types 
are commercially available.  
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3.4.1.1 Particle Morphology, Size and Potency  
 The particle morphology of bulk ITZ and EPAS powder samples with 
different stabilizers (E1-E3) was examined by SEM (Figure 3.2). Bulk ITZ is 
shown to have a long needle-shaped crystal habit (Figure 3.2a). Large crystals of 
10-20 µm in length, with smaller crystals exhibiting a wide particle size 
distribution. In contrast, all cases of EPAS samples, the particles are composed of 
nanostructured aggregates containing nanoparticles of ITZ with stabilizer (Figure 
3.2b-3.2d). These aggregates have also been taken for the particle size 
determining by laser diffraction. Physicochemical characteristics of the EPAS 
processed powders are summarized in Table 3.2.The mean particle size of the 
EPAS processed powders ranged from 7 to 10 µm. According to the SEM 
micrographs, these particle sizes were very likely to represent the aggregate sizes 
of submicron particles. Different potencies of EPAS samples containing 
poloxamer 407 as stabilizer (E4-E6) are presented in Table 3.2. The high 
potencies result from the removal of a large amount of non-adsorbed stabilizer in 
the supernatant (11). The resulting EPAS powders had high drug-to-stabilizer 
ratios up to 10, corresponding to potencies up to 91%.  There was no significant 
difference in particle size (p>0.05) when potencies and drug-to-stabilizer ratio 
were increased.  
3.4.1.2 Contact Angle and Surface Area 
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The wettability of EPAS processed powders was assessed from the contact 
angle of dissolution media on the compacted surface of EPAS powders. The 
contact angle values for various samples are reported in Table 3.2. The mean 
contact angle value for bulk ITZ was 61.6° against water and it was observed that 
the powders were poorly wet in aqueous media. On the other hand, the measured 
contact angle of EPAS samples were in range of 30-40° indicating a high 
hydrophilic surface. Reduction in contact angle was achieved even in the highest 
potency sample with a drug-to-stabilizer ratio of 10.76. In all cases, EPAS 
samples had a significantly lower (p < 0.05) contact angle compared to bulk ITZ 
indicating the better wetting ability of EPAS samples. It was much lower in EPAS 
samples containing poloxamer 407 (E1 and E4-E6).  The result showed that 
poloxamer 407 acts as a good wetting agent for ITZ. Wong et al. (23) also 
revealed that the spray dried griseofulvin particles with poloxamer 407 had the 
highest dissolution rate and hence improving the absolute oral bioavailability of 
the drug in rats. 
 
The BET surface areas of various dry powders were analyzed and the results 
are illustrated in Table 3.2. The surface areas of EPAS samples were at least two 
times higher than that of the bulk ITZ. The large surface areas of the EPAS 
samples reflect the submicron primary particle domains of the nanostructured 
aggregates as observed in the SEM micrographs. The surface area was the highest 
for EPAS processed powders with poloxamer 407 system (8.79 m2/g), which was 
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significantly greater (p<0.05) than those of EPAS processed powders made by the 
other stabilizers investigated as reported in Table 3.2. This could be due to the 
stabilizing effect of the poloxamer 407 against particle growth during the particle 
formation step.  The presence of stabilizer in EPAS process inhibits crystal 
growth by adsorbing onto the newly created surface of the precipitated drug. 
3.4.1.3 Dissolution Study  
Dissolution testing of various dry powder samples were carried out and 
given in Figure 3.3a and 3.3b. The in vitro dissolution rates of EPAS samples 
(E1-E6) were significantly increased compared to bulk ITZ (p<0.05). The 
dissolution of ITZ was nearly 95% within the first 5 min for formulation E1 
containing ITZ with poloxamer 407, compared to 83% for formulation E2 
(poloxamer 188), 87% for formulation E3 (PVP K15) and 14% for the bulk ITZ, 
respectively. This observation of the high dissolution rates was consistent with 
high surface area produced by the intense atomization with rapid evaporation in 
the EPAS process along with improve wettability due to the presence of stabilizer 
on ITZ particle surface.   The decrease in contact angle correlated with an 
increase in dissolution rate as reported in Table 3.2. This significantly improves 
wettability allowing for close proximity of the drug to the dissolution media 
resulting in a further increase in the dissolution of ITZ.  
With the use of poloxamers, the dissolution rates of ITZ were greater for 
poloxamer 407 with the lower EO/PO ratio of 3.61 or less hydrophilicity of 
 115
stabilizers than poloxamer 188 with EO/PO ratio of 5.93. This indicates that 
lipophilicity and hydrophilicity of surfactant has an influence in the dissolution 
rate of ITZ. The finding in the present study is in agreement with our previous 
study (13) that the stabilizer adding during EPAS process must adsorb strongly 
onto particle surfaces in order to prevent particle agglomeration and the 
adsorption is greatly influenced with respect to its hydrophobicity. ITZ is highly 
hydrophobic drug and therefore a non-ionic stabilizer with high hydrophobicity or 
low HLB can be highly adsorbed onto ITZ particle surfaces allowing for 
sufficient wetting The PO block of poloxamer adsorbs onto the hydrophobic 
surface of ITZ while the EO block may be solvated by water providing highly 
hydrophilic surface in replace, as indicated by the reduction of contact angle 
values as discussed earlier in section 3.1.2. In the previous study, it was found that 
enhanced dissolution of ITZ is mainly due to high surface area and enhanced 
wettability of the EPAS processed powder. Based on the dissolution results, the 
amphiphilic character of poloxamer 407 appears to be sufficiently well-balanced 
to provide both adsorption onto the drug particle and steric stabilization. On the 
other hand, the lower dissolution rate of ITZ was observed in E3 sample than E1 
and E2 samples. In 10 min., 70% ITZ dissolved from sample E3 as compared to 
90% and 80% determined for the sample E1 and E2, respectively. The decreased 
in dissolution rate can be attributed to the observation that this sample remained 
for a longer time on the top of dissolution medium before being wetted 
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completely. We also observed that PVP Kl5 dissolves in water more slowly than 
the other stabilizers when preparing aqueous solutions. It is, therefore, important 
to ascertain which stabilizer type should be employed to obtain rapid dissolution 
of ITZ using EPAS process.  
 In this section, the effect of different stabilizer levels on the amount of 
dissolved drug was evaluated. The formulation E1 composed of ITZ and 
poloxamer 407 demonstrated the best rapid dissolution profile among the three 
EPAS formulations investigated by altering the types of stabilizer.  Therefore, this 
formulation was chosen to conduct this additional experiment. Formulations E4, 
E5 and E6 were prepared by varying drug-to-stabilizer ratio from 3.57 to 10.76. 
At 5 min, the amounts of ITZ dissolved from E1 was nearly 83% which higher 
than those of E6 (81%), E5 (78%) and E4 (75%) for the 3.57, 5.36 and 10.76 
drug-to-stabilizer ratios, respectively. However, no significant difference in the 
dissolution rates was observed indicating that only a small amount of stabilizer 
required to achieve high dissolution rates in EPAS process (p>0.05). This result 
was also consistent with our previous studies that showed the rapidly dissolving, 
high potency formulations of ITZ were able to prepare by EPAS (13, 24). 
 
3.4.1.4 Powder X-Ray Diffraction  
The solid-state physical structure by powder X-ray diffraction (PXRD) was 
established to analyze the crystallinity of the dry powders. The diffractogram of 
bulk ITZ powders from 5 to 45°θ (Figure 3.4) showed numerous distinctive peaks 
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that indicated a high crystallinity. The PXRD patterns of all EPAS samples also 
exhibited the identical characteristic diffraction peaks of crystalline bulk ITZ. 
This indicated that ITZ existed in the crystalline state in EPAS samples.  The 
degree of crystallinity for these samples did not appear to be correlated to their 
dissolution rates. As we seen from the dissolution results, all EPAS samples 
yielded very rapid dissolution profiles, indicating that high dissolution rates may 
be achieved for high surface area crystalline powders.  
3.4.2 Characterization of Tablets  
Optimized composition of tablet formulations (200 mg tablet) containing 
EPAS processed powders of ITZ are given in Table 3.3. The content of ITZ was 
maintained at 30 mg per tablet. Table 3.4 shows the physical characterization of 
the prepared tablets from each formulation. As can be seen, all examined tablets 
revealed the narrow range of weight variation with the coefficient of variation less 
than 1% and no significant differences (p>0.05) were observed between each 
formulations. Tablet hardness was in the range of 10-12 kg indicating a good 
handling property without breakage or excessive friability problems (23) thus 
confirming the excellent compactability properties of the EPAS processed 
powders for direct compression. The percentage weight loss in the friability test 
was 0.09-0.16% which were below 1% indicating the sufficient mechanical 
integrity and strength of the prepared tablets. All the tablets formulations rapidly 
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disintegrated within 23 seconds, indicating that the tablets disintegrated very fast 
after they contacted the dissolution media. Figure 3.5 shows the dissolution 
characteristics of tablets prepared with different stabilizers in EPAS compositions. 
In terms of dissolution, tablets formulated employing EPAS processed powders 
gave higher dissolution rates than Sporanox capsule used as powders. Within 
the first 10 min, the EPAS tablet samples had dissolved more than 70% whereas, 
Sporanox had dissolved 55% of ITZ. In contrast, all EPAS tablet samples 
revealed the similar dissolution profiles with their corresponding EPAS processed 
powders. The ability of EPAS processed powders consisting of ITZ nanoparticles 
to maintain high dissolution rates after compacted into tablets is very useful for 
developing rapidly disintegrating and dissolving tablets of ITZ in order to 
maintain the advantages of nanoparticles to improve biovailability of poorly water 
soluble drug, such as ITZ. 
3.5 CONCLUSIONS  
 Poorly-water-soluble compounds are often difficult to develop as drug 
products using conventional formulation techniques. In this study, EPAS has been 
proved to be an useful process to produce a rapid release dosage form for ITZ. 
High dissolution rates of ITZ were obtained from EPAS processed powders 
consisting of ITZ nanoparticles. Several reasons may explain the faster 
dissolution rates. The rapid evaporation and atomization in the EPAS process, 
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may lead to smaller primary particles resulting in high surface area along with the 
close proximity of the aqueous stabilizer to the ITZ surface particles. The type of 
stabilizer was shown to be an important factor to obtain dissolution rate of ITZ 
from EPAS processed powders by adsorbing onto the hydrophobic surface of ITZ 
resulting in a hydrophilic surface.  This phenomenon combined with high surface 
area leads to a rapid wetting and dissolution of the EPAS processed powders upon 
contact with aqueous media. In contrast, the level of stabilizer range from 0.62- 
10.76 has no effect on the dissolution rate of ITZ indicating that high dissolution 
rate of EPAS processed powders can be achieved using small amount of 
stabilizer. Additionally, EPAS processed powders were able to be direct 
compressed into tablets with desirable mechanical properties and maintained high 
dissolution rates of ITZ. The ability to maintain rapid dissolution rates of EPAS 
processed powders in tablet formulation offers great promise for pharmaceutical 
development and manufacturing to improve dissolution rates of a poorly water 
soluble drug for oral delivery system.  
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CHAPTER 4:  Dissolution Rates and Supersaturation Behavior of 
Amorphous Repaglinide Particles Produced by  
Controlled Precipitation 
4.1 ABSTRACT  
Rapidly dissolving nanostructured particles containing amorphous 
repaglinide (REP) were produced by controlled precipitation.  Rapid in vitro 
dissolution rates and high levels of supersaturation (drug concentration/crystalline 
equilibrium solubility) were achieved using different stabilizing polymers 
including hydroxypropylmethylcellulose (HPMC) E5, polyvinylpyrrolidone 
(PVP) K15, polyvinyl alcohol (PVA) and polyethylene glycol (PEG) 8000. The 
dissolution and supersaturation characteristics of amorphous REP depended on 
the surface area of the particles and the miscibility of REP with the polymer 
employed to prevent drug crystallization in the solid phase. Each of the polymers 
contained hydrogen bonding groups to favor miscibility with the drug.  Of the 
various formulations investigated, REP/HPMC E5 had the highest surface area 
leading to the highest dissolution rate in aqueous media under sink conditions. For 
each of the polymers, except for PVA, the level of supersaturation was on the 
order of 5 and decayed only slightly for up to 24 hr. In addition, the amorphous 
REP/HPMC E5 system produced high supersaturation after 3 months storage at 
25 °C/60% RH indicating it was stable against crystallization.  This understanding 
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of the effect of polymer stabilizers on drug morphology and subsequently, 
dissolution rates and supersaturation, may be used to facilitate rational design of  
dosage forms with the potential for improved bioavailability. 
 
4.2 INTRODUCTION   
Oral drug delivery is the dominant route of administration, especially 
when repeated or routine administration is required [1]. However, oral 
bioavailability of poorly water soluble drugs is often limited by their dissolution 
rate when the drug can be readily absorbed across the gastrointestinal membrane 
following dissolution [2, 3]. Therefore, the enhancement in dissolution rate of 
these drugs in order to attain desirable blood levels has become one of the major 
challenges in pharmaceutical technology. The problems associated with low 
solubility drugs that contribute to insufficient dissolution rates of drug from oral 
dosage forms have important consequences impacting drug absorption leading to 
poor and variable drug absorption [4]. Many approaches to improve dissolution 
rates aim to increase surface area available for dissolution by reduction of particle 
size [5-9].  In addition, enhancement of particle surface wettability by adsorption 
of surfactants or hydrophilic polymers during particle formation may further 
increase the dissolution rate. Particle size [10] reduction by mechanical milling or 
high pressure homogenization often requires long times, introduces impurities, 
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and limits flexibility in controlling particle morphology [11].  Solubility can be 
enhanced with co-solvents, surfactants, or complexing agents [12-14] as well as 
the formation of emulsions and solid dispersions [10, 15]. However, use of 
excipients limits the drug potency in the final product, in some instances to below 
50% (%w/w).  Additionally, formation of an amorphous material may increase 
the solubility up to 100-times compared to that of its crystalline form[16]. An 
increase in the solubility (Csat) of the drug increases the dissolution rate driving 
force dramatically, according to the Noyes-Whitney equation: 
      ( )CC
h
DArate sat −=                                                         Eq. 1 
where C is concentration of drug in the bulk media away from the drug surface,  
D is diffusivity, A is the surface area, and h is the boundary layer thickness for the 
concentration gradient.  
 Controlled precipitation (CP) of water insoluble drugs from solution offers 
the ability to manipulate and control particle size distribution as well as 
morphology.  The drug dissolved in an organic solvent is rapidly mixed with an 
antisolvent in the presence of polymeric and/or non-polymeric stabilizers. If 
mixing is done rapidly, a higher level of supersaturation is created before 
significant nucleation occurs [17].  The rate of primary nucleation is given by the 
following equation [17]: 
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where B0 is the nucleation rate, γ is interfacial tension, VM is molar volume, S0 is 
degree of supersaturation (C/equilibrium crystalline solubility) and NA is 
Avogadro’s number.  Once nucleation occurs, particles can grow by condensation 
of drug molecules onto the surface and by coagulation of particles.  The 
nucleation rate depends more strongly on S than does the rate of condensation, 
which is linear in S [18].  High nucleation rates offer the potential to produce a 
large number of submicron particles in the final suspension, if the growth can be 
quickly arrested by the adsorption of stabilizers to the nuclei.   
 By forming amorphous drug particles with high surface areas, dissolution 
rates may be enhanced, and high supersaturation levels (metastable solubilities) 
may be achieved compared to the crystalline form of the drug.  In the case of 
dissolution, supersaturation (Sd) may be defined as follows: 
        
eq
d C
tCS )(=                                                            Eq. 3 
where C(t) is the measured concentration at time t and Ceq is the equilibrium 
solubility of crystalline drug in the dissolution media.  Amorphous drugs have 
been used to form supersaturated solutions that show large increases in membrane 
flux when compared to saturated solutions [19-22].  Drug molecules may 
precipitate from a supersaturated state by nucleation and growth to reach the 
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equilibrium solubility.  In order to maintain supersaturation created by an 
amorphous drug, a crystallization inhibitor may be used to prevent precipitation 
from the aqueous media after dissolution.  Several water soluble polymers, such 
as PVP and HPMC, have been used successfully to maintain supersaturated 
solutions for up to 24 hours [23-25].  Raghavan et al. have suggested H-bonding 
between the polymer and drug may play a primary role in the mechanism for 
crystallization inhibition [26].  Additionally, polymers may help maintain 
supersaturation by coating and passivating small embryos to arrest growth by 
preventing condensation of drug molecule onto the surfaces embryos.  Extension 
of the time for high levels of supersaturation in the stomach and intestinal fluids 
may have a profound impact on increasing the bioavailability of poorly water 
soluble drugs, as has been suggested recently [27, 28]. 
Repaglinide (REP) is an oral prandial glucose regulator agent for the 
management of type 2 diabetes mellitus [29, 30]. It lowers blood glucose levels 
by stimulating the release of insulin from the pancreas.  REP was chosen as the 
model drug for this study due to its low solubility and poor wettability in water 
[29]. It has a relatively low and variable bioavailability, as the absolute 
bioavailability of REP administered as a tablet was 62.5% (49.2% - 79.5%) 
relative to an intravenous infusion of the same dose [31]. High inter-individual 
variability in REP plasma concentrations has been reported in clinical trials [32, 
33].  
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The objective of this study is to investigate the influence of different 
water-soluble polymers, including HPMC E5, PVP K15, PVA and PEG 8000, on 
the dissolution rate and supersaturation behavior of amorphous REP particles 
formed by CP. The mechanisms of drug dissolution and supersaturation are 
discussed from the view point of miscibility, as characterized by thermal analysis, 
and the ability of the polymer to form hydrogen bonds with REP. Also, the degree 
of crystallinity, morphology, and surface area of the REP particles were 
considered in order to understand the dissolution behavior under sink and 
supersaturated conditions.  
 
4.3 MATERIALS AND METHODS   
4.3.1 Materials 
 
REP (C27H36N2O4 ; molecular weight = 452.6) and HPMC type 2910 
(methoxyl content: 28–30%; hydroxypropyl content: 7–12%) with nominal 
viscosity for a 2% (w/v) aqueous solution of 5 mPas (Methocel Cellulose Ethers 
E5LV Premium) were kindly provided by The Dow Chemical Company 
(Midland, MI). PVP (K15 grade, Mw = 10, 000), PEG 8000 and PVA were 
purchased from Spectrum Chemical Mfg. Corp. (Gardena, CA).  The chemical 
structures of REP and these polymers are presented in Table 4.1. Stabilized 1,3 
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dioxolane was obtained from ACROS Organics (Morris Plains, NJ).  All other 
solvents used were of HPLC grade unless noted otherwise. 
4.3.2 Controlled Precipitation 
 
A schematic of the Controlled Precipitation apparatus is shown in Figure 
4.1[8] . A 5% (wt./tot. wt.) solution of REP in dioxolane was prepared at room 
temperature and stirred until completely dissolved.  An aqueous solution of 
polymer used in formulation, in deionized water was prepared at room 
temperature, and 100 g was pre-cooled in the precipitation apparatus to 3°C.  
Using a 60 mL syringe, 20 g of organic solution was delivered to the temperature-
controlled mixing zone through 1/16” stainless steel tubing within approximately 
15 s.  The mixing rate of the loop was controlled by a centrifugal pump with the 
maximum fluid velocity measured at approximately 13 ft/sec.  The suspension 
product was then fed at 25 mL/min directly into a vacuum distillation apparatus 
for removal (stripping) of dioxolane at a pressure and temperature of 7-10 torr and 
38°C, respectively.  After completion of solvent removal, particle size of the 
stripped suspension was measured by static light scattering with a Malvern 
Mastersizer-S (Malvern Instruments Ltd., U. K.).  In some cases the suspension 
was sonicated in 30 s intervals within the Malvern unit and corresponding particle 
size measurements were taken.  In order to obtain dry powders, the stripped 
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suspension was frozen drop-wise into liquid nitrogen and freeze-dried using a 
Virtis Advantage Tray Lyophilizer (Virtis Company, Gardiner, NY).   
4.3.3 Scanning Electron Microscopy (SEM) 
 
A Hitachi S-4500 scanning electron microscope (SEM) (Hitachi 
Instruments Inc., Irvine, CA) at an accelerating voltage of 15 kV with a secondary 
electron detector was used to obtain digital images of the samples.  Powders were 
gently applied to adhesive carbon tape on an aluminum SEM stage.  The stage 
was then coated with Au for 25 s using a Pelco Model 3 sputter-coaler under an 
Ar atmosphere before viewing.   
4.3.4  Specific Surface Area Measurement 
 
Specific surface area was measured using a NOVA-2000 instrument 
(Quantachrome Corporation, Boynton Beach, FL). A known amount of bulk REP 
or CP REP powder (~0.03 g) was loaded into a Quantachrome sample cell and 
degassed for approximately 12 hours prior to analysis.  With nitrogen as the 
adsorbent, the surface area per gram of degassed sample weight was determined 
using a relative pressure range from 0.05 – 0.35.   
 
4.3.5 X-Ray Diffraction (XRD) 
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X-ray diffraction was performed using a Philips PW 1720 X-ray generator 
(Philips Analytical Inc., Natick, MA) with CuK α1 radiation at a wavelength of 
1.54054 Å at 40 kV and 20 mA.  Reflected intensities were detected by a Philips 
goniometer.  Diffraction patterns were obtained for the bulk materials as well as 
CP samples.  Dry powders were gently pressed onto a glass slide to a thickness of 
approximately 1 mm.  XRD patterns were taken at a rate of 20 degrees/min with a 
step length of 0.05 degrees from 5-45 degrees. 
4.3.6 Thermal Analysis 
 
The glass transition temperature (Tg) of CP powders  was determined by 
modulated differential scanning calorimeter (MDSC) carried out using a TA 
Instrument (City, State) differential scanning calorimeter (Model 2920). 
Approximately 5 mg of sample was placed into an aluminum pan (Perkin-Elmer 
Instruments, Norwalk, CT) and crimped with an aluminum lid. The samples were 
initially heated to 200 °C at 10.00 °C/min to remove all residual moisture. 
Subsequently, the sample was cooled to -20oC and then reheated up to 200 °C at 
heating rate of 3oC/min. An empty pan was used as the reference, and calibrations 
for temperature and enthalpy have been carried out using an indium standard. 
 
4.3.7 Dissolution Testing at Sink Conditions 
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 A USP dissolution apparatus (Vankel 7000, Vankel Technology Group, 
Cary, NC) Type II (paddles) at a rotation speed of 50 rpm was used for in vitro 
testing of drug dissolution from the powders. An amount of powder equivalent to 
2 mg of drug was weighed out and placed into 900 mL of dissolution medium 
containing citric acid/sodium phosphate dibasic buffer with a pH of 4.5. The 
dissolution media was maintained at 37.0±0.5 °C and degassed prior to use by 
sonication for 2 min.  Sink conditions (10 percent of Ceq) were maintained 
throughout the testing based on REP solubility in the dissolution medium.  A 
sample volume of 5 mL was collected at 2, 5, 10, 20, 30 and 60 minutes using a 
VK8000 autosampler (Varian, Inc.  Cary, NC).  The samples were then filtered 
through a 0.45µm filters (Gelman GHP Acrodisc 0.45µm, VWR, West Chester, 
PA) into an HPLC vial for drug content analysis using reverse phase HPLC. 
Dissolution profiles of powders were determined in replicates of 6. 
4.3.8. Supersaturated Dissolution 
 
 Dissolution experiments to determine supersaturation were performed 
similarly to USP dissolution testing at sink conditions, except the volume of the 
dissolution apparatus was only 100 mL.  It was equipped with a paddle stirring 
mechanism.  Drug formulations were weighed out corresponding to 
approximately 10-times (21 mg REP in each sample) or 25 times (53 mg REP) the 
equilibrium solubility in 100 mL of  dissolution medium (citric acid/sodium 
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phosphate dibasic pH 4.5).  Paddle speed and bath temperature were maintained at 
50 rpm and 37oC, respectively.  A 1 mL aliquot of sample was taken at 5, 10, 20, 
30, 60, 120, and 1440 minutes.  This aliquot was immediately filtered through a 
0.2 µm nylon filter and a 0.5 mL portion of this solution was dissolved in 1 mL of 
acetonitrile.   The collected samples were analyzed for REP concentration using 
HPLC as described above.  All experiments were performed in triplicate. 
4.4 RESULTS AND DISCUSSION  
4.4.1 Particle Morphology  
 
 SEM was used to visually observe the primary particle size and surface 
morphology of the particles. SEM micrographs of the various formulations are 
shown in Figure 4.2. SEM micrographs show variable morphology, depending on 
the stabilizer used. The SEM micrograph of bulk REP (Figure 4.2a) revealed a 
large and long needle-shaped crystal habits that ranged in length from 20-23 µm. 
The SEM image of the HPMC E5 stabilized powders (Figure 4.2b) show distinct 
aggregates of particles with smooth surfaces and confirms the primary particle 
size of about 100 nm.   The particles prepared in the presence of PVP K-15, PEG 





4.4.2 Surface Area 
 
 The specific surface area of the CP powders for all compositions was higher 
than that of bulk REP (1.53 m2/g). The surface areas of the HPMC E5, PVPK15, 
PEG 8000 and PVA stabilized powders were 9.35 m2/g, 5.08 m2/g, 4.97 m2/g and 
3.57 m2/g, respectively (listed in Table 4.2).  The large surface areas of CP 
powders reflect the submicron primary particle domains of the nanostructured 
aggregates observed in the SEM micrographs.  For example, a surface area of 
9.35m2/g would correspond to 640 nm diameter particles, assuming spherical 
geometry and 1g/cm3 density.  The surface areas of REP/PEG 8000, 
REP/PVPK15 and REP/PVA were lower than that of REP/HPMC E5, consistent 
with the larger particle sizes and less porous morphologies observed by SEM. A 
number of studies have shown that increasing the surface area of a hydrophobic 
drug enhanced the dissolution in aqueous media [34, 35]. Because all CP 
micronized powders possessed higher surface areas, compared to bulk REP, faster 
dissolution profiles were expected.  
4.4.3 X-ray Powder Diffraction 
 
 The degree of crystallinity of REP in the CP powders was determined by 
powder XRD.  The XRD patterns of powder samples investigated in this study are 
shown in Figure 4.3A. Bulk powder is highly crystalline, as determined by 
 136
distinct peaks between 12 and 36 2θ degrees.  No characteristic diffraction peaks 
of the crystalline forms of REP were seen in any of the CP formulations 
regardless of stabilizer type. The lack of diffraction peaks indicated that the REP 
was in a high energy amorphous form. Since the drug content was approximately 
50% (47 + 2% ) in all cases, even small amounts of crystallinity would be 
apparent in the XRD pattern.  For example, the characteristic crystalline peaks 
were readily apparent in the physical mixture of REP and HPMC E5 at 50% drug 
content. It was also found that REP/HPMC E5 remained stable in the amorphous 
form following storage at 25°C /60 % relative humidity (RH) for 3 months 
(Figure 4.3B). Problems related to physical stability of amorphous drugs, which 
have a great tendency to undergo conversion to crystalline forms, often limit their 
physicochemical advantages and their application in dosage form design. The 
presence of high Tg polymers such as HPMC E5 produced an increase in the 
physical stability of the amorphous REP by increasing the Tg of drug formulation 
as discussed in section 3.6. For this reason, a high Tg stabilizer was included in 
the formulation and is discussed in the next subsection. 
3.4.4 Thermal Analysis 
 
The MDSC measurement of Tg in the CP compositions was determined by 
constructing a tangent to the thermogram baseline above and below the glass 
transition. The glass transition for amorphous REP was observed at 51.8°C (data 
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not shown). In all CP formulations, REP was incorporated at the same drug 
loading of 50% w/w. The presence of a single Tg intermediate to those of the drug 
and polymer was observed in the binary mixtures of REP/HPMC E5 and 
REP/PVP K15 (Figure 4.4). These results suggest a high degree of miscibility 
between REP and these polymers. However, two glass transitions were found for 
the REP/PVA system, one associated with glassy REP at 45.7°C and one 
originating from the drug–polymer mixture at 100.7 °C (close to the Tg of pure 
PVA, 107°C). This result indicates only partial miscibility. In the case of REP: 
PEG 8000, a Tg peak was not observed, as the Tg of the polymer was very low.  
The Tg of homogeneous binary mixtures can be described by Gordon 
Taylor equation [36] which is based on the free volumes of the individual 
components. 







                    Eq. 4 
where w1 and w2 are the weight fractions of the individual components and Tg1 
and Tg2 are their glass transition temperatures. K is a constant that can be 
calculated using the Simha-Boyer equation [37], 




ρ gT≈                                             Eq. 5 
where ρ1 and ρ2 are the densities components 1 and 2, respectively.  Figure 4.5 
shows the comparison between experimental and theoretical Tg values predicted 
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by the Gordon–Taylor equation. The experimental Tg values were higher than the 
predicted Tg values, resulting from relatively strong interactions (i.e. H-bonding) 
between electron donating and electron accepting functional groups of the 
individual components. The more H-bonding between drug and polymer would 
allow less H-bonding sites available to water which can cause crystallization of 
amorphous drug. It is well known that the presence of moisture leads to a 
decrease in the Tg due to plasticizing and increasing molecular mobility by 
absorbed water. The recent study by Tanaka et al. [38] showed a dramatic 
decrease in Tg of amorphous FK888 from 89 to 57 °C when exposed to 4.5% of 
moisture, leading to physical instability. The Tg of the amorphous solid is an 
important indicator for predicting its physical stability. The increase in the Tg of 
the formulation with the inclusion of the polymers is important for maintaining a 
rigid system to prevent relaxation from the amorphous state to the crystalline 
state, over long storage times.  In this study, the Tgs of CP formulations are about 
two fold higher than that of bulk REP (51.8oC).   At the Tg, amorphous solid 
undergoes a transition from a glassy state to a rubbery state due to high molecular 
mobility resulting in the crystallization and crystal growth of particles. It is 
recommended that the Tg be 50°C above the highest storage temperature to 
prevent crystallization and to ensure physical stability of the amorphous 
formulations over the product shelf-life. In the present study, we also found that 
the Tg of REP/HPMC E5 was similar to its initial Tg value when stored at 25°C 
 139
/60% RH for three months. This result also supports the physical stability 
determined by XRD (Figure 4.3B), which revealed the typical amorphous halo 
pattern indicating that the amorphous sample did not significantly convert to the 
crystalline form of REP. 
3.4.5 Dissolution Testing at Sink Conditions 
 
 Using a USP apparatus II, the dissolution rate of all formulations was 
measured and is shown in Figure 4.6. The bulk REP powder was observed to wet 
and dissolve poorly during dissolution. Only 13 % of the micronized bulk REP 
dissolved in 2 minutes after addition to the dissolution media.  As was expected, 
the dissolution rate of all CP formulations was significantly greater than that of 
the bulk powder.  In all cases, the powders were wet much more rapidly as was 
apparent from their immediate dispersion into the dissolution media.  The 
dissolution characteristics of amorphous REP produced by CP depended on the 
polymer used to stabilize the drug during CP. The rank order of dissolution rates 
and extent was REP/HPMC E5>REP/PVPK15>REP/PEG 8000>REP/PVA>Bulk 
REP, in direct correlation with the powder surface areas. Both dissolution rate and 
extent were much higher for the formulation containing HPMC E5 than the other 
stabilizing polymers within the first 30 min upon addition to the dissolution 
media. In 5 min., 86% of REP from the REP/HPMC E5 composition was 
dissolved as compared to only 13% determined for the bulk REP powder.  The 
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fast dissolution rates and high extents of REP particles produced by CP were 
primarily attributed to the formation of a high energy amorphous drug, to 
increased Csat compared to crystalline, bulk drug.  
 The initial dissolution rate was calculated with Eq. 1 for all samples in 
Figure 4.6 and compared to the experimental value.  Table 4.2 lists the parameters 
for each calculation, including the total surface area (BET specific surface area 
times the total sample weight) and the boundary layer thickness, h.  The value of 
h, was estimated to be the same as the average primary particle diameter, which 
was determined from the BET specific surface area.  To estimate the primary 
particle diameter, it was assumed that the particles were monodisperse spheres 
without any agglomeration.  In Table 4.2, the calculated and experimental rates 
were reported relative to the 1:1 REP/PVA case, since the exact values for Csat 
and D (both constants for all cases) were unknown.  The agreement between the 
experimental and calculated rates was reasonable, except for the REP/HPMC E5 
case.  In this case where the particle size was the smallest according to BET and 
SEM, the effect of particle agglomeration on the diffusion layer thickness may be 
expected to be more significant than for the lower surface area formulations.  The 
diffusional layer thickness is likely larger than the estimated value and thus, the 
calculated rate was too high.  Additionally, the calculated rate does not take into 
account possible inhibition by polymer domains that block exposure of the REP to 
the media.  In particular, the dissolution of HPMC is known to be slow as 
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hydration forms a gel layer [39].  Both of these factors may explain why the 
calculated relative rate was higher than the experimentally observed relative rate.  
Overall, the agreement between theory and experiment suggested that the 
dissolution rate was primarily a function of the surface area of CP powders, which 
varied with the properties of the polymeric stabilizer. 
3.4.6 Supersaturation Dissolution 
 
The supersaturation dissolution of REP formulations with various 
polymers was investigated to observe the effects of polymer stabilization of 
amorphous REP in the solid phase on maximum supersaturation levels.  Figure 
4.7 shows the supersaturated dissolution of REP containing about 10 times the 
solubility limit of REP. For all of the polymers, REP concentration exceeded its 
equilibrium solubility in the dissolution medium to form a supersaturated 
solution. The high degree of supersaturation of REP was due to the stabilizing 
effect of the polymers against particle crystallization and/or growth by 
condensation and coagulation during the particle formation step.  The degrees of 
supersaturation were comparable among REP/HPMC E5, REP/PVPK15 and 
REP/PEG 8000.  However, considering the REP/PVA composition, the 
supersaturation reached 4 within a few minutes, and then decreased slightly over 
24 hours.  
 142
According to MDSC results, the REP/PVA formulation gave two glass 
transition peaks (Figure 4.4).  A REP-rich phase and a PVA-rich phase were 
present, since the two observed Tgs were relatively close to those of bulk REP and 
PVA.   The REP-rich phase is susceptible to crystallization in the dosage form 
and upon addition to aqueous media, producing a less a soluble form of the drug. 
Any crystallized portion of the undissolved solid phase would then be unavailable 
to contribute to supersaturation of the dissolution media, thus limiting the 
maximum supersaturation to less than that of other formulations, which would 
remain amorphous in the solid phase.  It is therefore reasonable to consider drug 
miscibility with the polymer to be essential in crystallization inhibition of the 
solid phase and thus, an important factor for maximizing supersaturation. 
 In this study, HPMC E5 was slightly more efficient at achieving high 
supersaturation and maintaining it for 24 hr that the next best two formulations. 
For these reasons, the REP/HPMC E5 formulations were studied in greater detail.  
Dissolution media were dosed with two amounts of drug powder,  21 and 53 mg, 
corresponding to 10 and 25-times (noted 10X and 25X, respectively) the 
equilibrium solubility limit in the dissolution media.  In the case of  the 10X dose, 
Sd, defined by Eq. 3, quickly exceeded the equilibrium solubility and continued to 
increase to 5 over two hours.  For the 25X dose, Sd reached only 2.  In both cases, 
the supersaturation level changed little for up to 24 hours.  After storage of the 
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REP/HPMC E5 dry powder for 3 months at 25°C and ambient humidity, the 
supersaturation profile was almost identical to that of the initial powder.   
 Since the supersaturation provides a strong driving force for homogeneous 
nucleation, as described by Eq. 2, precipitation of the drug might be expected.  If 
there is surface area available for heterogeneous nucleation to occur, rates may be 
even faster than homogeneous nucleation [18]. When a large amount of 
amorphous material is added to the solution, it may raise the supersaturation.  In 
addition, excess undissolved particles may facilitate heterogeneous nucleation.  
The two processes could compete, resulting in a metastable equilibrium value of 
Sd.  In the case of the 10X dose, the supersaturation reached 5X which left 5X in 
excess particles (approximately 10mg).  Similarly, 23X in excess particles 
(approximately 49 mg) remained undissolved in the case of 25X dose (Figure 
4.8).  This large difference in heterogeneous nucleation sites is likely to be the 
cause for a lower Sd in the higher dose case.  In both cases, however, the 
supersaturation level was maintained for up to 24 hours, in agreement with other 
work utilizing HPMC as a crystallization inhibitor [40].  In contrast to previous 
studies, which focus on low surface area solid dispersions at 10-30% drug 
loading, the CP process is capable of producing high surface area amorphous 
powders at much higher drug content which can supersaturate aqueous media at a 
rapid rate.   These levels of supersaturation would be expected to increase flux of 
drug across the gastrointestinal membrane 5-fold for increased bioavailability.   
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 With the solid drug in a high energy amorphous state, there is a 
thermodynamic drying force to convert to the lower energy crystalline state.  Use 
of a high Tg polymer, such as HPMC, prevents mobility of the drug molecules and 
slows down the rate of transformation from amorphous to crystalline morphology 
[42]. The stability of REP morphology is readily apparent from the identical 
supersaturation profile of the powder after storage for 3 months at 25oC. 
Moreover, the ability of formulations to supersaturate the dissolution media has 
been used to enhance bioavailability of poorly water soluble drugs[41]. In a 
supersaturated system, the concentration of drug in solution is greater than its 
solubility allowing high free drug concentration to available for absorption. This 
indicates the important role of supersaturation in enhancing the drug delivery of a 
poorly soluble drug. 
4.5 CONCLUSIONS  
Amorphous REP particles with high surface area were produced by CP.  
Rapid in vitro dissolution and supersaturation were achieved with various water 
soluble polymers including HPMC E5, PVP K15, PEG 8000 and PVA. Under 
sink conditions, the dissolution rate increased as the particle surface area 
increased, in good agreement with relative rates predicted by the Noyes-Whitney 
equation.  REP/HPMC E5 gave the highest surface area particles, leading to the 
highest dissolution rate.  The presence of polymer in CP inhibits drug 
crystallization of the solid phase during particle formation and storage to preserve 
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amorphous drug. This high miscibility between drug and polymer in the solid 
state favors the amorphous state for REP, as indicated by high supersaturation 
values up to 5 for levels up to 24 hr. in the dissolution media. MDSC data 
indicated that HPMC E5, PVP K15, PEG 8000 were miscible with REP, while 
partial miscibility was found with PVA. Accordingly, the PVA formulation 
produced a lower maximum supersaturation than the others.  In addition, 
REP/HPMC E5 was physically stable in the amorphous form, achieving a high 
degree of supersaturation after storage at 25 °C/60% RH for up to 3 months. The 
high physical stability was favored by a high Tg for the binary mixture.  Therefore 
selection of a stabilizing polymer to achieve high miscibility with the drug and a 
high Tg favors amorphous drug domains with high stability.  The amorphous state 
may be used to achieve high supersaturation, and ultimately enhanced 
bioavailability.  
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CHAPTER 5:  Nebulization of Nanoparticulate Amorphous or 
Crystalline Tacrolimus in Mice 
 
5.1 ABSTRACT  
The objectives of this study were to produce nanostructured aggregates of 
tacrolimus (TAC) intended for pulmonary delivery using ultra-rapid freezing 
(URF), and to investigate the physicochemical and pharmacokinetic 
characteristics of the nanostructured aggregates containing amorphous or 
crystalline nanoparticles of TAC.  Two URF formulations were investigated for 
pulmonary delivery, and compared to bulk unprocessed TAC, these were:  TAC 
and lactose (1:1 ratio; URF-TAC:LAC) and TAC alone (URF-TAC).  TAC and 
water soluble excipient i.e. lactose were dissolved in acetonitrile and water, 
respectively. Two solutions were mixed to obtain 60:40 ratio of the resulting 
organic/aqueous co-solvent system which was then frozen on the cryogenic 
substrate.  The cosolvent was then frozen on the URF cryogenic substrate and the 
frozen compositions were collected and lyophilized to form the dry powder for 
nebulization.  In vitro results revealed similar physiochemical properties for both 
URF formulations.  BET analysis showed high surface areas of 29.3 m2/g and 
25.9 m2/g for the URF-TAC:LAC and URF-TAC, respectively, and 0.53 m2/g for 
the unprocessed TAC, respectively.  Scanning electron microscopy (SEM) 
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showed nanostructured aggregates containing nanoparticles of TAC. The 
dissolution of TAC was 83.6% at 1 hr for the URF-TAC:LAC, compared to 
80.5% for the URF-TAC and 30% dissolved for the unprocessed TAC, 
respectively.  Similar aerodynamic particle sizes of 2-3 µm, and fine particle 
fraction between 70-75% for the URF-TAC:LAC and URF-TAC were determined 
by cascade impactor data. X-ray diffraction (XRD) results indicated that URF-
TAC was crystalline, whereas URF-TAC:LAC was amorphous.  The 
supersaturated dissolution profiles were in agreement with these results.  URF-
TAC:LAC displayed the ability to supersaturate in the dissolution media to about 
11-times crystalline equilibrium solubility.  In vivo studies were conducted in 
mice by dispersing the URF formulations in deionized water and nebulizing the 
dispersed URF formulations using a specially designed nose-only dosing 
apparatus.  The pharmacokinetic profiles obtained showed comparable AUC(0-24), 
higher Cmax, and lower Tmax for the URF-TAC:LAC compared to the URF-TAC .  
Therefore, rapidly dissolving, pulmonary formulations containing nanostructured 
aggregates of amorphous or crystalline TAC were developed using the URF 
technology.  The URF processed formulations were demonstrated to be 
effectively delivered as an aqueous dispersion of TAC nanoparticle via 
nebulization, with a similar in vivo performance by displaying the comparable 
extent of drug absorption. 
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5.2 INTRODUCTION   
Tacrolimus (TAC) is a widely used immunosuppressive agent isolated 
from Streptomyces tsukubaensis. It has proven to be a potent immunosuppressant 
in transplantation medicine for treatment of organ rejection and different 
immunological diseases such as pulmonary fibrosis and bronchiolar asthma [1-3]. 
TAC was first introduced as rescue therapy when cyclosporin A (CsA) therapy 
failed to prevent graft rejection.  It has a mechanism of action similar to that of 
CsA, but its immunosuppressive activity is 10- to 100-times more potent than 
CsA [4,5].  TAC is currently available in both an intravenous and oral dosage 
form (commercially known as Prograf®).  However, these current available 
dosage forms of the drug are poorly tolerated and provide a variable and/or low 
bioavailability [6].  The oral formulations of TAC present a considerable 
challenge as the drugs are practically insoluble in water and extensively 
metabolized from both CYP3A4 metabolism and p-glycoprotein efflux transport 
within the intestinal epithelium [7].  The oral bioavailability of TAC varies from 
4% to 93% [8].  Inefficient or erratic drug absorption is primarily the result of 
incomplete absorption from the gastrointestinal tract and first-pass metabolism, 
which is subject to considerable inter-individual variation [8]. 
This study focused on investigating a pulmonary drug delivery system 
based on, nanoparticles of TAC in order to overcome the above mentioned 
problems to improve bioavailability.  The appealing aspects of inhaled drug 
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nanoparticles include:  Rapid dissolution of nanoparticles in the lung and the 
avoidance of hepatic first pass metabolism (which is especially useful for a drug 
that undergoes extensive metabolism in liver) [9,11].  Additionally, inhaled 
nanoparticles can increase local drug concentrations in the lung for potential 
therapeutic use in lung transplantation and pulmonary diseases.  The treatment of 
lung transplant recipients is often limited due to poor penetration of drug into the 
lung following oral or intravenous administration [12].  Aerosolized drug will 
have direct access to the graft in lung transplant offering the possibility of much 
higher drug levels [13].  However, a major disadvantage of pulmonary delivery 
for drugs like TAC is limitations in the levels and types of excipients that are 
considered safe to use in pulmonary formulations.  Although many surfactants or 
polymers such as cyclodextrins, poloxamers, polyethylene glycols (PEG) and 
glycerol have been studied in pulmonary formulations to aid drug solubilization in 
many research studies [14-16], these excipients have not been approved yet for 
commercial use by the FDA because of potential toxicity in the lung.  Several 
clinical studies have demonstrated effective pulmonary delivery of CsA solutions 
in ethanol or propylene glycol prior to aerosolization in lung transplantation 
models [17-19].  However, the solvents have produced the results have shown 
unsatisfactory due to the irritating properties of these solventsation to the airways.  
In addition, the use of high levels of ethanol or propylene glycol in formulations 
intended for pulmonary delivery have yet to be widely studied in humans. 
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Recently, liposome technology has been investigated as a non-irritating 
alternative for pulmonary delivery of CsA, but the formulation had low drug 
loading and thus requires a lengthy nebulization period [20]. 
In this present study, pulmonary formulations containing TAC 
manufactured by ultra-rapid freezing (URF), without the inclusion of surfactants 
or polymeric excipients, were investigated.  URF technology is a continuous, 
scalable cryogenic process produces nanostructured aggregates with high surface 
area resulting in high enhanced drug dissolution rates.  Previously, spray freezing 
into liquid (SFL) was reported [21-26].  The rapid freezing rates achieved with the 
SFL process led to the production of amorphous nanostructured aggregates 
composed of primary particles, ranging from 100 to 200 nm, with high surface 
areas, high wettability and significantly enhanced dissolution rates.  The URF 
process yields particles with similar properties as those produced by SFL.  In URF  
a solution of the active and excipient in a suitable organic solvent or aqueous co-
solvent is applied to the surface of a cryogenic solid substrate. The is frozen 
instantaneously, in 50 ms to 1s, onto the surface of cryogenic solid substrate in a 
continuous manner [27,28].  URF powders exhibit desirable properties for 
enhancing bioavailability such as high surface area, increased drug dissolution 
rates, and amorphous character. 
The objective of this study was to demonstrate that nanostructured 
aggregates composed of amorphous or crystalline primary nanoparticles of TAC 
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produced by the URF process are suitable for pulmonary delivery by nebulization, 
resulting in high lung and blood concentrations.  The hypothesis is that high 
surface area and rapid dissolution rate obtained from nanostructured aggregates of 
TAC promote high systemic drug absorption via the lung, whilst still maintaining 
a desirable pulmonary residence time for potential local therapy.  Relevant 
physicochemical properties (e.g. surface area, dissolution, crystallinity) of TAC 
nanostructured aggregates were characterized in order to understand how they 
influence  in vivo drug absorption following single-dose nebulization of the 
particle dispersions.  
5.3 MATERIALS AND METHODS   
5.3.1 Materials  
 
TAC was kindly provided by The Dow Chemical Company (Midland, 
MI).  Lactose, magnesium chloride hexahydrate, sodium chloride, potassium 
chloride, sodium phosphate dibasic anhydrous, sodium sulphate anhydrous, 
calcium chloride dihydrate, sodium acetate trihydrate, sodium bicarbonate and 
sodium citrate dihydrate  were analytical grade and purchased from Spectrum 
Chemicals (Gardena, CA).  Dipalmitoylphosphatidylcholine (DPPC) was 
purchased from Sigma-Aldrich Chemicals (Milwaukee, WI).  High performance 
liquid chromatography (HPLC) grade acetonitrile (ACN) was purchased from EM 
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Industries, Inc. (Gibbstown, NJ).  Liquid nitrogen was obtained from Boc Gases 
(Murray Hill, NJ). Deionized water was prepared by a Milli-Q purification system 
from Millipore (Molsheim, France).  
5.3.2 Preparation of URF Formulations  
TAC formulations were processed using URF.  A schematic diagram of 
the URF process is illustrated in Figure 5.1.  Two URF formulations considered 
for pulmonary delivery were TAC:lactose in a 1:1 ratio (URF-TAC:LAC) and 
TAC alone (URF-TAC).  The compositions were prepared by dissolving TAC and 
hydrophilic excipient (if any) at a 1:1 ratio and 0.75% solids in a 60/40 mixture of 
acetonitrile and water. The solution of drug was applied to the surface of solid 
substrate, which is cooled using a cryogenic substrate maintained at -50oC. The 
frozen compositions were then collected and the solvent was removed by 
lyophilization using VirTis Advantage Tray Lyophilizer (VirTis Company Inc., 
Gardiner, NY). The lyophilization recipes used in this study is outlined in 
Appendix A. The dried powders were stored at room temperature under vacuum. 
 
5.3.3 In Vitro Characterization of Powders for Pulmonary 
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5.3.3.1 X-ray Powder Diffraction (XRD) 
The XRD patterns of the powders were analyzed using a Philips 1710 x-
ray diffractometer with a copper target and nickel filter (Philips Electronic 
Instruments, Inc., Mahwah, NJ).  Each sample was measured from 5 to 45 2θ 
degrees using a step size of 0.05 2θ degrees and a dwell time of one second. 
 
5.3.3.2 BET Specific Surface Area Analysis 
Specific surface area was measured using a Nova 2000 v.6.11 instrument 
(Quantachrome Instruments, Boynton Beach, FL).  A known weight of powder 
was added to a 12 mm Quantachrome bulb sample cell and degassed for a 
minimum of three hours.  The data recorded were then analyzed according to BET 
theory using NOVA Enhanced Data Reduction Software v. 2.13. 
5.3.3.3 Scanning Electron Microscopy (SEM) 
A Hitachi S-4500 field emission scanning electron microscope (Hitachi 
High-Technologies Corp., Tokyo, Japan) was used to obtain SEM micrographs of 
the powder samples.  Samples were mounted on conductive tape and sputter 
coated using a model K575 sputter coater (Emitech Products, Inc., Houston, TX, 
USA) with gold/palladium for 30 s. An accelerating voltage of 5-15 kV was used 
to view the images. 
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5.3.3.4 Dissolution Testing at Below Equilibrium Solubility 
Dissolution testing at below equilibrium solubility was performed on the 
URF powder samples using a United States Pharmacopeia (USP) 27 Type 2 
dissolution apparatus (VanKel VK6010 Dissolution Tester with a Vanderkamp 
VK650A heater/circulator, Varian, Inc.  Palo Alto, CA).  Powder samples (0.4 mg 
of TAC) equivalent to approximately 59% of the equilibrium solubility (6.8 
µg/mL) were added to 100 mL of modified simulated lung fluids (SLF) with 0.02 
% DPPC as dissolution media [29].  The dissolution media was maintained at 
37.0 ± 0.2°C and stirred at a constant rate of 50 rpm.  Samples (1 mL) were 
withdrawn at 10, 20, 30, 60 and 120 minute time points, filtered using a 0.45 µm 
GHP Acrodisc filter (VWR, Inc., West Chester, PA) and analyzed using a 
Shimadzu LC-10 liquid chromatograph (Shimadzu Corporation, Kyoto, Japan) 
equipped with an Alltech ODS-2, 5 µm C18 column (Alltech Associates, Inc., 
Deerfield, IL).  The mobile phase consisted of a 70:30 (v/v) ACN: Water mixture, 
used at a flow rate of 1 mL/min.  The maximum absorbance was measured at 
wavelength λmax= 214 nm. 
 
5.3.3.5 Dissolution Behavior in the Formation of Supersaturated Solutions 
 Supersaturated dissolution profiles were generated according to the 
method described above (Section 5.3.3.4) except using the small volume 
dissolution apparatus equipped with a paddle stirring mechanism.  Each drug 
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formulation was weighed out which corresponded to approximately 15-times the 
aqueous crystalline solubility of TAC in 100 mL of the modified simulated lung 
fluid with 0.02% DPPC.  Paddle speed and bath temperature were maintained at 
100 rpm and 37oC, respectively.  An aliquot (1 mL) were removed from the small 
volume dissolution vessel at 10, 20, 30 and 60 minutes, then at 2, 4 and 24 hours.  
Each aliquot was filtered through a 0.2 µm nylon filter, and a 0.5 mL aliquot of 
each filtered solution was immediately mixed with 1 mL of acetonitrile (to ensure 
no re-crystallization of drug previously dissolved at 37°C).  The samples were 
analyzed for TAC concentration using the same HPLC procedure described above 
(Section 5.3.3.4).  All experiments were performed in triplicate. 
 
5.3.3.6 In Vitro Aerosol Performance 
The in vitro deposition characteristics of the dispersed and nebulized TAC 
formulations were investigated using a non-viable 8-stage cascade impactor 
(Thermo-Electron Corp., Symrna, GA, USA).  The aerosolization behavior was 
described in terms of total emitted dose (TED), fine particle fractions (FPFs), 
mass median aerodynamic diameters (MMAD) and geometric standard deviation 
(GSD).  The cascade impactor was assembled and operated in accordance with 
USP method 601 to assess the drug delivered.  The powders were dispersed in 
water (10 mg/mL) and nebulized using an Aeroneb® Pro micropump nebulizer 
(Nektar Inc., San Carlos, CA) for 10 minutes at an air flow rate of 28.3 L/min.  
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The flow rate was maintained by a vacuum pump (Emerson Electric Co., St. 
Louis, MO, USA) and calibrated by a TSI mass flow meter (Model 4000, TSI 
Inc., St. Paul, MN, USA). The mass deposited on each of the stages was collected 
and analyzed by HPLC as in Section 5.3.3.4.  Each experiment was repeated in 
triplicate.  
 
5.3.4 In Vivo Mouse Studies 
5.3.4.1 Pulmonary Administration of URF Formulations 
Pulmonary dosing of URF formulations was performed in healthy male 
ICR mice (Harlan Sprague Dawley, Inc., Indianapolis, IN).  The study protocol 
was approved by the Institutional Animal Care and Use Committee (IACUCs) at 
the University of Texas at Austin, and all animals were maintained in accordance 
with the American Association for Accreditation of Laboratory Animal Care.  
Mice were acclimated and pre-conditioned in the restraint tube (Battelle, 
Inc.,Columbus, OH) for 10–15 min./day for at least 2 days prior to dosing.  Proper 
pre-conditioning is essential for reducing stress to mice, and maintaining a 
uniform respiration rate for the animals.  A small animal dosing apparatus for 
inhalation was used to dose the mice for this study.  The dosing apparatus was 
designed to hold up to 4 mice as shown schematically in Figure 5.2.  The dosing 
apparatus consists of a small volume hollow tube with dimensions of 20 x 4.5 cm 
(nominal wall thickness of 0.4 cm) with four 1.75 cm adapter holes drilled at 7 cm 
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intervals (2 holes along each side).  The adapter holes were constructed to accept 
rodent restraint tubes from the Battelle toxicology testing unit (Figure 5.3).  
The URF processed powders were re-dispersed in water (10 mg/mL) 
followed by sonication for 1 min. prior to dosing.  Nebulization of 3 mL of 
dispersions was conducted using an Aeroneb Pro ultrasonic nebulizer for 10 min. 
dosing period.  After pulmonary dosing, the mice were removed from the dosing 
apparatus and rested for 15 min.  Two mice were sacrificed at each time point by 
CO2 narcosis (0.5, 1, 2, 3, 6, 12, 24 and 48 hours).  Whole blood (1-mL aliquots) 
was obtained via cardiac puncture and analyzed according to the standard ELISA 
procedure outlined in Section 5.3.4.2.  In addition, necropsy was performed on 
each mouse to extract lung tissue.  Samples were stored at −20 C until assayed.  
TAC concentrations in lung tissue were determined using a previously HPLC 
assay as described in Section 5.3.3.4. 
 
5.3.4.2 Enzyme-Linked Immunosorbent Assay (ELISA) for Analysis of TAC 
Concentrations in Blood  
The determination of TAC in whole blood was performed using the PRO-
TracTM II FK 506 ELISA assay kit (Diasorin Inc., Stillwater, USA) in accordance 
with the manufacturer's instructions.  Specifically, 50 µL of whole blood sample 
or standards were placed into a conical 1.5 mL polypropylene tube.  Digestion 
reagent was freshly reconstituted, and 300 µL was added to all tubes.  The tubes 
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were vortexed for 30 seconds and incubated at room temperature for 15 min.  
These tubes was then placed on an aluminum heating block circulated with  75°C 
water bath for 15 min to stop proteolysis.  After vortexing, the tubes were 
centrifuged at room temperature at 1,800 xg for 10 min. The supernatant (100 µL) 
was transferred to microtiter plate wells in duplicate from each centrifuged tube.  
Capture monoclonal anti-FK506 (50 µL) was added to the each well, and the plate 
was shaken at room temperature at 700 rpm for 30 min.  TAC horseradish 
peroxidase conjugate (50µL) was then added to each well, and the plate was 
shaken at room temperature at 700 rpm for an additional 60 min.  The plate was 
washed, before the addition of 200 µL chromogen.  The plate was then shaken at 
700 rpm for a further 15 min at room temperature.  The subsequent reaction in 
each plate well was terminated by the addition of 100 µL of stop solution.  The 
absorbance in each well was read at the dual wavelengths of 450 and 630 nm.  
Data was plotted according to a four-parameter logistic (4PL) curve-fitting 
program.  
5.3.4.3 Solid Phase Extraction and Drug Analysis of Lung Tissues using HPLC  
Lung extraction was carried out using solid phase extraction to obtain 
TAC levels using reverse phase HPLC.  The total lung weight was recorded 
individually from each mouse.  Lung tissues were homogenized using a Polytron 
rotor-stator homogenizer (VWR Scientific Corporation, West Chester, PA) for 40 
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seconds in 1 mL of normal saline.  The homogenized lung samples were then 
mixed with 0.5 mL solution of 0.4 N zinc sulfate heptahydrate in the mixture of 
methanol/water (70:30) solution and vortex mixed for 30 seconds.  Acetonitrile (1 
mL) was added to the homogenized samples before a further vortex mixing for 
1.5 minutes, followed by centrifugation at 3000 rpm for 15 minutes to obtain a 
clear supernatant.  Next, the supernatant was collected into a clean vial containing 
1 mL purified water.  Meanwhile C18 cartridges for solid phase extraction 
(Supelco Inc., Bellefonte, PA) were preconditioned.  First, these columns were 
pretreated with 2 mL of acetonitrile, followed by 1 mL methanol and then washed 
with 1 mL of water before loading the supernatant through the column.  The 
sample was transferred and drawn slowly through the column by reducing the 
vacuum.  The column was washed again by passing 1.5 mL mixture of 
methanol/water (70:30) solution, followed by 0.5 mL of n-hexane and allowed it 
to dry under vacuum.  The sample was finally eluted with 2 mL of acetonitrile 
(0.5 mL x 4).  The eluted material was evaporated under a dry nitrogen stream 
and then reconstituted with 250 µL of mobile phase using the previously 
described HPLC assay (Section 5.3.3.4).  Data was expressed as µg TAC/gram 
wet lung tissue analyzed. 
 
5.3.4.4 Pharmacokinetics and Statistical Analysis 
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The lung tissue concentration vs. time was investigated using a non-
compartmental model, while the whole blood concentration vs. time was 
evaluated using one-compartmental analysis from extravascular administration 
(via the lung compartment).  Pharmacokinetic parameters were calculated using 
using WinNonlin version 4.1 (Pharsight Corporation, Mountain View, CA).  The 
pharmacokinetic profile of TAC was characterized by maximum concentration 
(Cmax), time to Cmax (Tmax), half-life (T1/2) and area-under-the-curve (AUC) 
between 0-24 hours.  AUC was calculated using the trapezoidal rule; Cmax and 
Tmax were determined from the concentration-time profiles; T1/2 was calculated by 
using the elimination rate constant (Kel); Kel was obtained from the ln 
concentration-time profiles.  
The data sets were compared using a Student’s t-test of the two samples 
assuming equal variances to evaluate the differences.  The significance level (α = 
0.05) was based on the 95% probability value (p < 0.05). 
 
5.4 RESULTS AND DISCUSSION  
 
5.4.1 In vitro characterization of URF formulations 
The physicochemical properties of TAC powders produced by URF were 
investigated and compared to the unprocessed TAC.  The XRD patterns of the 
URF formulations and unprocessed TAC are shown in Figure 5.4.  The 
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diffractogram of URF-TAC was similar to that of unprocessed TAC, indicating a 
high degree of crystallinity.  However, the XRD pattern of URF-TAC:LAC 
confirmed that this composition was amorphous. This suggests that lactose 
inhibited crystallization of TAC. It is well known that sugars such as lactose can 
be used to stabilize amorphous drugs, peptides and proteins during drying and 
subsequent storage [30,31].  The addition of sugars has been shown to extend the 
shelf life of amorphous systems by preventing crystallization.  In addition, lactose 
is generally regarded as safe (GRAS) for use as an excipient in inhalation systems 
[32].  This is due to its non-toxic and degradable properties after administration 
[33]. 
SEM micrographs of the two URF processed formulations are shown in 
Figure 5.5 reveal distinct differences in morphology. The morphology of URF-
TAC:LAC (Figure 5.5a-5.5b) showed highly porous, nanostructured aggregates.  
The micrograph at high magnification in Figure 5.5b revealed that the aggregates 
were composed of branched interconnected nanorods with a diameter of 
approximately 100-200 nm.  URF-TAC (Figure 5.5c-5.5d) appeared as more 
dense aggregates composed of submicron primary particles.  In contrast, the SEM 
micrograph of unprocessed TAC indicated an irregular, dense and large crystal 
plate measuring between 50-100 µm in size (Figure 5.5e).  Accordingly, the 
surface areas obtained by the URF processed formulations (URF-TAC:LAC and 
URF-TAC was 25.9 and 29.3 m2/g, respectively) were significantly higher than 
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(p< 0.05) that of the unprocessed drug (0.53 m2/g).  This result is corroborated by 
the porous nanostructured aggregates of the URF powders observed by SEM. 
The in vitro aerosol performance measured by cascade impaction for 
aqueous dispersions prepared from the URF processed powders are presented in 
Table 5.1.  Comparison of the data suggests similar aerodynamic properties of the 
drug particles aerosolized from the two URF formulations.  The MMAD was 2.86 
and 2.57 µm for URF-TAC:LAC and URF-TAC, respectively, and the GSD was 
less than 2.2 (Table 5.1).  It can be concluded that the aerosol droplets contain 
aggregates of nanoparticles that are in the respirable range by nebulization.  
Aerodynamic particle size is the most important parameter in determining drug 
deposition in the lungs and must be considered when developing formulations for 
pulmonary delivery [34].  Aerosolized particles or droplets with a MMAD 
ranging from 1 to 5 µm are suitable for deep lung deposition, at the site of the 
alveoli, where maximum absorption may take place [35].  The optimal 
aerosolization properties of both URF formulations are also reflected in the high 
%FPF ranging from 70% to 75%, illustrating efficient lung delivery of drug 
particles.  The TED was only slightly higher for URF-TAC:LAC (5082 µg) 
compared to that of URF-TAC (4823 µg). These values were not significantly 
different (p > 0.05). 
The in vitro dissolution profiles of TAC in SLF media under sink 
conditions are shown in Figure 5.6.  The dissolution rates for both URF processed 
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powders were significantly increased (p<0.05) as compared to the unprocessed 
TAC.  Nanostructured aggregates of the URF processed powders were able to wet 
and dissolve quickly upon contact in SLF containing 0.02% DPPC, although the 
formulations contained no surfactant.  For URF-TAC:LAC (i.e., amorphous, 
nanostructured aggregates), the dissolution of TAC was 72% in 30 minutes, 
compared to 67% for the URF-TAC (i.e., crystalline nanostructured aggregates) 
and 30% for the unprocessed TAC, respectively. The enhancement is most likely 
attributed to the high porosity and enhanced surface area of URF processed 
powders.  
Dissolution of TAC at supersaturated conditions was also conducted in the 
same media.  Supersaturated dissolution profiles of the URF processed 
formulations containing about 15-times the equilibrium solubility of TAC are 
compared in Figure 5.7.  The concentration obtained for the URF-TAC:LAC 
exceeded the equilibrium solubility of TAC, corresponding to a high degree of 
supersaturation in the SLF containing DPPC without the presence of surfactants 
or polymers in the formulation.  The level of supersaturation corresponded to 
about 11-times the equilibrium solubility.  This was due to the high-energy phase 
of the amorphous TAC particles.  The maximum concentration occurred at 1 hour, 
and then decreased to 3-times equilibrium solubility over the next 4 hours.  A 




5.4.2 In Vivo Pulmonary Studies  
The pharmacokinetic absorption studies were conducted in mice. The 
murine model has been very effective for small scale inhalation studies [36].  The 
lung tissue concentration-time profiles following a single inhalation dose are 
shown in Figure 5.8 while the corresponding pharmacokinetic parameters 
summarized in Table 5.2. Cmax for URF-TAC:LAC was significantly higher 
(14.09 µg/g) compared to URF-TAC (10.86 µg/g) whereas Tmax was significantly 
lower (p< 0.05) for 2 hours.  This could perhaps as a result of a greater dissolved 
concentration, as seen in the vitro supersaturation results. However, no significant 
differences in AUC-values (0-24 hr) were observed between the two URF 
formulations (p>0.05). The results indicated that the amorphous nature of the 
particles affects the rate of drug absorption. TAC in the URF-TAC:LAC was 
eliminated according to a biphasic pattern with distribution phase and elimination 
phase.  The similar elimination pattern was also found in the URF-TAC  The 
values of Kel were not significantly different between the two URF-formulations 
(p > 0.05).  The decreasing TAC concentration in the lung for both URF 
formulations is a consequence of drug distribution and transport into the systemic 
circulation, as well as particle elimination from the lung.  It can be seen clearly 
that the transfer of nanostructured aggregates (either amorphous or crystalline) 
from the lung into systemic circulation was likely in a sustained manner after 6 hr.  
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The measured levels for both URF formulations at 48 hours were below the limit 
of quantification of the assay (determined to be1 µg/g). 
The systemic in vivo pharmacokinetic of drug absorption from the lungs 
was investigated in mice.  Figure 5.9 shows a comparison of mean whole blood 
concentration-time profiles from each formulation, and the calculated 
pharmacokinetic parameters following pulmonary administration are presented in 
Table 5.3.  The whole blood concentration profile of each formulation has a 
similar absorption pattern, for example, Tmax,  compared to the lung concentration 
profiles (Figure 5.8).  However, both URF formulations demonstrated 
substantially lower TAC concentrations in the blood than was seen in the lung 
tissue.  The whole blood profiles following pulmonary dosing of URF-TAC:LAC 
and URF-TAC had peak concentrations of 402.11 ng/mL at 2 hr and 300.67 
ng/mL at 3 hr, respectively, before concentrations decreased.  The AUC(0-24) 
(1235.66 ng.hr/mL) of the URF-TAC:LAC processed by URF is slightly lower 
than that of the URF-TAC (1324.35 ng.hr/mL), although there is no statistical 
difference (p>0.05).  The levels of TAC decreased rapidly for URF-TAC:LAC 
with the last time point with a detectable levels occurring at 24 h, while URF-
TAC declined in a similar but slower manner (no significant difference in the Kel 
values (p > 0.05)).  Whole blood concentrations of TAC were below the limit of 
quantification for both formulations at 48 hours.  The systemic and lung 
concentrations observed after nebulization of both URF formulations in mice 
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suggest that a substantial lung and systemic exposure to TAC can be achieved in 
either amorphous nanostructed aggregates or crystalline nanostructed aggregates 
produced by URF.  The observation that either amorphous or crystalline particles 
produced high systemic concentrations may suggest that high surface area was an 
important factor.  High supersaturation, as a result of delivering amorphous 
particles in URF-TAC:LAC, correlated with faster absorption rates in both blood 
and lung tissue as compared to crystalline particles in URF-TAC . Use of 
supersaturated state in the lungs has not been previously studied yet.  However, it 
has been demonstrated to enhance transdermal and oral absorption of poorly 
soluble drugs [37-39].  The in vivo data reported by Yamashita et al. [37] showed 
a high and extended systemic absorption of TAC following oral administration of 
amorphous solid dispersions with HPMC in beagle dogs.  In the Yamashita et al. 
study, the solid dispersion of TAC with HPMC was prepared by solvent 
evaporation and was also shown to supersaturate in 0.1N HCl up to 25-times in 2 
hours, and this level was maintained for over 24 hours.  In our study, 
supersaturation of TAC from URF-TAC:LAC showed no effect on the extent of 
drug absorption in both lung tissue and systemic circulation.  This can be 
explained by the fact that supersaturation occurred over a short period of time for 
the absorption phase and then TAC concentration was rapidly decreased in the 
elimination phase.  
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5.5 CONCLUSIONS  
High surface area, nanostructured aggregates containing amorphous or 
crystalline nanoparticles of TAC were produced by the URF process and shown to 
be effectively aerosolized in an aqueous dispersion by nebulization.  Inclusion of 
lactose prevented crystallization of TAC and resulted in amorphous powder.  
URF-TAC:LAC (i.e., amorphous nanostructured aggregates) demonstrated the 
ability to supersaturate in SLF compared to the URF-TAC (i.e., crystalline 
nanostructured aggregates).  Dispersions of nebulized URF formulations 
exhibited high lung and systemic concentrations.  The AUC (0-24) of the URF 
formulations which reflects the total amount of drug absorbed over the 24 h time 
period was not significantly different (p > 0.05) for either lung or blood profiles.  
The results indicate that high drug absorption in lung tissue and blood following 
pulmonary administration was primarily due to high surface area of 
nanostructured aggregates from both formulations.  The ability to achieve high 
solubility in the lungs translated to higher Cmax and lower Tmax values based on 
results of the in vivo studies.  We have demonstrated that nanoparticles of TAC 
can be successfully delivered to the lungs without the use of polymers or 
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Table 1.1: Potential R&D targets by 2015 for U.S. National Nanotechnology 
Initiative. Reprinted with permission from G. A. Hughes, Dis. Mon. 51, 342, 
2005, Copyright Elsevier (2005). 
 
Nanoscale visualization and simulation of 3-dimensional domains 
Transistor beyond/integrated CMOS <10 nm 
New catalysts for chemical manufacturing 
No suffering and death from cancer when treated 
Control of nanoparticles in air, soils, and waters 
Advanced materials and manufacturing: one-half from molecular level 
Pharmaceuticals synthesis and delivery: one-half on nanoscale level 
Converging technologies from nanoscale 
Life-cycle biocompatible/sustainable development 








Table 1.2: Examples of different nanoparticles and their applications. Reprinted 
with permission from G. Orive et al., Trends Pharmacol. Sci. 25, 382, 




Table 2.1: Adsorption (Wsurf,ads /Wdrug,ppt) of stabilizers onto ITZ particle surface 
after  EPAS process at 80oC. Drug: organic stabilizer: aqueous stabilizer 
(0.75:0.1:1) (w/w) at final concentration of 15 mg/ml of ITZ in the aqueous EPAS 
dispersion. 
  





- - - 
Polysorbate 80 Poloxamer 407 10.72 ± 0.14 
PVP K-15 PVP K-15 5.38 ± 0.14 
Poloxamer 407 Poloxamer 407 6.46 ± 0.36 
Polysorbate 80 PVP K-15 5.86 ± 0.83 
PVP K-15 Poloxamer 407 5.70 ± 0.73 
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Table 2.2: Characterization of ITZ powders. Drug: organic stabilizer: aqueous 
stabilizer (0.75:0.1:1) (w/w/w) at final concentration of 15 mg/ml of ITZ in the 
aqueous EPAS dispersion. All dispersions were centrifuged and dried by 
lyophilization.   
/  not measured; * provided by manufacturer 


















Bulk powder / / 4.22 + 0.10 61.6 + 0.54 
Physical Mixture 
Polysorbate 80 Poloxamer 407 
   
3.09 + 0.27 
 
52.3 + 0.85 
Polysorbate 80 Poloxamer 407 90.5 9.5  3.25 + 0.22 30.3 + 0.66 
PVP K-15 PVP K-15 90.3 9.3 5.77 + 0.33 43.5 + 0.47 
Poloxamer 407 Poloxamer 407 93.8 15.1 6.31 + 0.61 35.1 + 0.63 
Polysorbate 80 PVP K-15 93.1 13.5 3.33 + 0.21 32.7 +0.79 
PVP K-15 Poloxamer 407 91.4 10.6 5.87 + 0.38 42.8 + 0.84 
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E1 Poloxamer 407 Poloxamer 407 0.62 a 
E2 Poloxamer 188 Poloxamer 188 0.60 a 
E3 PVP K15 PVP K15 0.64 a 
E4 Poloxamer 407 Poloxamer 407 10.76 b 
E5 Poloxamer 407 Poloxamer 407 5.36 b 
E6 Poloxamer 407 Poloxamer 407 3.57 b 
Dispersion concentration: 15 mg/ml 
a Without centrifugation 








































Bulk ITZ 1.43* 
 
n/a 100 2.02 + 0.10 
 
61.6 + 0.54 n/a 
E1 5.63 + 0.91 1.81 + 0.02 38.2 8.79 + 0.42 30.2 + 0.62 
 
0.62 
E2 9.75 + 1.43 1.22 + 0.02 37.7 5.82 + 0.62 36.8 + 0.41 0.60 
E3 15.5 + 1.84 1.43 + 0.05 38.9 4.16 + 0.37 39.5 + 0.39 0.64 
E4 5.94 + 0.83 1.81+ 0.02 91.5 7.25 + 0.58 35.7 +0.58 10.76 
E5 5.87 + 1.15 1.45 + 0.01 84.3 8.44 + 0.81 32.5 +0.52 5.36 
E6 6.12 + 1.22 1.66 + 0.04 78.1 8.51 + 0.69 30.6 +0.36 
 
3.57 






































Stearate    
(%) 
Tablet E1 40.0 34.0 20.0 5.0 0.5 0.5 
Tablet E2 40.0 34.0 20.0 5.0 0.5 0.5 
Tablet E3 40.0 34.0 20.0 5.0 0.5 0.5 
































Tablet E1 199.75 11.4 20 0.11 
Tablet E2 200.28 11.2 21 0.09 

























Table 4.1: Molecular structures of drug and polymers used in this study. 







































rate           
Calculated 
initial rate  
REP/HPMC E5 9.35 374 642 2.38 6.85 
REP/PVPK15 5.08 203.2 1180 1.66 2.02 
REP/PEG8000 4.97 198.8 1210 1.66 1.94 
REP/PVA 3.57 142.8 1680 1.0 1.00 
*Experimental rates were based on the 2 min. concentration value from Figure 6, all rates 
are reported relative to the 1:1 REP/PVA case. 
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Table 5.1: Physicochemical properties of TAC powder compositions prepared by 
the URF process and aerosol characteristics of aqueous dispersions of URF 
powder compositions delivery by nebulization. 
. 
 
TED: total emitted dose. 
MMAD: mass median aerodynamic diameters. 
GSD: geometric standard deviation. 





















URF-TAC:LAC Amorphous 29.3 5082 74.6 2.57 2.24 
URF-TAC  Crystalline 25.9 4823 70.2 2.86 1.97 
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Table 5.2: In vivo pharmacokinetic parameters for the lung tissue concentrations 
of the URF formulations. 
 










URF-TAC  10.86 +1.07 3 0.0346 20.02 111.19 + 20.16 
URF-TAC:LAC 14.09+1.50 2 0.0334 20.75 122.42 + 6.19 
Cmax : maximum concentration  
Tmax : time to Cmax  
Kel   : elimination rate constant 
T1/2  : half-life  















Table 5.3: In vivo pharmacokinetic parameters for the whole-blood concentrations 
of the URF formulations following the pulmonary administration. 
 
 
Cmax : maximum concentration  
Tmax : time to Cmax  
Kel   : elimination rate constant 
T1/2  : half-life  





















URF-TAC  300.67 + 27.04 3 0.123 5.63 1324.35+ 318.07 
URF-TAC:LAC 402.11+ 35.99 2 0.115 6.02 1235.66+ 65.86 
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URF-TAC: Mannitol 21.8 
 
URF-TAC: Glucose 15.6 
 
Unprocessed TAC 0.53 
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Temperature of organic (MeCl2) and aqueous solution 80O C 
Flow rate Q (ml/min)/pressure drop ∆P (MPa) 1.0/~20 
Crimp Nozzle: stainless steel tube    1/16 in. o.d. 
Drug concentration in feed solution 15% w/v 
Conc. of  Pluronic F127 in aqueous and organic phases 2% w/v 
Conc. of  Ammonium Carbonate  
(add in organic solution and sonicate for 40 sec.) 
0, 0.5 and 1% w/v 
Volume of receiving aqueous solution Vrec  50 ml 
Spraying time 5 min 
Drug/surfactant ratio (w/w) in dispersion 0.68 


























Organic phase: 15% w/v ITZ + 2% w/v Poloxamer 407 in MeCl2 
Aqueous phase: 2% w/v Poloxamer 407 
Drug :Surfactant Ratio : 1:1.47 by weight 
All dispersions were dried by rapid freezing into liquid nitrogen and lyophilization 

























30.9 + 0.67 
31.5 + 0.58 
30.4 + 0.52 
Contact angle  
(o)
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Figure 1.1: Schematic representation of different nanotechnology-based drug 
delivery systems. Reprinted with permission from S. K. Sahoo and V. 
Labhasetwar, 8, 1112, 2003, Copyright Elsevier (2003). 
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Figure 1.2: Targeting of intracellular bacteria with antibiotic colloidal carriers, 
liposomes or nanoparticles. P, Phagosome, L, Lysosome, PL, Phagolysosome. 
Reprinted with permission from H. Pinto-Alphandary et al. Int. J. Antimicrob. 










Figure 1.3: Schematic diagrams of the (a) RESS, (b) GAS, and (c) 
PCA/SAS/ASES processes. Reprinted with permission from B. Subramaniam et 
al., J. Pharm. Sci., 86, 885, 1997, Copyright American Scientific Publishers 
(1997). 
       (a.) 
             (b.) 
    (c.)   
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Figure 1.4: Schematic flow diagram of the SEDS process along with the cross-
section of the co- and tri-axial fluid nozzles. Reprinted with permission from J. 














Figure 1.5: Adsorption isotherms and corresponding adsorption models, (A) 
particles <1 µm, (B) particles>1 µm. Reprinted with permission from G. Ponchel 








Figure 2.1: Schematic representation of EPAS process and the photograph 














































Figure 2.3: Dissolution profile of itraconazole with different surfactant systems. 
The weight ratios shown are ITZ:organic stabilizer: aqueous stabilizer. All 
dispersions were centrifuged and dried by lyophilization.  The final drug 
concentration was 15 mg/ml. The dissolution media was enzyme-free simulated 
gastric fluid containing 0.5% SLS (pH 1.2) and dissolution profiles were 























ITZ: poloxamer 407: polysorbate 80 (0.75:0.1:1) ITZ: poloxamer 407: poloxamer 407 (0.75:0.1:1)
ITZ: PVP-K15: polysorbate 80 (0.75:0.1:1) ITZ: poloxamer 407 : PVP-K15 (0.75:0.1:1)







Figure 2.4: TEM micrograph of of  itraconazole EPAS particles with  
poloxamer 407 as organic stabilizer and polysorbate 80 as aqueous stabilizer. 
The ratios of ITZ:organic stabilizer:aqueous stabilizer were 0.75:0.1:1. The 
dispersion was centrifuged and dried by lyophilization.  The final drug 












Figure 2.5: EDS Spectrum of  itraconazole EPAS particles with  poloxamer 
407 as organic stabilizer and polysorbate 80 as aqueous stabilizer. The ratios 
of ITZ:organic stabilizer:aqueous stabilizer were 0.75:0.1:1. The dispersion 
was centrifuged, frozen and dried by lyophilization.  The final drug 









Figure 2.6: X-ray diffraction patterns of ITZ formed by EPAS (a) control: bulk 
ITZ, (b) ITZ: PVP K15: PVP K15, (c) ITZ:PVP K15:poloxamer 407, (d) 
ITZ:poloxamer 407:poloxamer 407, (e) ITZ:poloxamer 407:polysorbate 80 and 
ITZ:poloxamer 407:PVP K15. The ratios of ITZ:organic stabilizer:aqueous 
stabilizer were 0.75:0.1:1. All dispersions were centrifuged and dried by 
lyophilization.  The final drug concentration was 15 mg/ml. The patterns clearly 




























Figure 3.1: Schematic representation of EPAS process and the photograph 


























Figure 3.2: SEM micrographs of (a) Bulk ITZ; (b) EPAS with poloxamer 407 (E1 





(a)      (b) 
 
(c)      (d) 
 








Figure 3.3: (a) Dissolution profile of EPAS processed powders with different 
stabilizer systems. ( , E1 powders) EPAS with poloxamer 407, (▲, E2 powders) 


































(b) Dissolution profiles of ITZ EPAS powders with poloxamer 407 at different 
drug-to-stabilizer ratios. ( , E1 powders) 0.62, (♦, E4 powders) 10.76, (x, E5 
powders) 5.36, (∆, E6 powders) 3.57 and ( ) Bulk ITZ. Each result shows the 



































Figure 3.4: X-ray diffraction profiles of ITZ systems (a) bulk ITZ (b) E1 
powders (c) E2 powders (d) E3 powders (e) E4 powders  (f) E5 powders 







































Figure 3.5: Dissolution profile of EPAS tablets with various stabilizer systems. 
( ,Tablet E1) Tablet prepared from EPAS processed powders of ITZ with 
poloxamer 407, (▲,Tablet E2) Tablet prepared from EPAS processed powders of 
ITZ with poloxamer 188 and (■,Tablet E3) Tablet prepared from EPAS processed 







































Figure 4.2: SEM  images of  REP particles with  different stabilizing polymer 
systems (1:1).  The dispersion was frozen dropwise into liquid nitrogen and 
lyophilized.  (a) Bulk REP (b) REP: HPMC E5, (c) REP: PVP K 15, (d) REP: 
PEG 8000, (e) REP: PVA. 
(a)      (b) 
          
 
(c)       (d)   
           





















Figure 4.3A: X-ray diffraction patterns of  REP powders formed by controlled 
precipitation technology. (a) control: Bulk REP, (b) Physical mixture of 
components REP: HPMC E5 (1:1),  (c) REP: HPMC E5 (1:1), (d) REP: PEG 

































Figure 4.3B: X-ray diffraction patterns.(a) control: Bulk REP, (b) Physical 
mixture of REP: HPMC E5 (1:1),  (c) REP: HPMC E5 (1:1)-initial, (d) REP: 
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Figure 4.4: The reversing heat flow curves of REP with different stabilizing 





































Figure 4.5: Glass transition temperatures of REP containing PVP K15 and HPMC 

























Figure 4.6: Dissolution profiles of REP with different stabilizing polymer 
systems. (x) REP: HPMC E5 (1:1), ( )REP: PVP K 15 (1:1), (■)REP: PEG 8000 
(1:1), (▲)REP: PVA (1:1),  ( ) Bulk REP . The dissolution media was citric 
acid/sodium phosphate dibasic buffer with a pH of 4.5 and dissolution profiles 































Figure 4.7: Supersaturated dissolution of REP with various compositions at drug 
loading (10x). (▲)HPMC E5 ; (x) PVP K15 (■) PEG 8000 ; ( )PVA. The 
dissolution media was citric acid/sodium phosphate dibasic buffer with a pH of 
4.5, 50 rpm, 37oC, small volume paddle method. The dissolution profiles were 



































Figure 4.8: Supersaturated dissolution of REP: HPMC E5. (▲)Drug loading (25x) 
at initial time point ; (■) Drug loading (10x) at initial time point ; ( )Drug 
loading (10x) after 3 months at 25°C /60% RH. The dissolution media was citric 
acid/sodium phosphate dibasic buffer with a pH of 4.5, 50 rpm, 37oC, small 
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 227
 























































Figure 5.5: SEM micrographs of (a) URF-TAC:LAC (1:1) at low magnification, 
(b) URF-TAC:LAC (1:1) at high magnification, (c) URF-TAC at low 
magnification, (d) URF-TAC at high magnification t, (e) Unprocessed TAC at 
low magnification. 
(a)       (b) 
 
(c)       (d) 
 















Figure 5.6: Sink dissolution profiles for (■) Amorphous URF composition TAC: 
lactose (1:1), (▲) Crystalline URF composition TAC alone and ( )Unprocessed 
TAC. The dissolution media was modified simulated lung fluids (SLF) containing 
0.02 % DPPC at 100 rpm and 37oC (equilibrium solubility of TAC in this media ~ 































Figure 5.7. Supersaturated dissolution profiles. for ( ) Amorphous URF 
composition TAC: lactose (1:1); (■) Crystalline URF composition TAC alone and 
(---) Equilibrium solubility of TAC in the dissolution media (6.8 µg/mL). The 
dissolution media was modified simulated lung fluids (SLF) containing 0.02 % 































Figure 5.8: Comparison of mean lung concentration (µg TAC/g tissue) versus 
time profiles of the URF formulations. ( ) Amorphous URF composition TAC: 






























Figure 5.9: Comparison of mean whole-blood TAC concentration profiles of the 
URF formulations after a single inhalation administration. ( ) Amorphous URF 















































































Figure B.2: In vivo dosing based on individual wet lung weights for mice dosed 



























































Figure C.1:  SEM micrographs of TAC particles processed by URF with (a) 


















Figure C.2: X-ray diffraction patterns of processed TAC compositions compared 






















































URF TAC :Lactose 





Figure C.3: Dissolution profiles of processed TAC compositions compared to 
unprocessed TAC (●) URF-TAC:Inulin ;(■) URF-TAC:Lactose ;(▲)URF-TAC: 
Mannitol ;(x) URF-TAC: Glucose ;(○) Unprocessed TAC. The dissolution media 
was modified simulated lung fluids (SLF) containing 0.02 % DPPC at 100 rpm 
and 37oC (equilibrium solubility of TAC in this media ~ 6.8 µg/mL). Dissolution 
















































































Figure D.2: SEM micrographs of EPAS  powders containing  0%(NH4)2CO3 , E1 




















Figure D.3: Dissolution profiles of EPAS powders in 0.1N HCl, 0.5% SLS  at 










































Appendix A: Lyophilization Recipes used in Chapter 5 
Lyophilization Recipe A1 (long recipe) used in for URF-TAC: LAC (1:1) 
Step Temperature (°C) Time (min) Vac (mT) R/H 
1 -60 500 200 H 
2 -40 500 200 H 
3 -30 1440 100 R 
4 -20 180 100 R 
5 -10 180 100 R 
6 0 180 100 R 
7 10 180 100 R 
8 25 180 100 R 
9 25 500 100 H 
 
Lyophilization Recipe A2 (short recipe) used in for URF-TAC 
Step Temperature (°C) Time (min) Vac (mT) R/H 
1 -40 180 400 H 
2 -30 180 200 R 
3 -20 180 200 R 
4 -10 180 200 R 
5 0 180 300 R 
6 10 180 400 R 
7 20 180 500 R 
8 30 240 600 H 
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Appendix B: In Vitro and In Vivo Evaluation of a Nose-Only 
Aerosol Dosing Apparatus for Rodents 
B.1 PURPOSE 
 
 Appendix B is a supplement to Chapter 5.  In Appendix B, the dosing 
uniformity and variability of itraconazole (ITZ) was investigated both in vitro and 
in vivo using the nose-only aerosol dosing apparatus described in Chapter 5. This 
dosing apparatus was designed to deliver the aerosol directly to the nose. Such 
design is required a small amount of test material thereby it is useful for 
delivering ‘expensive’ drugs. 
 




The following materials were purchased: ITZ (ITZ; Hawkins Chemical, 
Minneapolis, MN); poloxamer 407, polysorbate 80, potassium phosphate 
monobasic, sodium hydroxide (NaOH) and sodium chloride (NaCl) (Spectrum 
Chemicals, Gardena, CA); high performance liquid chromatography (HPLC) 
grade acetonitrile and dichloromethane (EM Industries Inc., Gibbstown, NJ). 
Liquid nitrogen was obtained from Boc Gases (Murray Hill, NJ). 
  
B.2.2 Production of an Amorphous ITZ Pulmonary Composition 
Amorphous nanoparticles of ITZ were produced using the particle 
engineering process spray freezing into liquid (SFL). A solution of ITZ, 
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polysorbate 80 and poloxamer 407 was prepared at a 1:0.75:0.75 ratio in 
acetonitrile with 4% w/w dichloromethane as a cosolvent. This solution was 
atomized through a 63 µm poly-etherether-ketone (PEEK) nozzle (Upchurch 
Scientific, Oak Harbor, WA) via an HPLC pump (Jasco PU-2086plus, Jasco Inc., 
Easton, MD) at 20 mL/min below the surface of liquid nitrogen. The frozen 
microparticles were then separated from the liquid nitrogen and the solvent was 
removed by lyophilization (VirTis Advantage, VirTis, Gardiner, NY). The dried 
powders were stored under vacuum until dispersion and administration. 
B.2.3 In Vitro Aerosol Exposure 
An aliquot sample of the aerosol was taken from each exposure port 
following nebulization. ITZ concentration was determined using a Shimadzu LC-
10 liquid chromatograph. The mobile phase for in vitro assay consisted of 
acetonitrile: water (70:30 v/v) containing 0.02% diethylamine. The flow rate was 
1.0 mL/min and the absorption wavelength (λmax) was 263 nm. ITZ was eluted 
from an Inertsil 5um ODS-2 column (4.6 mm i.d. x 150 mm; Alltech Associates, 
Inc., Deerfield, IL) at 5 min using an injection volume of 50 µl.  
B.2.4 In Vivo Aerosol Exposure in a Mouse Model 
Eight male ICR mice were placed in the chamber and dosed with an 
amorphous ITZ formulation for 10 minutes using the nose-only dosing apparatus 
described in Chapter 5.2.4.1 A schematic diagram of this dosing apparatus is 
shown in Figure. 5.2. The processed powders were redispersed in water (20 
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mg/mL) followed by sonication for 1 min prior to dosing. Nebulization of 4 mL 
dispersions was conducted using an Aeroneb® ultrasonic nebulizer for 10 minutes. 
Following dosing, the mice were removed from the chamber and allowed to 
equilibrate for 15 minutes. The mice were sacrificed and lungs (all lobes) were 
harvested from each animal. 
B.2.5 Lung Extraction Analysis Using HPLC 
Homogenized lung samples were analyzed using HPLC. Briefly, normal 
saline (1mL) was added to each harvested lung sample, this was then 
homogenized using tip ultrasonication. Aliquots of homogenate (250 µL) were 
transferred to 4 separate vials and drug was extracted similarly to the serum 
samples. Barium hydroxide 0.3 N (50µL) and 0.4 N zinc sulfate heptahydrate 
solution (50 µL) was then added to each to precipitate out water-soluble proteins. 
The samples were then vortex mixed (30 seconds). Acetonitrile (1 mL) containing 
100 ng/mL ketoconazole as an internal standard was added before a further vortex 
mixing (1.5 minute), followed by centrifugation at 3000 rpm (15 minutes). The 
supernatant was transferred to 1.5 mL centrifuge tubes and seated in an aluminum 
heating block (60°C), under a stream of nitrogen to dryness over 1 hour. Samples 
were then reconstituted with 250 µL mobile phase (62% acetonitrile:38% 0.05M 
potassium phosphate monobasic buffer adjusted to pH 6.7 with NaOH) and vortex 
mixed (1 minute) before filtering (0.45 µm) into HPLC glass injection vials with 
low volume inserts (150 µL). The sample was then analyzed using a Shimadzu 
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LC-10 liquid chromatograph (Shimadzu Corporation, Columbia, Maryland) 
equipped with a heated (37°C) C-18 base-deactivated column (5 µm, 250 x 4.6 
mm) protected by a C-18 guard column (5 µm, 7.5 x 4.6 mm) (Alltech Associates, 
Inc., Deerfield, IL).  
B.3 RESULTS 
The variability of ITZ concentrations was measured in vitro at the 4 
adapter ports, and in vivo from the lungs of 8 outbred-ICR mice in the appropriate 
mice restraining tubes at the adapter ports.  For in vitro study,   ITZ 
concentrations were determined to be 3.35 + 0.75 µg/mL at the adapter ports 
following 5 minutes nebulization (Figure B.1).  For in vivo study, the lung 
concentrations of ITZ were found to be 18.71 + 2.77 µg/g wet lung weight (n=8). 
This result was found to be two times higher than had previously been determined 
using a restraint-free whole body exposure unit in the same strain of mouse and 
double the exposure period.  The variation in the exposures received is shown in 
Figure B.2. Each mouse showed a similar lung concentration with relative 
standard deviation (RSD) of only 15%. The low variability of ITZ concentrations 
obtained in lung demonstrated the effectiveness of the nose-only dosing apparatus 
to generate a uniform dosing. Therefore, high concentrations of ITZ can be 
achieved in the mouse lung with low variability using nose-only aerosol dosing 
apparatus. In addition, the simplicity and inexpensive design of this aerosol 
dosing apparatus makes it very useful to study any kind of aerosol delivery. 
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Appendix C: Formulation Development of TAC for Aerosol 
Delivery to the Lung 
                                                                                                                                                                     
C.1 PURPOSE 
The objective of the study in the Appendix C was to investigate the effect 
of various excipients on physicochemical properties of nanostructured aggregates 
of TAC produced by URF intended for pulmonary delivery. Four types of 
excipient used in this study, including glucose, lactose, mannitol and inulin. The 
samples were characterized by x-ray diffraction (XRD), scanning electron 
microscopy (SEM), specific surface area, contact angle and dissolution testing. 
 




The four excipients used in this study, including glucose, lactose, mannitol 
and inulin were purchased from Spectrum Chemicals (Gardena, CA).  All other 
materials used were analytical grade and described in Chapter 5.3.1. 
C.2.2 Production of URF formulations 
The method for manufacture of URF formulations was described in 
Chapter 5.3.2. 
C.2.3 X-Ray Powder Diffraction 
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The method for measurement of crystallinity using X-ray powder 
diffraction is outlined in Chapter 5.3.3.1. 
C.2.4 BET Specific Surface Area 
The method for measurement of surface area is outlined in Chapter 
5.3.3.2. 
C.2.5 Scanning Electron Microscopy 
The method for scanning electron microscopy is outlined in Chapter 
5.3.3.3. 
C.2.6 Dissolution Testing at Below Equilibrium Solubility 





  The morphological characteristics of TAC particles processed by URF 
with different compositions have been observed by SEM, showing the presence of 
porous nanostructed aggregates comprised of small particle domains (Figure C.1). 
The XRD patterns of the various samples investigated are shown in Figure C.2. 
X-ray diffraction of the unprocessed TAC yielded the intense characteristic 
crystalline peaks at 19.10, 19.95 and 23.45 2θ degrees.  The XRD patterns for 
TAC processed powders with lactose, mannitol and inulin at drug-to-excipient 
ratio of 1:1 demonstrated the lack of crystalline peaks, indicating an amorphous 
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morphology. In contrast, the TAC composition with glucose displayed a slight 
peak at the location of the major peak for TAC, indicating a small degree of 
crystallinity. The BET method was used to measure the surface area of the sample 
powders. Specific surface areas of the various samples investigated are shown in 
Table C.1. Unprocessed TAC had a surface area of 0.53 m2/g. The surface areas 
of TAC processed powders with inulin, lactose, mannitol and glucose ranged 
from 15-33m2/g, which were much larger than that of the unprocessed TAC. The 
high surface area was evident in the nanostrutured aggregates shown in the SEM 
micrographs. The dissolution profiles of the TAC processed powders and 
unprocessed TAC are shown in Figure C.3. In 30 min, 78, 72, 60 and 48% of 
TAC dissolved from the URF formulations with inulin, lactose, mannitol and 
glucose, respectively. Unprocessed TAC dissolved much more slowly, achieving 
only 29% in the first 30 min of the dissolution testing period. The enhanced 
dissolution rates of TAC processed powders prepared with glucose, lactose, 
mannitol, and inulin may be due to many factors such as the hydrophilic character 












Appendix D: Investigation of the Effect of evaporating the volatile 




The objective of the study in the Appendix D was to investigate the effect 
of evaporating the volatile salt on the physicochemical properties of EPAS 
powders. It was hypothesized that the surface area of EPAS powders can be 
increased by adding ammonium carbonate ((NH4)2CO3) as pore forming agent. 
The powders were characterized by x-ray diffraction (XRD), scanning electron 
microscopy (SEM), specific surface area, contact angle and dissolution testing 
 
D.2 MATERIALS AND METHODS 
D.2.1 Materials 
The materials used for this study were described in Chapter 3.3.1. 
D.2.2 Production of EPAS powders 
The method for manufacture of EPAS powders was described in 
Chapter 3.3.2 and the experimental conditions are summarized in Table D.1. 
D.2.3 Scanning Electron Microscopy 
The method for scanning electron microscopy is outlined in Chapter 
3.3.3.1. 
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D.2.4 Contact Angle 
The procedure utilized for determination of contact angle is outlined in 
Chapter 3.3.3.4. 
D.2.5 BET Specific Surface Area 
The method for measurement of surface area is outlined in Chapter 
3.3.3.5. 
D2.6 X-Ray Powder Diffraction 
The method for measurement of crystallinity using X-ray powder 
diffraction is outlined in Chapter 3.3.3.6. 
D.2.7 Dissolution Testing 
The procedure utilized for determination of dissolution rate is outlined in 




In all case, EPAS powder showed the major peaks for ITZ, indicating a 
high degree of crystallinity (Figure D.1). Similar contact angles were also 
observed for all formulations (E1-E3) as shown in Table D.2.  The contact angles 
for water on the E2 and E3 compacted pellets were 31.5° and 30.9°, respectively, 
compared to 30.4° for E1 formulation.  This result showed that the addition of 
ammonium carbonate has no effect on wettability of formulation.  SEM 
micrographs of ITZ processed by EPAS are shown in Figure D.2. EPAS powders 
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generally show non-porous particles composed of submicron sizes which are 
aggregated to form larger particles. However, SEM micrograph of the E3 powder 
displays a higher porous structure compared to E1 and E2. The specific surface 
area shown in Table D.2 also illustrates the differences in porosity and primary 
particle sizes seen in the E1, E2 and E3 particles, with surface areas of 8.79 m2/g, 
9.65 m2/g and 14.89 m2/g, respectively. Surface area of ITZ EPAS powders 
containing 1% (NH4)2CO3 is almost 2 folds higher than EPAS powders without 
(NH4)2CO3. The dissolution profiles shown in Figure D.3 illustrates the enhanced 
dissolution rate achieved through E1-E3 formulations compared to bulk ITZ. 
Dissolution rate of  77, 80 and 89% ITZ in only 2 minutes from EPAS powders 
containing 0, 0.5 and 1%(NH4)2CO3 respectively. This finding was further 
established through BET specific surface area measurements, where E3 particles 
showed higher specific surface area, due to a high porosity and nanostructured 
network of polymer and drug.  Within 10 minutes, the E1-E3 dissolution rates 
were similar and were much higher than for the bulk ITZ. A possible explanation 
for the high initial drug release might be the evolution of NH3 and CO2 gases 
leads to pore formation and consequently, both increase surface area and 
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